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Abstract 
 
 
Meniscectomy is a common treatment for a young patient with a traumatic meniscal 
tear, despite the known negative consequences. Meniscal allograft transplantation 
has been performed for over thirty years in young symptomatic patients following a 
meniscectomy but it has never been rigorously evaluated for effectiveness. Therefore 
the aim of this thesis was to perform the development and pilot work to inform a 
future multi-centre pragmatic randomised controlled trial comparing meniscal 
allograft transplantation to physiotherapy. 
 
Systematic reviews in this thesis showed that in case series, meniscal allograft 
transplantation resulted in improved patient reported outcome measures in the short 
and medium term, although there were no comparator groups. There was no strong 
evidence for chondroprotection with either meniscal allograft transplantation or 
physiotherapy in this patient population. 
  
In the systematic review it was also identified that full thickness cartilage lesions 
were a contraindication to meniscal allograft transplantation for most surgeons. A 
Cox proportional hazards model was used on a case series of meniscal allograft 
transplantations performed locally, which showed that a full thickness cartilage 
lesion was a strong predictor of failure. It was therefore determined that these 
patients should be excluded from the pilot trial. 
 
A comprehensive cohort study incorporating a pilot randomised controlled trial was 
performed, with 36 participants being recruited over one year. The trial processes 
worked successfully and the pilot randomised trial recruitment rate was 55%. There 
were no losses to follow up in the randomised arm of the trial. Patient reported 
outcome measures showed a trend towards a bigger improvement in the meniscal 
allograft transplantation group, which was statistically significant in the KOOS score 
when the randomised and preference groups were merged. Sample size calculations 
for the data in the trial using the KOOS score suggest that between 70 and 114 
participants would be needed in a full trial.  
 
The results of this thesis suggest that a full trial is warranted and could be deliverable 
within the UK, with some small adjustments to the trial design. 
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1 Introduction, Aims and Objectives 
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1.1 Introduction 
 
Menisci are complex fibrocartilage structures located between the two tibiofemoral 
articulations of each knee. Their main role is to distribute the forces through the 
knee83. Meniscectomy is a common treatment for a meniscal tear, despite a trend 
towards meniscal preserving surgery141. This is partly because many tears are not 
amenable to repair and of those that are, there is a high failure rate200.  
 
Meniscectomy is strongly associated with osteoarthritis (OA) of the knee and young 
symptomatic patients with a history of meniscectomy are a challenge to treat213. 
These patients meet the definition of OA on clinical grounds alone and are at a high 
risk of OA progression177, 296. Joint replacement is an effective pain relieving 
treatment for severe OA of the knee, but is a poor option in a young person. A 
treatment that is able to improve symptoms and reduce or delay OA progression 
would be the ideal solution. The National Institute of Health and Care Excellence 
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(NICE) have reported in their OA guideline that treatments modifying the joint 
structure in people with OA are likely to improve symptoms and may reduce OA 
progression204. They also stated that treatments with the potential to do this should 
be studied using appropriate outcome measures, including magnetic resonance 
imaging (MRI) and patient reported outcome measures (PROMs). 
 
There are two treatments currently available on the National Health Service (NHS) 
that may be used to treat patients with a symptomatic meniscal deficient knee: 
Meniscal allograft transplantation and physiotherapy. Despite this, there has been no 
definitive evaluation of whether meniscal allograft transplantation may be a better 
treatment than physiotherapy for this patient population.  
 
 
1.2 Thesis Aims and Objectives 
 
The overall aim of this thesis was to provide the development and pilot work to 
inform a definitive evaluation of meniscal allograft transplantation in treating 
patients with a symptomatic meniscal deficient knee, compared to physiotherapy. 
 
It is widely accepted that randomised controlled trials (RCT) are the best way to 
determine the effectiveness of a health care intervention54. Meniscal allograft 
transplantation and physiotherapy are ‘complex interventions’ because they have 
several interacting components. In 2008 the Medical Research Council (MRC) 
updated their widely adopted framework for the development, evaluation and 
implementation of complex interventions in order to help researchers use appropriate 
methods54, 75. Figure 1-1 details the MRC key stages in the development and 
evaluation process of a complex intervention.  
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Figure 1-1: MRC key stages diagram for the development and evaluation of complex 
interventions 
 
Whilst best practice is to develop interventions systematically and then test them in a 
structured way, it is accepted that in practice this process may not happen in a 
structured progressive way75. This is the case with meniscal allograft transplantation 
as the intervention has existed and evolved over many years without a true 
development, piloting or definitive evaluation process. At University Hospitals 
Coventry and Warwickshire NHS Trust (UHCW) the knee surgeons have adapted 
the intervention to suit the latest evidence base and local setting. The same is true for 
physiotherapy; specific physiotherapy techniques have developed over time and 
these have been adapted for patients with a symptomatic meniscal deficient knee at 
UHCW into a programme called ‘personalised knee therapy’. Therefore it would not 
be possible, or even appropriate, to try and modify these interventions. Therefore, a 
more pragmatic approach of testing the interventions as they existed in their current 
form was taken.  
 
Feasibility/Piloting 
Testing procedures 
Estimating recruitment/retention 
Determining sample size 
Evaluation 
Assessing effectiveness 
Understanding change process 
Assessing cost-effectiveness 
Development 
Identifying the evidence base 
Identifying the theory 
Modelling process and outcomes 
Implementation 
Dissemination 
Surveillance and monitoring 
Long term follow-up 
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Despite the constraints, it was still important to perform some development work. 
There were two key phases needed before a pilot trial could be considered. Firstly, 
there was a need to identify the theoretical basis for why an intervention may work 
in order to determine the plausibility or ‘prior probability’ of the proposed 
intervention being effective75. It is more likely that an intervention will be effective 
if its mechanism of action is understood and thought to produce a specific clinical 
effect5. Secondly, the existing evidence base needed to be identified with the use of 
systematic reviews75. This was necessary to ensure that there was evidence the 
intervention had a reasonable chance of working. It was also used to identify any 
recent development of the intervention to ensure that the interventions in the pilot 
trial were reasonably representative of interventions in other centres. There are a 
number of aspects of meniscal allograft transplantation considered controversial, for 
example selecting suitable patients. If a systematic review demonstrated that an 
aspect of meniscal allograft transplantation performed at UHCW was not broadly 
representative of most other studies (and was modifiable), a regression analysis of 
the current case series data could be performed. This would identify whether the 
controversial part of the intervention was a predictor of a poorer outcome. If it was 
found to be the case, the intervention in the pilot study could have been be modified. 
If no significant effect, or a positive effect was found, the intervention would not 
need to be modified.    
 
The next stage was the feasibility or piloting phase. Although there is considerable 
overlap, a feasibility study is used to answer the question of whether a RCT can be 
successfully achieved. It commonly uses a mixed methods approach and is used to 
identify important parameters that are needed to design a full RCT. These may 
include willingness of participants and surgeons to take part and the ability to deliver 
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the interventions14. A pilot is usually a small version of the main study and is 
designed to test whether the processes of the trial can work together, as well as 
collecting data on the primary outcome measure14. It was considered that a RCT was 
likely to be deliverable for the following reasons: Both interventions were already 
being delivered on the NHS without major problems; a number of similar RCTs had 
been successfully delivered from the department; the number of eligible patients 
could be approximated from a service evaluation over the last two years; the 
operating surgeons were fully engaged with randomising and delivering the trial. 
Due to these reasons, it was determined that a pilot trial was most appropriate, as it 
could assess the variability and distribution of outcome measures in order to inform a 
sample size calculation for a full RCT. It was also used to identify specific issues 
with the processes of the trial, which could be addressed, if required, before 
undertaking a full RCT.  
 
The MRC framework also recognises that where strong patient preferences may 
exist, non-standard trial designs may be used, for example comprehensive cohort 
studies75. A comprehensive cohort increases the external validity of a study and may 
improve the precision of the estimate of the variability of the sample. 
 
Therefore the objectives of this thesis were to: 
 
• Identify the theoretical basis for why meniscal allograft transplantation may 
result in a symptomatic improvement and/or reduce or delay the progression 
of OA in patients with a symptomatic meniscal deficient knee.  
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• Systematically review the current evidence base for whether it does result in 
a symptomatic improvement and/or reduce or delay the progression of OA in 
patients with a symptomatic meniscal deficient knee. 
• Identify the theoretical basis for why physiotherapy may result in a 
symptomatic improvement and/or reduce or delay the progression of OA in 
patients with a symptomatic meniscal deficient knee.  
•  Systematically review the current evidence base for whether physiotherapy 
does result in a reduction or delayed progression of OA in patients with a 
meniscal deficient knee. 
• Perform a regression analysis of the current series of meniscal allograft 
transplantations at UHCW to determine significant predictors of failure.  
• Develop and undertake a comprehensive cohort study incorporating a pilot 
RCT comparing meniscal allograft transplantation to personalised knee 
therapy in patients with a symptomatic meniscal deficient knee. 
• Discuss whether a full RCT would be deliverable, in the light of the results of 
the findings of this thesis. 
 
Objectives one to five contributed to the development stage and objectives six and 
seven formed the pilot stage. Objectives one and three were met in chapter two by 
identifying the scientific plausibility of the two interventions. Objective two was met 
in chapters three and four by systematically reviewing the current evidence base for 
outcomes following meniscal allograft transplantation, using in patient reported 
outcomes and OA progression measures respectively. Objective four was met in 
chapter five by systematically reviewing the evidence base for whether 
physiotherapy reduces or delays the progression of OA. Objective five was met in 
chapter six by performing a regression analysis on the current case series of meniscal 
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allograft transplantations performed at UHCW. Objective six was met in chapters 
seven and eight by designing and performing a comprehensive cohort study, 
incorporating a pilot RCT. Objective seven was met in chapter nine by discussing 
the implications of the findings in this thesis in the context of whether a full RCT 
would be deliverable. 
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2 Scientific Plausibility of the Interventions 
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2.1 Meniscus Anatomy and Microstructure 
 
The menisci are two fibrocartilage structures that sit between the tibiofemoral 
articulations of the knee. In the axial plane they are crescent-shaped and cross-
sectionally they are wedge-shaped. They are attached to the tibia by their insertional 
ligaments in both the anterior and posterior horns, as well as attachments to the deep 
medial collateral ligament, anterior intermeniscal ligament (sometimes called 
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transverse ligament) and two menisco-femoral ligaments (Figure 2-1)181. They are 
also attached to the joint capsule along their convex peripheral rim.  
 
 
Figure 2-1: The meniscal root attachments are shown (numbers 1 and 2 - medial; 3 
and 4 - lateral). The anterior intermeniscal ligament (transverse ligament (TL)) and 
cruciate insertions on the tibia are also shown (source: Messner and Gao192) 
 
The anterior insertional ligament of the medial meniscus is a flat structure, inserting 
in the anterior intercondylar fossa, just in front of the anterior cruciate ligament 
(ACL) insertion192. Posteriorly, the insertional ligament is attached to the posterior 
intercondylar fossa between the posterior insertion of the lateral meniscus and the 
insertion of the posterior cruciate ligament (PCL)192. The anterior insertional 
ligament of the lateral meniscus is also attached to the anterior intercondylar fossa, 
between the lateral intercondylar tubercle posteriorly and the ACL insertion 
anteriorly. Its posterior insertional ligament attaches posterior to the lateral 
intercondylar tubercle and anterior to the posterior insertion of the medial meniscus. 
The anterior intermeniscal ligament attaches to the anterior horns of both menisci, 
connecting them. 
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The blood supply to the knee is mainly from the superior and inferior branches of the 
medial and lateral genicular arteries17. Branches from these arteries form a meniscal 
capillary plexus within the synovial and capsular tissue of the knee112. This plexus 
(on each side) supplies the meniscal horns and peripheral portion of the meniscus. At 
birth, the whole meniscus has a blood supply, but this is reduced to the horns and 
outer twenty-five to thirty-three per cent by around eighteen months17. After the age 
of fifty years, the blood supply is reduced to the outer ten to thirty-three per cent. 
The blood supply is thought to play a crucial role in the ability of a meniscal tear to 
heal. The vascular outer third is often referred to as the red-red zone, the variable 
middle third as the red-white zone and the avascular inner third as the white-white 
zone48. Tears in avascular areas have been shown to heal extremely poorly, 
compared to the vascular region17. 
 
The meniscus also has a similar pattern of nerve supply, with the horns and outer 
two thirds of the body being richly supplied with nociceptors and 
mechanoreceptors112. The inner third of the body does not have a nerve supply. 
 
Although the functions of the medial and lateral menisci are similar, they do have 
differences. The medial meniscus is often described as ‘C’ shaped, whereas the 
lateral meniscus is closer to ‘O’ shaped. The medial meniscus is thinner and larger 
when compared to its lateral counterpart, which is illustrated in a three dimensional 
(3D) reconstruction in Figure 2-263. The medial meniscus is less mobile, mainly due 
to its attachment to the deep medial collateral ligament. Bloecker et al. performed a 
3D analysis on magnetic resonance imaging (MRI) scans of normal knees, finding 
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that the lateral meniscus had a greater surface area. They also found that the lateral 
meniscus covered fifty-nine per cent of the lateral tibial plateau, compared to fifty 
per cent for the medial meniscus (Figure 2-2). A further study showed that the lateral 
meniscus carried seventy per cent of the load through the knee, compared to the 
medial meniscus carrying fifty per cent239. 
 
 
Figure 2-2: A 3D reconstruction from MRI images illustrating the differences in 
shape and tibial plateau coverage between the lateral meniscus (left) and medial 
meniscus (right) (source: Bloecker et al.41) 
 
The menisci are made up of roughly seventy-five per cent water, twenty per cent 
type one collagen and five per cent other substances, including proteoglycans, elastin 
and type two collagen188, 286. The microstructure of the meniscus is highly complex 
and varies depending on anatomical region. Overall, the collagen fibres form a dense 
framework, with the majority of fibres running circumferentially, and some 
radially51. Peterson and Tillmann examined the meniscus under a scanning electron 
microscope and found three distinct layers: A peripheral fibril network with fibres of 
no specific direction, a lamellar layer and a central main portion of circumferentially 
orientated fibres218. Andrews et al. used optical projection tomography on bovine 
menisci, finding that there was a clear transition from an outer meniscus of highly 
aligned collagenous fibres in the circumferential direction to a woven, less aligned 
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structure in the inner meniscus (Figure 2-3)10. They described the outer portion being 
close to a ligament in structure, with the inner portion being close to hyaline 
cartilage in structure. Two types of fascicle organisation were seen within the 
meniscus: Braided and woven10. Braiding, commonly seen in ropes, results in 
increasing stiffness with increasing deformation of the fascicles. This is because they 
compress around each other creating increased friction between them. This would be 
well suited to the circumferential stress that the meniscus is put under during 
loading; also known as hoop stress48. A woven structure is commonly used to 
withstand compressive loads by converting compressive forces into tensile forces, 
such as a woven basket10. The progressing understanding of the microstructure of the 
menisci gives an insight into stresses that they are under and provides a greater 
understanding of their function within the knee.   
 
 
Figure 2-3: The left side shows a schematic representation of the fascicle structure in 
two different locations in the meniscus, with the corresponding optical projection 
tomography images on the right side (source: Andrews et al.10) 
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2.2 Meniscus Function 
 
The tibiofemoral joint is the largest and most complex in the human body. Both of 
the semi-circular bony condyles of the femur rest in an incongruent manner on the 
mostly flat tibial plateau. The concave upper surface of the menisci and flat lower 
surface increase the congruency of the articulations. Menisci are found in all 
mammals, although there is variation in their shape and attachments192. It is 
generally accepted that the primary role of the menisci is load distribution83, 162, 240. 
In the loaded knee, the lateral meniscus transmits seventy per cent and the medial 
meniscus fifty per cent of the load through the knee. Biomechanical studies have 
shown that meniscectomy decreases the tibiofemoral contact area by fifty to seventy-
five per cent and increases the peak contact pressure by 200 to 300 per cent22, 184, 277. 
Figure 2-4 illustrates the relative differences in contact area and pressures with and 
without a meniscus. The menisci have also been shown to provide secondary 
constraint to the knee171, 172, 179. Further roles have been proposed, including joint 
lubrication224 and proprioception192. Shock absorption is commonly stated as a 
function of the menisci, although there is little evidence to support this and arguably 
some refuting this hypothesis9. 
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Figure 2-4: Illustration showing the changes in contact pressures before and after a 
meniscectomy (source: McDermott and Amis183) 
 
2.3 Meniscal Tears: Incidence, Classification and Treatment 
 
Meniscal tears are common; the yearly incidence of operated meniscal tears has been 
estimated at 90 and 42 per 100 000 for males and females respectively, based on a 
study in a suburban area of Copenhagen, Denmark125. They also found that the tear 
was associated with an acute traumatic event in seventy-seven and sixty-four per 
cent of cases in males and females respectively. Bucket handle tears were most 
common in males (thirty-five per cent), whereas peripheral detachments were most 
common in females (forty-one per cent). In an historical study based on a population 
in New York, USA, Baker et al. estimated a yearly meniscectomy incidence of 61 
per 100 000 population20. They also found that it was more common in males (three 
to one males to females respectively) and medial meniscectomy was more common 
(eighty-one to nineteen per cent medial to lateral respectively). More recently, a 
review of NHS knee operations found that the yearly incidence of meniscus-related 
operations was 35 per 100 000 population141. These differences may reflect the 
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changes in management of meniscal tears over time, as well as geographical 
differences in treatment. 
 
The treatment of meniscal tears has evolved considerably throughout orthopaedic 
history. In 1897 the meniscus was described as a remnant of leg muscle that served 
no biomechanical function39. In 1889 Annandale, who had previously reported a 
meniscal repair, advocated complete excision of tears, which became standard 
practice for the next eighty years11, 97. In 1948 Fairbank was the first to associate OA 
changes on plain radiographs with meniscectomy101. However, total meniscectomy 
continued to be standard treatment for meniscal tears until a number of studies 
reported high rates of OA following total meniscectomy, in long term case series12, 
108, 140. These studies, combined with the rise of arthroscopic surgery, created a 
paradigm shift in practice to meniscal preserving surgery (partial meniscectomy and 
meniscal repair) whenever possible.  
 
Meniscal tears may be broadly categorised as traumatic or degenerative. Traumatic 
tears have an acute onset and are often caused by a sporting injury. Figure 2-5 shows 
common tear patterns of the meniscus. Longitudinal tears (in line with the 
circumferential collagen fibres) are as a result of axial loading and rotating of the 
femoral condyles. This tear pattern can result in a bucket handle tear that can 
dislocate into the knee, causing knee locking. Traumatic radial and root tears can 
also occur, which can cause extrusion and potentially defunction the meniscus. 
Symptomatic traumatic meniscal tears are usually treated with either meniscal repair 
or meniscectomy. Meniscal repair has been shown to improve PROMs, when 
compared to meniscectomy, in a recent meta-analysis290. However it is not always 
possible to repair a meniscal tear; a delayed presentation and certain tear patterns can 
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reduce the chance of being able to perform a repair. There is also a high failure rate 
of meniscal repairs, with one meta-analysis reporting a pooled failure rate of twenty-
three per cent at five years post-operatively200. These patients then often have a 
meniscectomy. 
 
 
Figure 2-5: Different meniscus tears patterns (source: www.aidmymeniscus.com) 
 
Patients with degenerative meniscal tears are usually older and do not usually 
describe a single traumatic event. The tear is usually complex (more than one tear 
pattern), and fibrillation of the meniscus is commonly seen at arthroscopy. 
Degenerative tears are not normally repairable and partial meniscectomy has 
commonly been performed if patients are symptomatic50. However a number of 
methodologically strong studies have found no significant benefit of this approach to 
the general population. Herrlin et al. performed a RCT comparing meniscectomy and 
physiotherapy to physiotherapy alone in patients with a non-traumatic medial 
meniscal tear, finding no significant differences in outcomes127. Katz et al. 
performed a RCT comparing partial meniscectomy and physiotherapy to 
physiotherapy alone in patients over forty-five years of age with a meniscal tear and 
knee OA, finding no benefit of meniscectomy146. However, there was a high 
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crossover to the surgical group, with those patients having a low patient reported 
outcome scores before crossover. Sihvonen et al. also performed a RCT comparing 
partial meniscectomy with sham surgery in patients with a degenerate (non-
traumatic) medial meniscal tear in the absence of knee OA, finding no benefit of 
partial meniscectomy over sham surgery245.  
 
It has been shown that degenerative meniscal tears are common incidental findings 
in older people. Englund et al. found that over fifty per cent of men between seventy 
and ninety years selected from a random sample of ambulatory people had meniscal 
tears94. Bhattacharya et al. looked at the prevalence of meniscal tears in a sample of 
older patients (mean age sixty-six years) with symptomatic knee OA, and aged 
matched controls, finding ninety-one compared to seventy-six per cent of patients 
had a tear respectively. It is likely that degenerative meniscal tears are part of the OA 
disease process. Englund et al. clinically and radiographically reviewed 317 patients 
that had a meniscal resection between fifteen and twenty-two years previously93, 96. 
They found that a degenerative type meniscal tear and obesity were the most 
strongly associated risk factors for symptomatic and radiographic knee OA. They 
also found that hand OA was associated with an increased likelihood of knee OA 
following meniscal resection. They concluded that surgical resection may only 
remove the evidence of early OA, rather than address it.  
 
2.4 Knee Osteoarthritis and Meniscectomy 
 
OA is a clinical syndrome of joint pain with associated functional limitation and 
reduced quality of life. It is the outcome of a range of disorders in which mechanical 
factors play a central role, resulting in the structural and functional failure of the 
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whole joint180, 208. It is the biggest cause of musculoskeletal disability in the 
developed world and in the top ten of causes of disease burden in high income 
countries174. The knee is one of the most commonly affected joints and more than 
250 million people worldwide may suffer from it198. The 1986 classification, 
developed by the American College of Rheumatology, is often used to standardise 
the diagnosis of OA in a research setting8. More recent evidence-based 
recommendations refer specifically to the diagnosis of knee OA296. These gave 
recommendations to the aid diagnosis of OA, considering risk factors, symptoms, 
signs and radiographic features. 
 
Meniscectomy is a strong predictor of future knee OA136, 213. In 1948 Fairbank 
radiologically reviewed 107 patients at three to fourteen months following 
meniscectomy, commonly finding flattening of the femoral condyle and narrowing 
of the joint space in the affected compartment101. Since then there have been 
numerous studies reporting clinical and radiological changes following 
meniscectomy. Roos et al. compared 123 patients that had open meniscectomy for an 
isolated tear to age and sex matched controls twenty-one years after surgery, finding 
a relative risk of fourteen (95% CI 3.5 to 121.2) for definite radiological OA230. 
Hunter reviewed 257 patients with symptomatic knee OA over thirty months, finding 
a strong association between meniscal damage and cartilage loss136. The same group 
also found that loss of meniscal coverage and height was associated with cartilage 
loss. Papalia et al. performed a systematic review looking at risk factors for OA after 
the surgical management of meniscal tears, in studies with a follow up of between 
five and thirty years213. They identified 4642 patients in thirty-two studies, with a 
mean prevalence of knee OA of fifty-four per cent (range sixteen to ninety-three per 
cent). When comparing radiological evidence of OA, the mean prevalence in the 
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operated group was forty per cent compared to the contralateral (control) knee of six 
per cent. They also found a higher incidence of OA with lateral compared to medial 
meniscectomies and with total compared to partial meniscectomies. They concluded 
that there was a strong association between meniscectomy (medial or lateral) and 
OA. One study looked specifically at isolated traumatic meniscal tears, finding that 
the mean time from injury to first radiological signs of OA was ten years for the 
study group overall, or fifteen years in the age group seventeen to thirty229. Salata et 
al. also performed a systematic review of outcomes following meniscectomy, finding 
that total meniscectomy, removal of the peripheral rim and lateral meniscectomy 
were all predictors of a poor clinical and radiological outcome236. Englund et al. 
looked specifically at patients with meniscal damage that had not had surgery to 
identify whether meniscal damage was a risk factor for OA, independently of 
meniscectomy95. They performed a case control study over a thirty month period, 
finding a odds ratio of six for developing OA if meniscal damage was present, 
compared to no meniscal damage. They concluded that meniscal damage by itself 
(i.e. without associated surgery) is a potent risk factor for developing OA. 
 
These clinical studies provide evidence of a strong and consistent association 
between meniscal damage and OA. It is thought that damage to the meniscus causes 
changes to the biomechanical and therefore biochemical environment of the knee, 
which results in OA initiation and progression in susceptible patients183. A number 
of studies have shown the biomechanical changes following meniscectomy. Krause 
was the first to show an increased stress on the knee joint following meniscectomy in 
a study on human cadavers162. Baratz et al. performed a study, also on human 
cadavers, showing that total meniscectomy decreased tibiofemoral contact area by 
seventy-five per cent and increased peak contact stresses by 235 per cent22. They 
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also found that peak contact stresses increased in proportion to the amount of 
meniscus removed. Paletta et al. also found similar results, with contact area 
decreasing by forty-five to fifty per cent and peak contact stresses increasing to 
between 235 and 335 per cent following total lateral meniscectomy212. More recent 
studies have been able to show the local biomechanical changes to the articular 
cartilage and knee joint following meniscectomy. Song et al. performed a MRI study 
on sheep where they cyclically loaded sheep knees at a physiologic magnitude and 
frequency over two days, taking multiple images249. They found that meniscectomy 
accelerated articular cartilage deformation during loading and that it remains 
chronically deformed and dehydrated on unloading, when compared to the normal 
knee. They hypothesised that central fibrillation of the articular cartilage may be 
started by the direct strain induced damage to the articular cartilage matrix, or the 
chronic changes in tissue hydration. Haemer et al. used the images in the study by 
Song et al. to create a finite element analysis model118. They found a significantly 
increased strain in the articular cartilage and subchondral bone centrally in the knee. 
These increased strains were close to the reported failure limits for these tissues, 
including the surface zone of the articular cartilage. They hypothesised that this 
could lead to cartilage fibrillation and eventual breakdown. Peripherally, they found 
a significant loss of articular fluid pressurisation, which is thought to have a negative 
effect of cartilage maintenance. This loss of articular cartilage hydrostatic pressure 
may allow capillary invasion with subsequent endochondral ossification and 
osteophyte formation56. These changes in the articular cartilage have also been seen 
after partial meniscectomy147.  
 
Evidence of joint degeneration following meniscectomy has also been reported in 
animal studies, with macroscopic, histological and biochemical changes. Articular 
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cartilage fibrillation, swelling, fissures and cleaved type two collagen have been seen 
following meniscectomy in a number of animal studies123, 164. Lanzer and Komenda 
reported a loss of proteoglycans in the meniscectomised knee164. Young et al. used a 
sheep model to evaluate proteoglycan four levels and regulation following 
meniscectomy293. Proteoglycan four is thought to be involved in joint lubrication and 
is present in the superficial zones of the articular cartilage of the normal knee. They 
found that following meniscectomy and the onset of early OA, proteoglycan four 
was lost from the superficial zones as well as a reduction in its expression from 
chondrocytes. Oakley et al. performed medial meniscectomies in sheep and observed 
the macroscopic and biochemical changes210. They reported gross structural damage 
including cartilage softening and fibrillation as well as proteoglycan loss throughout 
the joint, with the greatest severity being closest to the meniscectomy site. They 
suggested that the observed changes pointed to biochemical and cytokine mediated 
responses, in addition to a change in the biomechanical environment. Appleyard et 
al. observed the variable responses in different regions of knee articular cartilage in 
response to meniscectomy, in a sheep model13. They found that the entire articular 
cartilage of the lateral tibial plateau underwent degenerative changes. They also 
found that the joint margins became biomechanically softer than normal cartilage, 
which they hypothesised would undergo degeneration and progression of joint OA.  
 
2.5 Meniscal Allograft Transplantation: History, Development and 
Clinical Outcomes 
 
In response to reports of the clinical consequences of meniscectomy, meniscal 
replacement began to emerge in the 1980’s. Canham and Stanish reported the 
successful implantation of medial meniscal allografts in dogs, showing for the first 
time that a completely detached meniscus could be implanted successfully55. They 
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also showed that the preservation technique was important; the tissue culture 
preservation group did considerably better than the gluteraldehyde group. In 1989 
Milachowski, Weismeier and Wirth reported a series of meniscal allograft 
transplantations in thirty sheep and then twenty-two patients194. This group 
performed the first human detached meniscal allograft transplantation in May 1984. 
They used two types of graft preservation: Deep frozen and lyophilised, reporting 
that the deep frozen ones had better outcomes. They concluded that meniscal 
allograft transplantation was a reasonable procedure and that they observed no 
adverse immunological reactions. Figure 2-6 shows arthroscopic images of a modern 
meniscal allograft transplant in the knee. 
 
 
Figure 2-6: Meniscal allograft transplant in a right lateral compartment of the knee at 
time zero (left) and at seven months (right) 
 
 
Other attempts have been made to substitute the meniscus, but with limited success. 
Kohn et al. attempted to use tendon autograft as a substitute, but this was found to be 
weaker than a native meniscus160. Attempts to use a fat pad autograft were also 
unsuccessful as although it had the macroscopic appearance of a meniscus by six 
months, it had degenerated by one year and did not prevent OA changes159. These 
results led to a shift towards meniscal allograft surgery191.  
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Since the first reported human meniscal transplantation, there have been numerous 
case series reported in the literature3, 35, 53, 60, 117, 165, 274. It is difficult to get an 
accurate estimate of the total number of transplantations performed worldwide as 
only a small percentage of case series are reported in the literature91. In 2003 it was 
estimated that over 4000 transplantations had been performed in the USA alone, with 
a yearly rate approaching 800243. In a consensus meeting amongst Danish surgeons, 
it was estimated that the yearly need for meniscal allograft transplantations in 
Denmark was between ten and fifty, in their population of five million19. Although 
not directly comparable, extrapolating these figures would give a yearly need for 
between 126 and 630 in the UK and between 628 and 3139 in the USA. Despite this, 
there have been no RCTs of meniscal allograft transplantation performed. Therefore, 
the best evidence for the efficacy and controversies in meniscal transplant surgery 
come from systematic reviews of case series.  
 
In 2007 Lubowitz et al. provided an overview of meniscal allograft transplantation, 
highlighting many dilemmas involving the treatment of symptomatic meniscal 
deficient patients175. Nevertheless they concluded that meniscal allograft 
transplantation may reliably result in pain relief and increased function in the short 
and medium term. These conclusions were echoed two years later in a further 
systematic review76. In 2011 (search performed in January 2010) a comprehensive 
systematic review, with limited data pooling was performed91. They reported on the 
results of 1136 grafts across forty-four case series. Pooling the Lysholm scores 
(score 0 to 100, with 100 being the best), they found an improvement from forty-four 
pre-operatively to seventy-seven at final follow up (mean follow up 4.6 years). They 
concluded that the procedure was safe, reliable and that it should not be considered 
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experimental surgery. However, there were no randomised or other comparative 
studies reported. More recently, a systematic review focussing on long term 
outcomes after meniscal allograft transplantation found that improvements in clinical 
scores were maintained in the long term167. The authors concluded that the procedure 
was effective at reducing symptoms and improving knee function in the long term. 
Since the publication of these systematic reviews, there have been a number of new 
studies reporting their results3, 37, 59, 60, 79, 143, 154, 156, 158, 170, 178, 238, 252, 295. These studies 
report either longer term follow up or results from more recent surgery. A systematic 
review was needed to update the literature, both in terms of clinical outcome and to 
identify any trend changes amongst surgeons performing meniscal allograft 
transplantation. Trend changes were considered to be highly likely because there 
were many areas of controversy in meniscal transplantation, for example patient 
selection, graft type and surgical technique.  
 
2.6 How Might Meniscal Allograft Transplantation Work? 
 
As shown, there is evidence of a sustained improvement in PROMs following 
meniscal allograft transplantation, but it is important to understand how this might be 
caused. Clinically, OA may be defined as joint pain with varying levels of functional 
limitation and a reduced quality of life204. Pathologically, it may be characterised by 
the failure of the repair process of damaged cartilage due to biomechanical and 
biochemical changes in the joint36. This results in localised loss of cartilage, 
remodelling of adjacent bone and inflammation. NICE have acknowledged that 
structural changes in the joint are more closely linked to symptoms than previously 
thought and that interventions altering the joint structure could be expected to deliver 
symptomatic relief as well as delaying OA progression204. It has been shown that 
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meniscectomy adversely alters the biomechanical and biochemical environment of 
the knee and this translates to a high rate of OA in affected patients. The 
pathogenesis of OA is not fully understood but abnormal loading patterns are 
thought to result in focal excessive mechanical stresses of the joint surfaces40, 221. 
This results in cumulative tissue micro-damage and re-modelling and is a source of 
pain281. It has been shown that reducing joint or compartment forces improves pain 
and other symptoms in patients with OA65, 103, 190. Patients that undergo meniscal 
allograft transplantation have usage related knee pain (the primary indication for 
surgery) often with functional limitation and radiographic features of joint disease91. 
These symptoms (even without radiographic features) meet the criteria for the 
diagnosis of knee OA, especially in the presence of risk factors for OA (knee injury 
and meniscectomy), using the EULAR evidence based recommendations296. It is 
thought that meniscal allograft transplantation restores the biomechanical 
environment closely to that of the pre-injury knee, thus reducing excessive and 
abnormal joint forces. This may then result in a symptomatic improvement and 
reduced or delayed progression of OA. Therefore, evidence that a meniscal allograft 
improves the knee biomechanics is vital to the scientific plausibility that it could be 
an effective intervention.  
 
A number of biomechanical studies have been performed to compare the load 
sharing ability of meniscal allografts with the native meniscus, as well as a knee with 
no meniscus. In 1997, Paletta et al. used young human cadaveric knees to test the 
total contact area and peak contact pressure changes following meniscectomy and 
then subsequent allograft transplantation212. They found that the total contact area 
decreased by forty-five to fifty per cent following meniscectomy and then increased 
by forty-two to sixty-five per cent after allograft transplantation (compared with 
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meniscectomy scores) at all tested knee flexion angles. They also found that peak 
contact pressures increased by 235 to 335 per cent following meniscectomy, and 
were decreased by fifty-five to sixty-five per cent after allograft transplantation 
(compared with meniscectomy scores) at all tested knee flexion angles. The 
improvements following transplantation however did not reach the level of the native 
knee. These results were similar to another study historic study7, whilst a further 
study found that normal biomechanics were restored at low compressive loads, but 
not high132. Dienst et al. compared contact pressures with under and oversized 
menisci, finding that oversized menisci allowed greater forces across the articular 
cartilage whilst undersized menisci restored normal forces across the articular 
cartilage but resulted in higher forces across the meniscus81. They reported that two 
undersized menisci failed, potentially showing the importance of appropriately sized 
grafts in meniscal allograft transplantation. More recently, McDermott el al. reported 
a human cadaveric study comparing the native knee with a bone plug fixation, an all 
suture allograft fixation and meniscectomy184. They found that both the bone plug 
technique (p=0.0029) and the all suture technique (p=0.0199) of allograft fixation 
significantly reduced peak contact pressures, compared to meniscectomy. They also 
found that the peak contact pressures of the knees with meniscal allografts (either 
technique) were not significantly different to the native knee. Based on their study, 
they hypothesised that meniscal allograft transplantation was likely to have a 
chondroprotective effect.  
 
All these studies reported an improvement in contact biomechanics following 
meniscal allograft transplantation. The majority of studies showed that normal 
biomechanics could not be restored, but the most recent study, which used 
techniques that most closely match the most used modern transplantation techniques 
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showed no significant difference between the transplanted and native knee184. These 
results support the hypothesis that the meniscal allograft functions in a similar way 
to a native meniscus. However there are limitations of the application of these results 
to patients. These studies were cadaveric and cannot simulate living conditions. In 
living patients, the meniscus is subject to a different immunological, biochemical 
and biomechanical environment. Therefore at best, these results only really apply to 
a newly implanted meniscal allograft. There are also differences in living loading 
patterns that cannot be biomechanically simulated. Also, for logistic reasons the 
surgical technique used in the cadaveric studies was very different to that used in 
living patients. In the study that best replicated that surgical techniques used today, 
an open technique with lateral collateral ligament (LCL) detachment and capsular 
opening was performed184. Whilst the LCL was repaired, the capsule was left open. 
Finally, the cadaveric specimens were usually older than patients that usually 
undergo meniscal transplantation. The effect of these limitations can only be 
speculated upon, but the overall results do increase the scientific plausibility that 
meniscal allograft transplantation can improve the biomechanical environment of the 
knee. 
 
2.7 Is Meniscal Allograft Transplantation Chondroprotective? 
 
Animal models have been used extensively to record changes in the knee following 
meniscectomy and was further used to show that meniscal allograft transplantation 
could be successfully performed. Since then, it has been used to see whether 
meniscal transplantation is chondroprotective. Szomor et al. compared four groups 
using sheep: sham operation, meniscal allograft, meniscal autograft and 
meniscectomy256. At four months they compared the knee articular cartilage 
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macroscopically and microscopically, finding significant protection of the articular 
cartilage in the allograft and autograft groups, compared to the meniscectomy group. 
They did not see a noticeable difference between the allograft and autograft groups. 
Kelly et al. performed a similar study, with a proportion of sheep being assessed at 
twelve months, as well as two and four months150. They also used MRI T2 mapping 
to assess the articular cartilage. They found that the meniscal allograft group showed 
a significant decrease in articular cartilage degeneration compared to the 
meniscectomy group. When comparing the allograft to the control group, there was 
no difference at two months, but by four months the allograft group had evidence of 
more cartilage degeneration. 
 
These results suggest that in animal models meniscal allograft transplantation may 
be chondroprotective, but does not completely reverse the effects of meniscectomy. 
This evidence builds on the biomechanical studies that show meniscal allograft 
transplantation improves contact mechanics. Whilst these results support the 
chondroprotective hypothesis, direct inferences cannot be drawn between animal and 
human studies. There are many reasons that the application of animal studies to 
human patients is severely limited: Animal knees are different in shape, movement 
and function; the surgical technique is different; the pathology of traumatic meniscal 
tears cannot be accurately be recreated and the timeline is short. As well as this, 
there have been strong doubts raised about the design and quality of animal 
studies220.  
 
Authors of meniscal allograft transplantation case series often comment on the likely 
chondroprotective benefit, but the evidence to support this is in humans limited and 
circumstantial. Whilst a few studies have reported radiological outcomes following 
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meniscal allograft transplantation, they largely lack an adequate control group and 
no RCTs have been performed79, 154, 266, 274. Prior to this thesis, there had been no 
systematic reviews focussed on addressing whether meniscal allograft 
transplantation is chondroprotective. 
 
Hergan et al. stated that the most important question was whether meniscal allograft 
transplantation can preserve the knee articular cartilage126. Further, they state 
‘Without a prospective, randomized [sic] trial comparing MAT [meniscal allograft 
transplantation] in a meniscectomized [sic] knee with a control group, we will 
continue to lack an evidence-based answer for our patients.’ 
 
2.8 Meniscal Substitutes and Tissue Engineering 
 
Whilst there has been renewed interest in alternative treatments for patients with a 
symptomatic meniscal deficient knee, there have been no clear breakthroughs in 
clinical studies. A device called Collagen Meniscus Implant (also known as 
Menaflex, Regen Biologics, Hackensack, NJ) is a collagen scaffold, designed to 
encourage new meniscus growth. It is used to treat partial meniscal defects and 
although case series show improvements in clinical scores, a RCT showed it to be no 
better than partial medial meniscectomy225. Biopsies also showed that the new tissue 
formed was a hybrid repair tissue, rather than meniscus fibrocartilage. A 
polyurethane implant, Actifit, (Orteq, London, UK) is also used to treat partial 
meniscal defects, but is not yet proven (Figure 2-7). In 2012 NICE published a 
guideline on partial meniscal replacement using a biodegradable scaffold202. They 
stated that the evidence for scaffolds over standard surgery was limited and the 
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procedure should only be carried out with special arrangements for clinical 
governance, consent and research.  
 
 
Figure 2-7: Actifit Scaffolds (source: Orteq Sports Medicine) 
 
There has been an increased interest in tissue engineering and the use of stem cells 
with polymeric scaffolds in pre-clinical studies216. These studies are interesting and 
may be successful future therapies, but are currently in the early stages of 
development. Contrastingly, meniscal allograft transplantation is an established 
treatment for patients with a symptomatic meniscal deficient knee and is available on 
the NHS without restriction.  
 
2.9 Physiotherapy: Definition and Clinical Outcomes 
 
Physiotherapy aims to restore movement and function to people affected by illness, 
injury or disability through physical treatments203. Interventions that a 
physiotherapist may use include movement and exercise, manual therapy, education 
and advice. Physiotherapy has a long history and is widely used on the NHS as a 
primary intervention, an adjunct to other interventions and for rehabilitation 
following surgery. Physiotherapy used for musculoskeletal conditions can aim to 
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improve strength, co-ordination, balance, proprioception, flexibility and aerobic 
capacity. Physiotherapy usually has a number of advantages over drug and surgical 
interventions as it is safe, inexpensive and is patient-driven to achieve long term self 
management. 
 
Physiotherapy has a strong evidence base for use in patients with knee OA. Uthman 
et al. published a sequential meta-analysis in the British Medical Journal showing 
that by 2002 there was enough evidence to show a clear benefit of exercise 
compared to no exercise for pain and functional improvement in patients with lower 
limb OA263. They also concluded that further evidence was unlikely to overturn the 
results. Of the sixty RCTs, forty-four were involving the knee alone and fourteen 
included mixed lower limb joints including the knee (two were hip alone). They 
showed that there was evidence for strengthening, flexibility and aerobic exercises, 
as well as combinations of the three. In a recent update, the authors of the Cochrane 
review on exercise for OA of the knee reported similar findings106. They concluded 
that there was high quality evidence for an improvement in pain for at least two to 
six months following the cessation of exercise interventions and moderate quality 
evidence for functional improvement; the magnitude of effect was reported to be 
similar to non-steroidal anti-inflammatory drugs (NSAIDs). In 2014, NICE 
recommended exercise as a core treatment for people with OA, in their OA care 
guideline204. Specifically, they recommended local muscle strengthening and general 
aerobic fitness, which could be tailored according to each individual’s needs. A 
further RCT compared two different types of physiotherapy (neuromuscular training 
and quadriceps strengthening) in people with moderate to severe OA. They found 
significant improvements in pain and function in both groups but no between group 
differences. 
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Physiotherapy has also been advocated for rehabilitation following meniscectomy. In 
2013, a systematic review found eighteen RCTs comparing post-operative 
rehabilitation to controls or other rehabilitation programmes. In their subsequent 
meta-analysis of six suitable studies, they found a statistically significant 
improvement in patient reported knee function and knee range of motion in 
participants that had outpatient physiotherapy and a home exercise programme, 
compared to a home exercise programme alone80.  
 
2.10 How Might Physiotherapy Work? 
 
One of the common features of a structured physiotherapy programme is strength 
training (sometimes called resistance training). Patients with knee pain and OA have 
been shown to have lower limb weakness, compared to controls21, 209. It has also 
been shown that quadriceps strength is reduced following partial meniscectomy, 
which is still not fully recovered at four years following surgery99. It has been 
proposed that lower limb muscle weakness reduces the ability to decelerate leg 
movement and is less able to absorb joint forces, with resulting pain, reduced 
function and a resulting negative effect on articular cartilage31, 33, 82. The findings by 
Ding et al. supported this hypothesis as they found that reduced lower limb strength 
was independently associated with femoral cartilage loss82. It has also been shown 
that physiotherapy (with incorporated strength training) improves strength and 
endurance in people with OA104, 142 and people with a history of meniscectomy98. 
These studies in people with OA also found a corresponding improvement in pain 
and function.  
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An integral part of physiotherapy is the encouragement of a return (or start) to 
exercise. This may improve functional and quality of life scores due to the general 
benefits of exercise to fitness, function and health-related quality of life28, 29, 193. 
  
2.11 Is Physiotherapy Chondroprotective? 
 
Despite a large amount of evidence to show an improvement in pain and function for 
people with OA, there is very little evidence to determine whether it may be 
chondroprotective.  
 
Thorstensson et al. used the surrogate outcome measure knee adduction moment 
(KAM) to determine whether an eight week exercise programme had the potential to 
reduce the risk of OA, in a pilot study259. They compared peak KAM during a one-
leg rise in the exercised limb to the contralateral limb, finding a statistically 
significant reduction in the exercised knee. KAM is determined from gait analysis 
and reflects medio-lateral joint distribution. It has been shown to correlate well with 
medial tibiofemoral contact force163 and is associated with OA progression195. 
However these results have been challenged by other studies. One RCT compared 
neuromuscular rehabilitation to quadriceps strengthening in patients with medial 
tibiofemoral OA and varus alignment, finding similar improvements in pain and 
function between groups but no changes in KAM32. In another RCT by the same lead 
author, hip strengthening was compared to no intervention in patients with medial 
tibiofemoral OA and varus alignment30. They found pain, function and muscle 
strength were all improved in the intervention group, but no significant changes in 
KAM were observed. A further RCT supported these findings, finding no significant 
differences in KAM between patients that had a six month resistance training 
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intervention compared to a sham intervention, despite symptoms improving104. This 
led the authors to conclude that the mechanism of action could be something other 
than improved joint loading. 
 
Chapter five in this thesis specifically identified studies treating patients with a 
meniscal deficient knee and systematically appraised the evidence for whether 
physiotherapy may reduce the risk of OA in these patients. 
 
2.12 Summary 
 
The menisci are complex structures that are not fully understood. They have a 
variable microstructure, which is thought to reflect the different stresses (and 
functions) in different parts of the meniscus. The primary function of the meniscus is 
load distribution; the loss of a meniscus results in negative biochemical and 
biomechanical changes and is a strong predictor of future OA. Both meniscal 
allograft transplantation and physiotherapy are used to treat patients with 
symptomatic meniscal deficient knees.  
 
Meniscal allograft transplantation has been used for over thirty years with multiple 
case series showing an improvement in PROMs. It is also scientifically plausible that 
it could reduce or delay the progression of OA. In chapters three and four, the 
literature was systematically reviewed to determine the current best evidence for 
whether meniscal allograft transplantation improves PROMs and reduces or delays 
the progression of OA respectively. 
 
 57 
Physiotherapy has a strong evidence base for improving pain and function in patients 
with symptomatic OA of the knee and is recommended as a treatment by NICE204. It 
is also a relatively safe treatment. It was therefore determined that physiotherapy was 
an appropriate comparator to meniscal allograft transplantation for the treatment of 
patients with a symptomatic meniscal deficient knee. 
 
It is less clear whether physiotherapy can reduce or delay the progression of OA in 
patients with a history of meniscectomy. In chapter five, the literature was 
systematically appraised to determine whether there was evidence that physiotherapy 
is chondroprotective in patients with a history of meniscectomy. 
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3.1 Introduction 
 
It was shown in chapter two that meniscal allograft transplantation was first 
performed over thirty years ago and then since then there have been many cases 
reported in the literature91. It has been advocated for the treatment of post-
meniscectomy symptoms, which can consist of pain, swelling and loss of function91, 
165. In 2011 a systematic review and meta-analysis (search performed in January 
2010) showed an improvement in symptoms and function but highlighted a lack of 
good quality studies91. Since then there have been a number of further studies, and 
longer follow up of some older studies have been reported. The primary objective of 
this study was to perform an updated systematic review of meniscal allograft 
transplantation for the treatment of the symptomatic meniscal deficient knee, using 
PROMs as the primary outcome measure. The secondary objective was to provide a 
review of the indications, associated procedures, operative technique, rehabilitation, 
failures, complications, radiological outcomes and graft healing. This was needed to 
identify whether there had been changes in the major components of meniscal 
allograft transplantation as a complex intervention. It also allowed a comparison 
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between common worldwide practice and local protocols. Ideally, they should be 
similar to allow a definitive evaluation to have high external validity. Deviations 
from common practice would need to be carefully considered before being 
implemented in the context of a definitive evaluation. 
 
3.2 Materials and Methods 
 
3.2.1 Quality of methodology 
 
This study has been reported in accordance with the PRISMA statement for 
reporting systematic reviews173. The protocol was published on PROSPERO, the 
York prospective register of systematic reviews prior to undertaking the searches 
(Appendix A).  
 
3.2.2 Eligibility criteria 
 
• Study type 
Any case series or clinical comparative study (including RCTs) written in the 
English language. Biomechanical studies, case reports and systematic 
reviews that did not contain new patient data were excluded 
 
• Participants 
Any human of any age 
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• Intervention 
Meniscal allograft transplantation using any allograft preserving method and 
any grafting type 
Any rehabilitation regime post-operatively 
 
• Comparator 
If a comparator group existed, it had to be a reasonable alternative treatment 
to meniscal allograft transplantation or a difference in meniscal allograft 
transplantation methodology, for example different allograft fixation 
technique 
 
• Outcome measures 
A study had to include a PROM at a minimum of one year post-operatively 
for every patient. Commonly used PROMs included Lysholm, IKDC and 
Tegner activity index, but any other PROM was accepted 
 
3.2.3 Search strategy 
 
A search was undertaken for both published and unpublished studies. The design of 
the search strategy was sensitivity maximising in order to reduce the risk of missing 
eligible studies. The published search strategy was developed using a combination of 
keywords and ‘subject headings’, which were exploded to maximise the inclusion of 
potentially relevant studies. The search strategy for Medline (Ovid) (Table 3-1) was 
adapted for Embase (Ovid) and the Cochrane library (CENTRAL). The references of 
eligible studies and previous systematic reviews were searched for other potentially 
relevant studies. Unpublished studies were searched according to recommendations 
from a recent article published in the British Medical Journal61. The World Health 
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Organisation International Clinical Trials Registry Platform and Clinical Trials 
Registry were searched for on going or complete trials. The Web of Science was 
searched for conference proceedings. 
 
 
Table 3-1: Search strategy for Ovid Medline (1946 to March week 3 2014), 
performed on the 2nd April 2014 
 
1 exp Menisci, Tibial/ 6007 
2 Menisc*.mp. 10957 
3 (allograft* or transplant*).mp.  519356 
4 1 or 2 10957 
5 3 and 4 796 
6 (case series or compar* or randomi* or clinical or 
trial*).mp. 
6121278 
7 5 and 6 469 
8 limit 7 to (english language and humans) 338 
 
 
3.2.4 Selection and appraisal method 
 
Figure 3-1 andFigure 3-2 are flow diagrams of the selection processes for published 
and unpublished studies respectively. Results of the database searches were 
transferred into EndNote and duplicates were automatically discarded. Pre-defined 
criteria were used to assess the eligibility of the remaining studies from their title and 
abstract. The full papers of the remaining studies were then reviewed.  
 
Data from eligible studies was extracted and studies that contained some or all of the 
same patients were grouped. In order to reduce the risk of duplicate publication 
bias138, the study with the longest mean follow up was included in the analysis, with 
the other studies cited in the references but excluded from further analysis.  
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Failures and complications were collected as reported by each study. If failures were 
not specifically defined, a failure was considered to be either the complete removal 
of the allograft, revision meniscal allograft transplantation or conversion to joint 
replacement. If complications were not defined, a complication was considered to be 
any reported adverse event that the patient experiences. 
 
Figure 3-1: Flow diagram for the appraisal of published studies 
 
Number of records 
identified through 
database search - 862 
  Medline      338 
  Embase    486 
  CENTRAL    38 
Number of duplicates 
removed - 214 
Records remaining 
after screening - 73 
Number of records 
removed after 
screening - 575 
Records remaining 
after full article review 
- 48 
Records remaining 
after duplicates 
removed - 648 
Number of records 
removed after full 
article review - 24 
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Figure 3-2: Flow diagram for the appraisal of unpublished studies 
 
3.3 Results 
 
Of the forty-eight eligible studies, thirteen contained some or all of the same patients 
as other eligible studies and were excluded34, 57, 110, 154, 155, 166, 168, 264-267, 274, 278. 
Therefore there were 1332 patients (1374 knees) in thirty-five studies included in 
this systematic review (Table 3-2). There were no prospective controlled trials, 
randomised or otherwise, eligible for inclusion.  
 
Number of records 
identified through 
search - 45 
Web of Science       39 
Clinicaltrials.gov      4 
WHO registry           2 
Number of duplicates 
removed - 0 
Records remaining 
after screening - 2 
Number of records 
removed after 
screening - 43 
Records remaining 
after full article review 
- 0 
Records remaining 
after duplicates 
removed - 45 
Number of records 
removed after full 
article review - 2 
Reasons for exclusion 
No PROMs included26 
 - 1 
Duplication of another study34
 - 1 
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The earliest study recruited patients from 1984287 and the last recruitment year from 
any study was 2010124. The follow up range across all studies was from one to 
twenty years, with a mean of 5.1 years. The youngest and eldest patients were 
thirteen205 and sixty-nine250 years old respectively, with a mean age at the time of 
surgery across all studies of 33.7 years. Of the 1332 patients, 762 were male and 343 
were female; the gender was not reported for 227 patients. There were 587 medial 
and 657 lateral allografts across all studies. 
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Table 3-2: Summary of included studies 
  
Author(s) Year Study type Participants PROM 
 
 
Chalmers et 
al.60 
2013 Retrospective case series 13 Lysholm, IKDC, 
Stone et al.252 2013 Case series 68 IKDC, Tegner, WOMAC 
Hardy et al.124 2013 Retrospective case series 22 Lysholm, IKDC, KOOS 
Abat et al.3 2012 Parallel prospective case 
series 
88 Lysholm 
Binnet et al.37 2012 Case series 4 Lysholm, Tegner 
Carter59 2012 Prospective case series 40 Lysholm, IKDC 
Kim et al.156 2012 Retrospective case series 106 Lysholm 
Koh et al.158 2012 Retrospective case series 99 Lysholm 
Marcacci et 
al.178 
2012 Prospective case series 32 Lysholm, IKDC, Tegner 
Saltzman et 
al.238 
2012 Retrospective case series 22 Lysholm, IKDC 
Zhang et al.295 2012 Prospective case series 18 Lysholm 
Jang et al.143 2011 Parallel prospective case 
series 
36 Lysholm 
Alenthorn et 
al.6 
2010 Retrospective case series 15 Lysholm, IKDC 
Ha et al.116 2010 Retrospective case series 36 Lysholm 
LaPrade et al.165 2010 Prospective case series 34 IKDC 
Vunderlinckx et 
al.279 
2010 Retrospective case series 34 Lysholm, Tegner 
Gommell et 
al.109 
2009 Case series 7 Lysholm, IKDC 
van der Wal et 
al.269 
2009 Case series 57 Lysholm, HSS 
Verdonk et 
al.275 
2009 Prospective case series 100 HSS pain and function 
Rue et al.233 2008 Prospective case series 30 Lysholm, IKDC, Tegner 
Bhosdale et 
al.35 
2007 Prospective case series 8 Lysholm 
Farr et al.102 2007 Prospective case series 29 Lysholm 
Hommen et 
al.131 
2007 Case series 20 Lysholm, Tegner 
Cole et al.68 2006 Prospective case series 36 Lysholm, IKDC, Tegner 
Rueff et al.234 2006 Retrospective case control 16 Lysholm, IKDC 
Sekiya et al.242 2006 Retrospective case series 25 Lysholm and IKDC follow 
up scores 
Stone et al.253 2006 Prospective case series 45 Self reported pain, activity 
and functioning 
Sekiya et al.241 2003 Retrospective case series 28 Lysholm follow up scores 
Yoldas et al.291 2003 Retrospective case series 31 Lysholm 
Ryu et al.235 2002 Retrospective case series 25 Lysholm, Tegner 
Wirth et al.287 2002 Prospective case series 
with retrospective control 
groups 
21 Tegner 
Rath et al.222 2001 Prospective case series 18 SF36 
Stollsteimer et 
al.250 
2000 Prospective case series 22 Lysholm, Tegner 
Cameron et al.53 1997 Case series 63 Tegner, Fulkerson 
Noyes et al.205 1995 Case series 82 ADLs and pain 
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3.3.1 Patient reported outcome measures 
 
The Lysholm score is graded from 0 (worst) to 100 (best) and was designed to assess 
outcomes following knee ligament surgery176. It was the most commonly used 
PROM, being used in 25 studies. The mean pre-operative score was 55.7 and at final 
follow up the mean score was 81.3 (Figure 3-3). A poor score is considered to be 
under 65, fair 65-83, good 84-90 and excellent over 90. Using these measures, the 
average pre-operative score was easily within the ‘poor’ range. At final follow up the 
score was ‘fair’, although close to the ‘good’ range.  
 
 
Figure 3-3: Follow up Lysholm scores. The y axis is ordered by length of follow up. 
Number of allografts in study (n). Jang a = Pollard size matched group, b = modified 
method of size matching. Koh a = medial allograft group, b = lateral. Abat a = suture 
only group, b = bone fixation group. 
 
5 0 6 0 7 0 8 0 9 0 1 0
0
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G o m m e ll  e t  a l .  (2 0 0 9 )  n = 7
Z h a n g  e t  a l .  (2 0 1 2 )  n = 1 8
J a n g  e t  a l .  (2 0 1 1 )  a  n = 1 8
J a n g  e t  a l .  (2 0 1 1 )  b  n = 1 8
H a  e t  a l .  (2 0 1 0 )  n = 3 6
K o h  e t  a l .  (2 0 1 2 )  a  n = 2 6
K o h  e t  a l .  (2 0 1 2 )  b  n = 7 3
C o le  e t  a l .  (2 0 0 6 )  n = 4 0
R y u  e t  a l .  (2 0 0 2 )  n = 2 6
Y o ld a s  e t  a l .  (2 0 0 3 )  n = 3 4
A b a t e t  a l .  (2 0 1 2 )  a  n = 3 3
A b a t e t  a l .  (2 0 1 2 )  b  n = 5 5
A le n th o rn  e t  a l .  (2 0 1 0 )  n = 1 6
R u e  e t  a l .  (2 0 0 8 )  n = 3 1
B h o s d a le  e t  a l .  (2 0 0 7 )  n = 8
C h a lm e rs  e t  a l .  (2 0 1 3 )  n = 1 3
S to lls te im e r  e t  a l .  (2 0 0 0 )  n = 2 3
M a rc a c c i  e t  a l .  (2 0 1 2 )  n = 3 2
K im  e t  a l .  (2 0 1 2 )  n = 1 1 0
F a r r  e t  a l .  (2 0 0 7 )  n = 2 9
R u e ff  e t  a l .  (2 0 0 6 )  n = 8
S a ltz m a n  e t  a l .  (2 0 1 2 )  n = 2 2
V u n d e r lin c k x  e t  a l .  (2 0 1 0 )  n = 3 5
C a r te r  e t  a l .  (2 0 1 2 )  n = 4 1
H o m m e n  e t  a l .  (2 0 0 7 )  n = 2 0
W ir th  e t  a l .  (2 0 0 2 )  n = 2 3
v a n  d e r  W a l e t  a l .  (2 0 0 9 )  n = 6 3
B in n e t e t  a l .  (2 0 1 2 )  n = 4
L y s h o lm  S c o r e  ( f o l lo w - u p )
F ig u r e  3 :  F o llo w -u p  L y s h o lm  s c o r e s
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The International Knee Documentation Committee (IKDC) subjective knee form 
evaluates symptoms and function in activities of daily living128. It was initially 
designed to assess ligament disruption in the knee but has been shown to be useful 
for a broad range of knee pathologies122. The range is from 0 (worst) and 100 (best). 
It was used in twelve studies; pre-operative and final follow up mean scores were 
47.8 and 70 respectively (Figure 3-4). These scores are consistent with the 
improvement seen in Lysholm scores, as pre-operative scores were very low for a 
young patient population and final follow up scores were significantly better but not 
near the best possible score.  
 
5 0 6 0 7 0 8 0 9 0 1 0
0
W e ig h te d  m e a n
G o m m e ll  e t  a l .  (2 0 0 9 )  n = 7
L a P ra d e  e t  a l .  (2 0 1 0 )  n = 3 4
C o le  e t  a l .  (2 0 0 6 )  n = 4 0
A le n th o rn  e t  a l .  (2 0 1 0 )  n = 1 6
R u e  e t  a l .  (2 0 0 8 )  n = 3 1
C h a lm e rs  e t  a l .  (2 0 1 3 )  n = 1 3
M a rc a c c i  e t  a l .  (2 0 1 2 )  n = 3 2
H a rd y  e t  a l .  (2 0 1 3 )  n = 2 2
R u e ff  e t  a l .  (2 0 0 6 )  n = 8
S to n e  e t  a l .  (2 0 1 3 )  n = 6 8
S a ltz m a n  e t  a l .  (2 0 1 2 )  n = 2 2
C a r te r  e t  a l .  (2 0 1 2 )  n = 4 1
I K D C  S c o r e  ( f o l lo w -u p )
 
Figure 3-4: Follow up IKDC scores. The y axis is ordered by length of follow up.  
Number of allografts in study (n). 
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The Tegner activity level scale is a single score from 0 (worst) to 10 (best) that 
denotes the highest activity level that the patient performs257. A level 0 would mean 
the patient is on sick leave due to knee problems, and 10 would mean the patient 
participates in national level football or rugby. It was used in 11 studies with pre-
operative and final follow up mean scores of 3.1 and 4.7 respectively (Figure 3-5). 
An activity level 3 is light work, 4 is moderately heavy work and 5 is heavy work, 
recreational jogging or competitive cycling. Levels 6 to 10 are recreational and 
competitive sports such as running, football and tennis. Based on the mean change 
between pre-operative and final follow up, there was a significant increase in activity 
levels. 
 
0 2 4 6 8
W e ig h te d  m e a n
C a m e ro n  e t  a l .  (1 9 9 7 )  n = 6 7
C o le  e t  a l .  (2 0 0 6 )  n = 4 0
R y u  e t  a l .  (2 0 0 2 )  n = 2 6
R u e  e t  a l .  (2 0 0 8 )  n = 3 1
S to lls te im e r  e t  a l .  (2 0 0 0 )  n = 2 3
M a rc a c c i  e t  a l .  (2 0 1 2 )  n = 3 2
S to n e  e t  a l .  (2 0 1 3 )  n = 6 8
V u n d e r lin c k x  e t  a l .  (2 0 1 0 )  n = 3 5
H o m m e n  e t  a l .  (2 0 0 7 )  n = 2 0
W ir th  e t  a l .  (2 0 0 2 )  n = 2 3
B in n e t e t  a l .  (2 0 1 2 )  n = 4
T e g n e r  s c o r e s  ( f o l lo w - u p )
 
Figure 3-5: Follow up Tegner scores. The y axis is ordered by length of follow up.  
Number of allografts in study (n). 
 
Some studies used other PROMs such as the Fulkerson questionnaire53, Short Form 
Health Survey (SF-36)222, Hospital for Special Surgery (HSS)275, Knee Injury and 
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Osteoarthritis Outcome Score (KOOS)124, Western Ontario and McMaster 
Universities Osteoarthritis Index (WOMAC)252, as well as pain and activities of 
daily living scores205. These showed improvements broadly in line with the more 
commonly used PROMs (results not shown).  
 
3.3.2 Indications 
 
The most frequently reported indications for meniscal allograft transplantation were 
a symptomatic (pain, swelling or stiffness) knee and a previous total or near total 
meniscectomy. Most studies did not define the extent of meniscectomy, although 
Farr et al. said that it should be within three millimetres of the posterior horn. The 
level or type of symptoms were not usually defined and only some studies required 
the symptoms to be present specifically on the same side of the knee as the 
meniscectomy. Most studies included an upper age limit or described eligible 
patients as ‘young’. Only two studies included patients over fifty-five years of age156, 
253. Severe cartilage damage or osteoarthritis were exclusion criteria for a significant 
number of studies68, 116, 131, 143, 156, 178, 222, 234, 242, 295, although were not for a limited 
number of other studies35, 53, 109. Normal alignment and/or a stable knee was a 
common requirement; this could usually be corrected intraoperatively68, 116, 143, 156, 178, 
222, 233, 242. 
 
3.3.3 Graft type 
 
The graft type was known in 1186 allografts. There were 796 fresh frozen, 269 
cryopreserved, 100 fresh and 21 lyophilized allografts used across all studies. 
Although cryopreserved and fresh frozen grafts were used in roughly equal numbers 
until 201091, all studies published since then have used fresh frozen grafts, with the 
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exception of a long term follow up case series of four grafts3, 37, 60, 124, 143, 156, 158, 178, 
295. This represents a significant change in practice from the previously reported 
systematic review by Elattar et al91. Grafts in earlier studies were irradiated53, 205 but 
this practice has now stopped. 
 
3.3.4 Operative technique 
 
The surgical technique was described in 1263 allografts. Earlier studies used an open 
technique, with collateral ligament detachment or joint distraction53, 235, 269, 287. Once 
an arthroscopic assisted technique had been pioneered, it quickly became the 
technique of choice. Bone bridge or plug fixation for the meniscal roots was the most 
common method, being used in 904 allografts (across twenty-six studies) whereas an 
all suture technique was used in 359 allografts (across thirteen studies). One study 
found more cases of major extrusion on MRI with their soft tissue fixation than their 
bone plug fixation, although PROMs were not significantly different between the 
groups3.  
 
3.3.5 Associated procedures 
 
Other knee procedures performed at the time of meniscal allograft transplantation 
were common. The inclusion criteria for a number of studies were a stable knee with 
normal alignment, which was often corrected intra-operatively with an osteotomy 
and/or ACL reconstruction. Other commonly reported procedures included articular 
cartilage repair procedures including autologous chondrocyte implantation (ACI) 
and microfracture. Only 243 allografts were clearly performed as isolated 
procedures, although this is likely to be higher as reporting of isolated meniscal 
allograft transplantation in some studies was either not clear or not described. In a 
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number of studies, all patients had associated procedures: ACI or osteochondral 
allograft transplantation234, ACL reconstruction241, chondroplasty and scar 
debridement253, ACL reconstruction and/or medial collateral ligament 
advancement287. 
 
3.3.6 Rehabilitation 
 
Although there were variations in post-operative rehabilitation, most studies reported 
a post-operative period of either partial or non-weight bearing and a restriction on 
flexion from zero degrees to between sixty and ninety degrees. Most studies had 
allowed full weight bearing by six weeks, with a gradual progression to running by 
three to six months. Return to full pivoting/cutting sports was controversial with 
some studies recommending lifelong limits116, 222, 241, 242, 291. However, it was more 
common to allow return to full sports, usually after six to twelve months6, 37, 60, 109, 
143, 178, 233, 250, 252, 275. Stone et al. reported a case series of patients with a pre-injury 
Tegner activity index score of eight or greater252. They found no correlation with 
post-operative sporting level and failure, concluding that patients with high pre-
injury sporting demands can return to sports after surgery. 
 
3.3.7 Failures and complications 
 
Failures were variably defined. One study defined failure as poor functional scores 
linked to poor appearance of the meniscus275, whilst another considered no 
improvement in pain or a poor Lysholm score to be a failure131. The most common 
definition of failure was conversion to a joint replacement or excision of the 
allograft. There were six studies (198 allografts) that did not show evidence of 
reporting possible failures37, 158, 234, 241, 242, 291. Therefore there were a total of 128 
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failures in 1174 allografts implanted at a mean of 4.8 years across included studies 
(10.9% failure rate). The study with the highest number of failures had 29 out of 96 
allografts at two year follow up205. They found no significant difference in mean 
activity of daily living and pain scores between failures and healed grafts.  
 
Complications were varied and included infection, synovitis, meniscal tears and 
partial meniscal detachments. Complications ascribed to concomitant procedures 
such as osteotomy or ACL reconstruction were also common. Six studies (238 
allografts) did not report complications59, 158, 234, 241, 242, 291. Therefore there were 154 
complications in 1134 allografts at a mean of 4.7 years across included studies 
(13.6% complication rate). 
 
3.3.8 Radiological findings  
 
Only a limited number of studies reported radiographic progression of OA at follow 
up. One study reported no change in Kellgren and Lawrence OA grade in twenty-
eight out of thirty-six knees on plain radiographs at a mean follow time of 2.6 
years116. One study reported no joint space narrowing110, whilst other studies 
reported small reductions in joint space at final follow up124, 131, 222. Two studies 
compared the joint spaces of the same compartment in the contralateral knee and 
found no statistically significant changes at baseline and final follow up in either 
compartment222, 241. Verdonk et al. reported no degeneration of femoral cartilage in 
forty-seven per cent and no degeneration in tibial cartilage in forty-one per cent of 
knees on MRI evaluation at an average of twelve years follow up275. 
 
MRI was commonly used to report meniscal extrusion at follow up. Major meniscal 
extrusion was most commonly defined as more than three millimetres extrusion on a 
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mid-coronal image. All studies reporting extrusion found evidence of significant 
extrusion, with most studies reporting either a mean extrusion of more than three 
millimetres or the majority of allografts classified as ‘extruded’ or ‘major’ 
extrusion3, 116, 124, 143, 156, 158, 178.  
 
3.3.9 Graft healing 
 
Ha et al. performed second look arthroscopy at an average of 26.3 months for 
various reasons116. They found that eleven allografts had completely healed to the 
capsule, whilst seven had partially detached; there were no cases of complete 
detachment. Rath et al. found that all ten allografts undergoing post-operative 
arthroscopy had completely healed to the capsule, and Wirth et al. found that 
seventeen of nineteen allografts had completely healed at post-operative 
arthroscopy222, 287.  
 
Hardy et al. performed MRIs on fourteen of twenty-one patients at six months post-
operatively finding fifty-seven per cent total healing, fourteen per cent partial 
healing and 29 per cent no healing according to the Henning criteria124. Noyes et al. 
devised a new score for graft healing using MRI and arthroscopy, reporting a forty 
per cent complete or partial healing rate205. 
 
3.3.10 Risk of bias 
 
• Missing studies 
There were no completed registered trials on any searched registry. Only studies 
written in the English language were reviewed, therefore some otherwise eligible 
studies may not have been included. 
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• Study type 
All studies included in this systematic review were case series. Some studies 
described control groups, but the selection for each intervention was for specific 
reasons, such as a change of technique part way through the study3. Therefore there 
is a high risk of selection bias in all included studies. A large number of studies were 
retrospective, which increases the risk of measurement error (Table 3-2).  
 
• Missing outcomes 
A number of studies did not report failures or complications. These were not 
included in the analysis of average complication and failure rate. A number of 
studies specifically excluded patients that had a ‘failed’ treatment from the analysis 
of PROMs68, 102, 238. It is likely that patients with failed treatments would have worse 
PROMs. Moreover, complications or failures were commonly not defined.  It is 
therefore unknown whether some studies did not consider some patients to have had 
a complication or failure when others did.  
 
3.4 Discussion 
 
This systematic review shows that there are significant improvements in all mean 
PROMs at final follow up. Given the average age at the time of surgery of 33.6 
years, baseline PROMs are very low, indicating the severity of the disease burden in 
patients undergoing meniscal allograft transplantation. It is also important to note 
that although there are significant gains in PROMs at final follow up, mean scores 
are still well below top scores in this young patient group. This may reflect either 
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non-modifiable damage to the knee or the failure of treatment to completely reverse 
symptoms. 
 
Indications for meniscal allograft transplantation varied amongst studies, but all 
studies required patients to have a symptomatic meniscal deficient compartment of 
the knee. Therefore it is reasonable that the success or failure of the treatment may 
be judged against symptom relief, as judged by PROMs. This systematic review has 
reported a consistent improvement in PROMs in the included studies. These results 
are roughly comparable to older systematic review results, despite there being many 
new studies reported76, 91, 126. This is the strongest evidence to date for the 
effectiveness of meniscal allograft transplantation in patients with a symptomatic 
meniscal deficient knee. The lack of RCTs means that inferences cannot be drawn 
with confidence, but the results do show that there is a reasonable chance that 
meniscal allograft transplantation is effective. This is an important MRC framework 
guidance objective to achieve before a pilot trial is undertaken75.    
 
One trend change in newer studies has been the more common usage of fresh frozen 
allografts over other preservative methods. Cryopreservation involves controlled 
freezing to around -196 degrees Celsius with the meniscus bathed in cryoprotectant 
and then thawed under strict protocols. There is no strong evidence that 
cryopreservation maintains the integrity of the meniscal allograft better than standard 
freezing185. Cryopreservation also requires strict thawing protocols, which are 
difficult to achieve in the clinical environment. These factors may have contributed 
to the increased use of fresh frozen allografts. 
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Performing meniscal allograft transplantation on patients with severe OA 
(radiographic or at arthroscopy) appears controversial, with the majority of studies 
excluding these patients. It is widely thought that these patients would have worse 
clinical outcomes and a high failure rate due to the adverse biomechanical 
environment in the knee276. However, this systematic review has shown that some 
studies did not exclude these patients, reporting reasonable results. Current practice 
at UHCW is to include patients with advanced cartilage damage. In chapter six a 
survival analysis was undertaken to determine whether severe cartilage damage is a 
predictor of failure. 
 
Another controversy is the method of meniscal root fixation. This systematic review 
shows that bone plug or bone bridge fixation remains the most popular method, 
although an all suture technique through bone tunnels is used in significant numbers. 
There is also a USA – Europe divide, with USA surgeons favouring bone techniques 
and European surgeons favouring soft tissue fixation. Abat et al. reported more cases 
of major meniscal extrusion on MRI in patients that had suture fixation of grafts 
when compared to bone plug fixation3. However conclusions from this should be 
drawn with caution as the two groups were not directly comparable and should thus 
the study should be considered as a parallel case series. Bone fixation is often done 
in the hope that it provides a stronger fixation, whilst an all suture technique is less 
technically demanding. A biomechanical study has shown a similar pull-out strength 
with either technique133, whereas another showed that a suture only technique allows 
a slightly higher contact pressure on the tibial cartilage186. 
 
In general the quality of evidence was low, with the vast majority of studies being 
case series. Due to the low quality of studies, there is a high risk of biased results. 
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Patients that were described as having a failed treatment were often excluded from 
analysis which could lead to an over estimation of the benefit of treatment. The wide 
variation in failures and complications also suggests that some reporting was more 
detailed than others. Therefore failures and complications may also be 
underreported. 
 
3.5 Conclusion 
 
This systematic review shows a consistent improvement in all used PROMs for 
meniscal allograft transplantation at final follow up. The quality of included studies 
was low and there were no RCTs. However, the results of this systematic review 
confirm that there is a reasonable chance that meniscal allograft transplantation 
improves PROMs in patients with a symptomatic meniscal deficient knee. The 
majority of studies excluded patients with severe radiographic OA (or advance 
cartilage damage on arthroscopy) due to the perceived increased risk of failure. This 
systematic review does not provide evidence to support the hypothesis that meniscal 
allograft transplantation is chondroprotective. This was addressed in chapter four of 
this thesis. 
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4.1 Introduction  
 
Chapter two demonstrated it is scientifically plausible that meniscal allograft 
transplantation might be chondroprotective. This is supported by animal studies150, 
256, but has yet to be adequately examined in humans126. Published systematic 
reviews have focussed on symptomatic relief and functional improvement following 
meniscal allograft transplantation76, 91, 126, 167. The systematic review in chapter three 
has also shown that clinical scores were consistently improved following meniscal 
allograft transplantation. Whilst longer term improvement (or lack of decline) in 
functional scores may be supportive of the hypothesis that meniscal allograft 
transplantation is effective, direct evidence that it is chondroprotective is needed. 
Therefore, the primary objective was to systematically review studies that have 
reported changes in radiological measures of OA progression following meniscal 
allograft transplantation. 
 
The scientific plausibility of the hypothesis that meniscal allograft transplantation is 
chondroprotective relies on the transplant functioning in a similar way to the native 
meniscus. Cadaveric studies have shown that it was able to perform the primary 
function of the native meniscus in a similar way by distributing load. The ability to 
perform this function in patients relies on the transplant maintaining its integrity 
within the knee over time. This cannot be replicated in cadaveric studies and must be 
assessed in patients following meniscal allograft transplantation. Therefore, the 
secondary objective was to systematically evaluate studies that had reported 
radiological measures of meniscal integrity following meniscal transplantation.   
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4.2 Materials and Methods 
 
4.2.1 Quality of methodology 
 
This study has been reported in accordance with the PRISMA statement for 
reporting systematic reviews173. The protocol was published on PROSPERO, the 
York prospective register of systematic reviews prior to undertaking the searches. A 
copy of the published protocol can be found in Appendix B. 
 
4.2.2 Eligibility criteria 
 
Study type 
• Any clinical study (RCT, non-randomised comparative study or case series) 
written in the English language. Studies that do not contain new patient data, 
biomechanical studies and case reports were excluded 
 
Participants 
• Any human of any age 
 
Intervention 
• Meniscal allograft transplantation using any allograft preserving method and 
any grafting technique 
• Any rehabilitation regime post-operatively 
 
Comparator 
• If a comparator group existed, it had to be a reasonable alternative treatment, 
for example a non-operative rehabilitation group. It was also considered 
reasonable to use the participants’ other knees as a comparator 
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Outcome measures 
• The primary outcome measure was change in any radiological OA 
progression measure at a minimum of one year post-intervention 
• The secondary outcome measures included MRI measures of the meniscus at 
a minimum of six months post-intervention, including: Meniscal appearance, 
signal intensity, healing and extrusion 
 
4.2.3 Search strategy 
 
The search strategy was sensitivity maximising in order to reduce the risk of failing 
to identify eligible studies. The published search strategy was developed using a 
combination of keywords and subject headings, which were exploded to maximise 
the inclusion of potentially relevant studies. The search strategy for Medline (Ovid) 
(Table 4-1) was adapted for Embase (Ovid) and CENTRAL. The references of all 
included studies were searched for further potentially relevant studies.  
 
Table 4-1: Ovid Medline search (1946 to May week 4, 2014), Performed on 9th June 
2014  
 
1 exp Menisci, Tibial/ 6117 
2 Menisc*.mp. 11153 
3 (allograft* or transplant*).mp.  526495 
4 1 or 2 11153 
5 3 and 4 808 
6 (case series or compar* or randomi* or 
clinical or trial*).mp.  
6223122 
7 5 and 6 473 
8 limit 7 to (English language and humans) 342 
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4.2.4 Selection and appraisal method 
 
Figure 4-1 shows a flow diagram of the selection process. Results of the database 
searches were transferred into EndNote reference manager and duplicates were 
discarded. Eligibility criteria were used to assess the remaining studies from the title 
and abstract. The full papers of any remaining studies were then reviewed. Two 
reviewers (NS and BP) independently assessed studies for eligibility. Any 
discrepancies were resolved by discussion and if that failed, by the judgement of TS.  
 
 
Figure 4-1: Flow diagram of the study selection process 
 
In order to reduce duplicate publication bias, if two or more eligible studies used 
some or all of the same participants, both studies were only included if different 
outcome measures were used138. If multiple studies with the same patient cohort 
were included on this basis, duplicated outcome measures were only be reported 
from the study with the longest follow up.   
Number of records 
identified through 
database search - 858 
  Medline      342 
  Embase    492 
  CENTRAL    24 
Number of duplicates 
removed - 223 
Records remaining 
after screening - 50 
Number of records 
removed after 
screening - 585 
Records remaining 
after full article review 
- 38 
Records remaining 
after duplicates 
removed - 635 
Number of records 
removed after full 
article review - 12 
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4.3 Results 
 
There were 1056 meniscal allograft transplantations included across thirty-eight 
studies that met the eligibility criteria (Table 4-2 and Table 4-3). A number of 
studies included some or all of the same patients as other included studies, but 
analysed different outcome measures3, 4, 79, 116, 143, 154-156, 166, 168-170, 265, 266, 272, 275. There 
were no RCTs, with the majority of studies being case series. Two studies used the 
contralateral knee as a comparator group222, 241. The indications for meniscal 
allograft transplantation in all studies were a symptomatic knee with a history of 
meniscectomy. Most patients were young, with nearly all patients being between 
fifteen and fifty years of age. The most common graft preservation technique was 
fresh frozen, although some studies used cryopreserved and some older studies used 
irradiation as well. Bone tunnels or bridges were the most common method of fixing 
the graft but a number of studies used an all suture technique. 
 
4.3.1 Osteoarthritis progression measures 
 
• Joint space width 
 
Sixteen studies with a total of 428 knees reported the change in joint space width 
between baseline and final follow up (Table 4-2). The semi-flexed weightbearing 
position was usually used for joint space width measurement, with Ha et al. also 
measuring joint space width in full extension116. The weighted mean joint space 
narrowing across all studies was 0.032 millimetres at a mean follow up of 4.5 years 
(Figure 4-2). Sekiya et al. used the contralateral knee for comparison of joint space 
width change, finding no significant differences and very similar mean joint space 
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width changes between the operative and contralateral (comparator) knees241. Rath et 
al. also used the same compartment in the contralateral knee, finding no significant 
differences, although there were only eleven patients222. Two studies looked for a 
correlation between meniscal extrusion and joint space narrowing, with Ha et al. 
finding a statistically significant intermediate correlation but Lee et al. finding no 
correlation116, 168. A number of studies found an increase in joint space width, but 
none were statistically significant4, 116, 154, 155. The majority of studies found a trend 
towards joint space narrowing, but only two studies reported a statistically 
significant joint space narrowing131, 168. 
 
 
Figure 4-2: Forest plot of joint space width loss in each study and a weighted mean 
using all studies. The X-axis denotes joint space width loss; therefore a negative 
number constitutes a joint space gain. Lateral meniscal allograft transplantation 
group (L), medial meniscal allograft transplantation group (M), bone fixation group 
(B), suture fixation group (S). 
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Abat et al. 2013 S
Abat et al. 2013 B
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Yoldas et al. 2003 M
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Sekiya et al. 2003 M
Sekiya et al. 2003 L
Ha et al. 2010
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• Kellgren and Lawrence classification 149  
 
The Kellgren and Lawrence (KL) classification is graded from 0 to 4, with grades 1 
and 2 depending on the size of the osteophyte, grade 3 depending on a moderate 
joint space narrowing and grade 4 needing additional subchondral sclerosis268. Three 
studies reported KL scores (Table 4-2). Vunderlinckx et al. had the longest mean 
follow up of 8.8 years, finding no change in nineteen of thirty-three patients279. The 
other two studies had a much shorter follow up, with Ha et al. reporting no change in 
twenty-eight patients and one grade worsening in eight patients at a mean 2.6 years; 
Chalmers et al. reported five patients with no change and five with progression at a 
mean of 3.3 years60, 116.  
 
• Fairbank classification 100  
 
Fairbank’s radiological signs include spurring of the tibial spines, marginal 
osteophytes, flattening of the femur/tibia and joint space narrowing100, 268. Three 
studies reported Fairbank’s classification, with varying outcomes (Table 4-2). Wirth 
et al. reported that twenty-one of twenty-three patients had less than two signs at 
baseline287. Eleven patients reached final follow up of fourteen years, all of which 
had progression to two or more signs. It was noted that seventeen of twenty-three 
patients had irradiated lyophilised grafts and only these patients had arthritic 
changes. Hommen et al. reported a mean pre-operative score of 0.5 and a mean score 
of 1.3 at follow up of 11.8 years (p=0.0001). They also reported a tendency for lower 
Lysholm scores if the Fairbank score had worsened, although this was not 
statistically significant131. The study by van Arkel et al. found no change in eighteen 
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and an improvement in five patients, although the study had a shorter follow up of 
three years265.  
 
• IKDC radiological scores139 
 
The IKDC radiological score was first presented in 1991, then modified in 2000 and 
is scored as: no changes, mild, moderate or severe - depending on the severity of a 
number of radiological markers (joint space narrowing, osteophytes and subchondral 
sclerosis)69, 139. Two studies used this classification, with Sekiya et al. finding 
minimal changes at a mean of 2.8 years and Graf et al. finding one grade worsening 
in one of eight patients at a mean of 8.5 years111, 241. 
 
• Articular Cartilage Changes on MRI 
 
Three papers had reported a modified Yulish score to grade articular cartilage 
degeneration on MRI (Table 4-3)294. The modified Yulish score consists of four 
grades, which correlate to the Outerbridge arthroscopic grading system of chondral 
lesions211, 274. Ha et al. noted an absence of further articular cartilage degeneration in 
seventy-eight per cent of patients at 2.6 years, with the remaining twenty-two per 
cent progressing by one or two grades116. Marcacci et al. reported a significant 
improvement in the mean articular cartilage degeneration by half a grade on both the 
femoral and tibial articular surfaces178. Verdonk et al. reported the longer term 
articular cartilage changes on seventeen patients over an average of twelve years274. 
There was no further progression of articular cartilage degeneration on the femoral 
condyle and tibial plateau in forty-seven per cent and forty-one per cent of patients 
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respectively, including thirty-five per cent of patients with no progression on both 
sides of the joint.  
 
• Other measures 
 
One study reported OA progression at two and ten year follow up with an 
indeterminate tool59. At two years there was no change in thirty-two of thirty-four 
patients, but by ten years nearly half of the patients had a mild change and five had 
moderate or severe progression of OA. 
 
Table 4-2: Studies with radiological OA progression measures. Bone fixation group 
(B), suture fixation group (S) 
 
Study Number of 
patients 
(allografts) 
Follow 
up mean 
– years 
(range) 
Number of 
allografts 
with x-ray 
follow up 
Joint space 
width - mm 
pre-op (follow 
up) 
Other OA 
progression measures 
Abat et al. 
(2013) 
88 (88) 5 (2.5-
10) 
88 S – 3.2 (3.2) 
B – 3.1 (3.5) 
 
Carter et al. 
(2012) 
40 (41) 10. 
X-ray 
follow up 
2 and 10 
years 
34  OA progression, 
number of patients: 
2 yrs: 32 no change, 2 
mild 
10 yrs: 14 no change, 
15 mild, 5 
moderate/severe 
Chalmers et 
al. (2013) 
13 (13) 3.3 (1.9-
5.7) 
10  KL change: 
5 - no change 
5 - 1 or more grade 
change 
Graf et al. 
(2004) 
8 (8) 9.7 (8.5 – 
10.3) 
8 Mean loss 
medial: 0.38 
(range -2.75 – 
1.75) 
Lateral: 
0.5mm (range 
0 – 1.75mm) 
IKDC radiographic 
scores: Pre op – 1 
normal, 5 abnormal, 
2 severely abnormal. 
Follow up – 1 
normal, 4 abnormal, 
3 severely abnormal 
Ha et al. 
(2010) 
36 (36) 2.6 (2 – 
3) 
36 Extension: 
5.07 (5.0) 
Rosenberg: 
4.14 (4.27) 
KL change: 
28 – no change 
8 – 1 grade worse 
Modified Yulish: 
78% no change 
22% 1 or 2 grades 
worse 
Hommen et 
al. (2007) 
20 (20) 11.8 (9.6 
– 13.9) 
15 5.15 (4) 12 of 15 patients had 
a worsening Fairbank 
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score. Mean scores: 
0.5 pre op and 1.3 
post op 
Kim et al. 
(2011) 
27 (29) 4.5 (2 – 
10.3) 
23 3.6 (3.7)  
Lee et al. 
(2010) 
43 (43) 5.1 (3.5 – 
8.3) 
43 All: 
3.65 (3.35) 
Extruded: 
4.14 (3.87) 
Non-extruded: 
3.3 (3.01) 
 
Marcacci et 
al. (2012) 
32 (32) 3.4 (3 – 
5.5) 
32 (MRI)  Modified Yulish 
(median): 
Femoral pre op 1.5, 
follow up 1 
Tibial pre op 1, 
follow up 0.5 
Noyes et al. 
(2004) 
38 (40) 3.3 (2 – 
5.7) 
40 3 knees 
showed joint 
space loss 
 
Rath et al. 
(2001) 
18 (22) 5.4 (2 – 
8) 
11 5.2 (4.5). 1 
patient lost 
more than 
1mm 
 
Ryu et al. 
(2002) 
25 (26) 2.8 (1 – 
6) 
8 (min 2 
years fu) 
5 - no change 
2 – 1-2mm 
loss 
1 – >2mm loss 
 
Saltzman et 
al. (2012) 
22 (22) + 3 
failed + 4 
not 
accounted 
for 
8.5 (6.8 – 
11.2) 
6 (mean 
8.8 years 
fu) 
2 – no loss 
2 – minor loss 
1 – mild/mod 
loss 
1 – loss 
 
 
Sekiya et al. 
(2003) 
28 (28) 2.8 (1.8 – 
5.6) 
26 Mean loss 
Medial: 
Transplant 
0.05 
Control 0.1 
Lateral: 
Transplant 
+0.6 
Control +0.4 
IKDC radiographic 
scores: 
Pre op: 6 normal, 13 
nearly normal, 7 
abnormal, 3 severely 
abnormal 
Post op: 4 normal, 12 
nearly normal, 10 
abnormal, 2 severely 
abnormal 
Stollsteimer 
et al. (2000) 
22 (23) 3.3 (1.1 – 
5.8) 
23 Mean loss 
0.88 (range 0-
3) 
 
van Arkel et 
al. (1995) 
23 (23) 3 (2 – 5) 23  Fairbank’s criteria: 
18 – no change 
5 - improvement 
Verdonk et 
al. (2006) 
38 (39) 12.1 (10 
– 14.8) 
25 (mean 
12 year fu) 
13 – no loss 
12 – 
unspecified 
loss 
Modified Yulish: 
No change femoral 
side in 47%. No 
change on tibial 
plateau in 41% 
Vunderlinck
x et al. 
(2010) 
34 (35) + 5 
failures 
8.8 (5.2 – 
14.1) 
33  KL grade: 
19 – no change 
8 – 1 grade worse 
6 – 2 grades worse 
Wirth et al. 
(2002) 
23 (23) 14 (14) 23  Fairbank’s criteria: 
Pre op: 8 no changes, 
13 grade 1, 1 grade 2. 
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3 year fu: 3 no 
changes, 9 grade 1, 4 
grade 2, 3 grade 3. 
14 year fu: 6 grade 2, 
5 grade 3 
Yoldas et al. 
(2003) 
31 (34) 2.9 (2- 
5.5) 
34 Medial: 
4.9 (5.2) 
Lateral: 
4.1 (4.9) 
 
Zhang et al. 
(2012) 
18 (18) 2.1 (1.5-
3.4) 
18 Median: 4.5 
(4.5) 
 
 
4.3.2 Magnetic resonance imaging measures 
 
Twenty-six of the thirty-eight studies included in this systematic review reported 
MRI findings following meniscal allograft transplantation.   
 
• Meniscal extrusion 
 
Eighteen of the twenty-six studies with MRI outcomes reported meniscal extrusion, 
with variable techniques (Table 4-3). The methods used to report meniscal extrusion 
included the absolute number of millimetres the graft extended beyond the edge of 
the tibial plateau, the relative percentage extrusion of the meniscus that extended 
beyond the edge of the tibial plateau, as well as a variety of classification systems. 
The most commonly reported classification defined extrusion as: No extrusion, 
minor extrusion (less than three millimetres) and major extrusion (more than three 
millimetres), in relation to the margin of the tibial plateau3, 72, 143, 168, 274, 295.   
 
All studies reported there was extrusion in the majority of patients, with eleven 
studies reporting an average extrusion of between 1.7 mm and 5.8 mm64, 79, 124, 143, 156, 
158, 168, 169, 207, 272, 292. Eight studies quantified extrusion by the relative percentage 
extrusion of the meniscal allograft and reported a mean range from 19.4 to 56.7%3, 79, 
124, 143, 156, 158, 169, 292. Six studies (eight groups) compared the amount of extrusion 
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between medial and lateral meniscal allografts, with three finding no difference3, 143, 
three finding more lateral extrusion79, 158, 178 and two finding more medial 
extrusion79, 292. 
 
The correlation between meniscal extrusion and clinical outcomes had been analysed 
by ten studies, with seven finding no significant association3, 124, 143, 158, 168, 178, 273. 
Potter et al. reported poorer clinical outcomes in eleven patients with meniscal 
extrusion, although these patients represented a subset that all had moderate to 
severe articular cartilage degeneration at the time of transplantation219. Yoon et al. 
and Lee et al. found an association between meniscal extrusion and Lysholm score 
but no did not discuss the finding any further168, 292.  
 
Four papers investigated the effect of surgical technique on the amount of meniscal 
extrusion. Abat et al. reported a relative percentage extrusion of 36.3% with root 
fixation using sutures through bone tunnels, compared to 28.1% with root fixation 
using bone plug fixation4. There was no association found between the degree of 
extrusion and functional scores. Choi et al. evaluated the position of the bone bridge 
in lateral meniscal transplants, finding an association with meniscal extrusion and 
increased lateral positioning of the bone bridge64. Jang et al. compared the traditional 
Pollard sizing technique to Pollard minus five per cent sizing143. The relative 
percentage extrusion decreased from 46.7% to 35.2%, but no difference in clinical or 
other radiographic outcomes was found. De Coninck et al. compared open to 
arthroscopic surgical technique for meniscal allograft transplantation79. In the open 
technique, the meniscal roots were sutured to the capsule and native meniscal 
remnants, while in the arthroscopic technique the meniscal roots were secured by 
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suture fixation through bone tunnels. They found significantly less meniscal 
extrusion with the arthroscopic technique. 
 
Three papers evaluated the change in meniscal extrusion over time. Lee et al. 
evaluated meniscal extrusion over the first year post-operatively by serial MRI scans 
(six weeks, three, six and twelve months), finding that average meniscal extrusion 
didn’t differ at any time point169. Hardy et al. reported 2.7 mm meniscal extrusion at 
six months post-operatively and 3.6 mm at final follow up of 4.4 years124. The series 
consisted of twenty-two patients and it was not stated if the MRI scans at final 
follow up were from the same patients as the six month MRI scans. Verdonk et al. 
evaluated the long term change in meniscal extrusion from one year to an average of 
twelve years, finding progressive meniscal extrusion in fifty-nine per cent of 
cases274. However extrusion had no correlation with progressive articular cartilage 
degeneration or any of the clinical outcome measures.   
 
All except two studies evaluated meniscal extrusion with knees in a non-weight 
bearing position. Noyes et al. performed MRI scans on twenty-nine meniscal 
allografts under weight bearing conditions and demonstrated a mean of 2.2 mm 
extrusion206. Verdonk et al. evaluated the effect of weight bearing on meniscal 
extrusion with the use of ultrasound272. Ten transplanted lateral meniscal allografts 
and ten healthy lateral menisci were studied in the supine non-weight bearing 
position, bipedal stance and unipedal stance. Mean extrusion was higher in all 
positions for the transplanted menisci compared to normal menisci. The mean 
extrusion however did not increase during weight bearing conditions in either group. 
 
• Signal intensity 
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Ten studies reported on the signal intensity characteristics of meniscal allografts, 
with all but one study reporting altered and increased signal changes in the majority 
of the meniscal allografts (Table 4-3). Lee et al. evaluated the intra-meniscal signal 
intensity of forty-three meniscal allografts with serial MRI scans over the first year 
(six weeks, three, six and twelve months)170. They standardised the signal intensity 
within the meniscal allograft to the normal ipsilateral meniscus. The intra-meniscal 
signal intensity was higher within all the allograft menisci at all time points, with a 
significantly increased signal starting at three and six months for the anterior and 
posterior horns respectively. They found no correlation between intra-meniscal 
signal intensity and clinical outcomes. Hardy et al. also reported on the meniscal 
allograft appearance at six months and 4.4 years124. At six months they found eighty-
six per cent of menisci returned a normal homogenous appearance, compared to only 
26% at 4.4 years. Verdonk et al. found the majority of meniscal allografts had 
increased signal intensity at twelve years, with eighty-two per cent having no 
progression of their signal intensity from one year to final follow up274.   
 
• Meniscal size and shape 
 
Ten studies reported size and shape changes of meniscal allografts after 
transplantation (Table 4-3). Meniscal shrinkage was reported by multiple studies, 
with Carter et al. demonstrating an average of seven per cent volume loss over the 
first six months58. Kim et al. and Zhang et al. found shrinkage to predominantly 
affect the anterior horn of the meniscus156, 295. Zhang et al. also performed a second 
look arthroscopy, which confirmed atrophy and fraying of the anterior meniscus 
horn that corresponded to the MRI changes in the same region.   
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• Meniscal healing  
 
MRI assessment of allograft healing to the capsule was reported by six studies 
(Table 4-3). Three studies reported a healing rate of 100%35, 168, 178, whilst the others 
reported some partial and non-healing menisci. The study by van Arkel et al. 
correlated MRI healing to arthroscopic healing at a mean of three years post 
operatively on nineteen patients. They found complete healing in sixty-three per 
cent, partial healing in twenty-six per cent and no healing in eleven per cent of cases 
on MRI scans. However, MRI was found to underestimate healing rates; the cases 
with partial healing on MRI were found to be completely healed at arthroscopy and 
the cases with no healing on MRI were found to be partially healed at arthroscopy. 
 
Table 4-3: Studies with MRI measures of meniscal integrity. Full weight bearing 
(FWB), partial weight bearing (PWB), week (w), month (m), suture fixation group 
(S), bone fixation group (B), medial meniscus group (MM), lateral meniscus group 
(LM) Relative percentage extrusion (RPE).  
 
 
Study No. 
patients 
(knees) 
Follow 
up mean 
– years 
(range) 
No. 
MRI 
MRI 
Signal 
Intensity 
MRI extrusion  
 
Minor <3mm 
Major >3mm 
MRI – size 
and shape 
MRI – 
allograft 
healing 
Abat et 
al. 
(2012) 
88 (88) Min 3 
yrs 
88  S: RPE 36.3% 
Minor 27% 
Major 73% 
B: RPE 28.1% 
Minor 69% 
Major 31% 
  
Bhosdale 
et al. 
(2007) 
8 (8) 3.2 (2-6) 5 Increased 
internal 
100% 
 Wedge 
100% 
Flattened 
40% 
Expanded 
20% 
Irregular 
surface 
margin 
80% 
Healed 
100% 
Carter 
(2013) 
25 (25) 0.5 25   Shrinkage 
avg 7% (0-
22%) 
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Choi et 
al. 
(2011) 
23 (23) 0.5 23  Mean 3.2mm   
Ha et al. 
(2010) 
36 (36) 2.6 (2 – 
3) 
36    Complete 
72% 
Partial 
28% 
Hardy et 
al. 
(2013) 
22 (22) 4.4 (2.8 – 
6) 
14 at 
6m 
17 at 
final 
6m - 
Heteroge
neous 
14% 
Final - 
Heteroge
neous 
74% 
6m – mean 
2.7mm 
RPE 36.7% 
Final – mean 
3.6mm 
RPE 46% 
 6m – 
Complete 
healing 
57% 
Partial 
healing 
14% 
Not healed 
29% 
Hommen 
et al. 
(2007) 
20 (20) 
+ 2 
without 
scores 
11.8 (9.6 
– 13.9) 
7 Grade 3 
71% 
 All 
moderate 
shrinkage 
 
Jang et 
al. 
(2011) 
36 (36) 2.6 (2-3) 36  Traditional 
Pollard: 
Mean 4.1mm 
RPE 46.7% 
None 6% 
Minor 11% 
Major 83% 
Modified 
Pollard: 
Mean 3.7mm 
RPE 35.2% 
None 6% 
Minor 28% 
Major 66% 
  
Kim et 
al. 
(2012) 
106 
(110) 
4.1 (2 – 
13.6) 
108 Normal 
7% 
Variable 
93% 
Mean 3.7mm 
RPE 42.6% 
Normal 
volume 
69% 
Atrophy 
3% 
Atrophy 
anterior 
horn 19% 
Atrophy 
posterior 
horn 4% 
Swollen 
anterior 
horn 5% 
 
Lee et al. 
(2012) 
31 (31) 1 31   Shrinkage: 
Minimal 
65% 
Mild 19% 
Moderate 
16% 
Severe 0% 
Width 
midbody 
89% 
Thickness 
midbody 
115% 
 
Lee et al. 43 (43) 1 43 Higher    
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(2011) signal 
intensity 
100% 
Lee et al. 
(2010) 
43 (43) 5.1 (3.5 – 
8.3) 
43  Mean 3.0mm 
Minor 60% 
Major 40% 
 Healed 
100% 
Lee et al. 
(2008) 
21 (21) 1 21  6w: Mean 
2.9mm RPE 
29.2% 
3m: Mean 
2.9mm RPE 
29.4% 
6m: Mean 
3.0mm RPE 
32.4% 
12m: Mean 
2.9mm RPE 
31.9% 
  
Koh et 
al. 
(2012) 
99 (99) 2.7 (2 – 
4.9) 
99  LM: Mean 
4.7mm RPE 
52% 
MM: Mean 
2.9mm RPE 
31.2% 
  
Marcacci 
et al. 
(2012) 
32 (32) 3.4 (3 – 
5.5) 
32  % of grafts 
with extrusion 
– 69% overall 
MM 50% 
LM 87% 
 Healed 
100% 
Noyes et 
al. 
(2004) 
38 (40) 3.3 (2 – 
5.7) 
29 
FWB 
or 
PWB 
condi
tions 
Normal 
3% 
Grade 1 
45% 
Grade 2 
38% 
Grade 3 
10% 
Mean 2.2mm 
<25% 
meniscal 
width 59% 
26 – 50% 
meniscal 
width 38% 
>50% 
meniscal 
width 3% 
  
Potter et 
al. 
(1996) 
24 (29) 1 (0.25 – 
3.4) 
29 Increased 
periphera
l signal 
100%. 
Increased 
signal 
posterior 
horn 
attachme
nt site 
63% 
Moderate 24% 
Severe 14% 
  
Rankin et 
al. 
(2006) 
8 (8) 2 (1.3 - 
2.8) 
8 
FWB 
  Mean 
height and 
width 
similar to 
normal 
meniscus 
 
Stollstei
mer et al. 
(2000) 
22 (23) 3.3 (1.1 – 
5.8) 
12 Increased 
signal 
42% 
No extrusion 
92% 
Minor 8% 
Volume 
shrinkage 
to 62% of 
normal 
 
van 
Arkel et 
16 (19) 2.6 (1.2 
4.6) 
19  Sub extrusion 
65% 
Moderate 
shrinkage 
Complete 
healing 
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al. 
(2000) 
Complete 
extrusion 35% 
 
21% 
Severe 
shrinkage 
21% 
63% 
Partial 
healing 
26% 
Failed to 
heal 11% 
Verdonk 
et al. 
(2004) 
17 (17) 2 (0.5 – 
9.25) 
17  Mean 5.8mm   
Verdonk 
et al. 
(2006) 
38 (39) 12.1 (10 
– 14.8) 
1yr: 
25 
1 & 
10yr: 
17 
10yr: 
Normal 
41% 
Increased 
signal 
59% 
 
Minor 24% 
Major 76% 
 
  
 
De 
Coninck 
et al. 
(2012) 
37 (37) 1 37  Open: 
MM - Mean 
4.7mm RPE 
56.7% 
LM – Mean 
4mm RPE 
50.3% 
Arthroscopic: 
MM – Mean 
2.4mm RPE 
40.1% 
LM – Mean 
3.4mm RPE 
35.1% 
  
Wirth et 
al. 
(2002) 
23 (23) 14 (14) 9   Fresh 
frozen 
grafts 
maintained 
size. 
Lyophilize
d grafts 
major 
shrinkage 
 
Yoon et 
al. 
(2014) 
91 (91) 3.3 (2 – 
10.4) 
35  LM Mean 
1.7mm RPE 
19.4% 
MM Mean 
2.6mm RPE 
36.4% 
  
Zhang et 
al. 
(2012) 
18 (18) 2.1 (1.5-
3.4) 
17 Normal 
18% 
Grade 1 
58% 
Grade 2 
12% 
Grade 3 
12% 
Minor 35.3% 
Major 64.7% 
Atrophy 
anterior 
horn 18% 
Absent 
anterior 
horn 18% 
 
 
 
 
 98 
4.3.3 Risk of bias 
 
• Missing studies 
Only published studies were searched for, which may exacerbate publication bias. 
Secondly, studies written in languages other than English were not included, which 
may have resulted in some important studies being lost. 
 
• Missing outcomes 
Most studies had patients that were lost to follow up. Whilst this is inevitable, 
especially in studies with long term follow up, it can introduce bias. It was common 
for studies to exclude failures from follow up assessment. This is highly likely to 
bias results towards better outcome scores. It was also common for some patients to 
not have imaging at follow up. It was not always clear why some patients did and 
others did not have follow up imaging, but this was a potential source of bias. 
 
4.4 Discussion  
 
There has been substantial research interest in assessing whether interventions can 
modify the long term disease process of OA. Radiological markers for joint damage, 
especially joint space narrowing, have become widely accepted as appropriate 
surrogate measures of OA progression and have been recommended as the outcome 
measure of choice by regulatory agencies in the United States and Europe38. It has 
been shown that joint space narrowing is highly predictive of the need for future OA 
related surgery (usually total knee replacement)49. Bruyere et al. found that the 
relative risk for future OA related surgery with a joint space narrowing of 0.7 mm or 
more over three years was 5.15 (95% confidence interval 1.7 – 15.6)49. A recent 
systematic review assessing the imaging options for OA progression concluded that 
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joint space narrowing was the only imaging tool that should be recommended for the 
assessment of OA progression in clinical trials115. Given that patients with a 
symptomatic meniscal deficient knee have a high rate of knee OA progression, the 
negligible (0.032 mm) joint space narrowing at 4.5 years in patients following 
meniscal allograft transplantation provides some support for the hypothesis that it 
may be chondroprotective. As well as this, the two studies that used the contralateral 
normal knee as a comparator of joint space changes found no significant differences 
between the groups at final follow up.  
 
It is possible that joint space width on plain radiography is not an accurate measure 
of cartilage loss in patients undergoing meniscal allograft transplantation because 
joint space width is affected by meniscal volume and position137. Other limitations of 
plain radiography is that it is insensitive to early changes or focal disease, and joint 
space width can be affected by changes in the other compartment62. The NICE OA 
guidelines state that valid structural measures of OA progression include MRI 
features of OA, as well as joint space width204. High resolution MRI is increasingly 
being used as a surrogate endpoint for OA in studies as it is has been shown to be 
more sensitive and precise42. Common MRI measures include cartilage volume or 
thickness change, T2 mapping, bone marrow lesions, measurement of focal cartilage 
lesions and bone shape change. Recent studies have shown that statistically 
significant changes in cartilage volume and thickness can be seen at one year on 
MRI223, 283. It has further been shown that higher cartilage losses are predictive of the 
need for future knee replacement66, 223. A recent systematic review on the use of MRI 
measures concluded that cartilage volume or thickness change was a viable 
alternative to joint space width and likely to require fewer participants in RCTs, 
compared to joint space width215. Therefore cartilage volume change was thought to 
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be the most appropriate primary outcome measure in the pilot RCT comparing 
meniscal allograft transplantation to physiotherapy. 
 
One of the difficulties with measuring joint space width is that it is time consuming 
and requires expertise in MRI segmentation techniques. There are relatively few 
groups that have published studies with MRI volume analysis. One such UK based 
company is IMorphics, who are based in Manchester. They are world leaders in 
image analysis and have published their measurement error associated with their 
techniques, which is favourable to other published studies46, 283. There is also a 
history of previous successful collaborations between IMorphics and Charles 
Hutchinson, the author’s supervisor. Therefore IMorphics were used in the pilot 
RCT to perform the MRI image analysis.  
 
The underlying principle of meniscal allograft transplantation is to restore normal 
meniscal coverage of the tibial plateau so that it can improve contact biomechanics 
of the knee. Meniscal extrusion is a surrogate marker to assess the extent to which 
this has been achieved; minimal extrusion implies good tibial plateau coverage, and 
vice versa. Studies on native menisci have shown that extrusion is associated with 
accelerated chondral loss and OA137, 152, 244, 255. It has not been established whether 
extrusion is an appropriate measure in meniscal allograft transplantation. This 
systematic review found no clear association between extrusion and other adverse 
outcomes, suggesting that extrusion may not be an appropriate outcome measure. 
This may be because meniscal sizing is imprecise and it is possible for an oversized 
meniscal allograft to restore adequate tibial plateau coverage, whilst exhibiting a 
large amount of extrusion187. It is also possible that an undersized or shrunken graft 
does not restore plateau coverage, whilst having minimal extrusion. An additional 
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limitation is that extrusion was measured in the coronal plane at a single point (the 
midbody position). Noyes et al. and Marcacci et al. demonstrated minimal extrusion 
in the sagittal plane, suggesting the assumption that extrusion is uniform may be 
incorrect for meniscal allograft transplantation178, 206. Therefore measuring extrusion 
at a single point on a single plane may not be an accurate measure of either total 
extrusion or tibial plateau coverage. High resolution MRI may be able to provide a 
better measure by 3D modelling the meniscus and tibial plateau.  
 
MRI has become the investigation of choice to assess meniscal allograft integrity 
and healing, as it is cost effective and non-invasive. This systematic review found 
high rates of meniscal healing to the capsule, whilst signal intensity and meniscal 
shape was predominantly altered. Studies have shown that the meniscus is 
repopulated by cells resembling fibrochondrocytes in the first six months, but the 
normal meniscal collagen architecture, orientation and histological appearance was 
changed15, 16. A correlation between MRI and histological appearance has been 
shown, with biopsies from areas of homogenous low signal demonstrating a near 
normal collagen appearance and biopsies from areas of high signal showing a 
disorganised collagen appearance219. Concerns remain over the consequences of this 
altered tissue structure and the ability of a meniscal allograft to provide 
chondroprotection, but no association with clinical outcomes has been found170, 206, 
274. 
 
4.4.1 Limitations 
 
The quality of included studies was low, with a high risk of selection and 
measurement bias. The limited number of studies using control groups also limits the 
value of results, especially when interpreting OA progression. The studies included 
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in this systematic review are also heterogeneous, with different inclusion criteria, 
techniques, graft type, associated procedures, rehabilitation and follow up. This 
makes a formal meta-analysis inappropriate and limits the strength of conclusions. 
 
4.5 Conclusions 
 
Given the lack of high quality controlled trials, it is difficult to draw definitive 
conclusions. It appears that meniscal allograft transplantation cannot universally 
reverse or prevent OA changes in patients with a symptomatic meniscal deficient 
knee. Some studies showed minimal progression of OA in the long term and the 
mean weighted joint space narrowing was also negligible. These results provide 
limited for support the hypothesis that meniscal allograft transplantation may be 
chondroprotective. Given the scientific plausibility that meniscal allograft 
transplantation may reduce or delay the progression of OA and the limited 
supporting clinical evidence, a formal evaluation of the intervention is warranted. 
The first stage of this is developing a pilot trial, which was achieved in chapter seven 
of this thesis. 
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5 Physiotherapy for the Treatment of the Meniscal 
Deficient Knee: A Systematic Review 
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5.1 Introduction 
 
In chapter two it was shown that meniscectomy results in deleterious biomechanical 
changes in the knee, with a subsequent high risk of developing OA. It was also 
shown that it is scientifically plausible that physiotherapy could alter the adverse 
biomechanics, with a potentially delayed or reduced progression of OA in these 
patients.  
 
Physiotherapy has been shown to be effective in treating patients with symptomatic 
OA of the knee and is recommended by NICE204, 263. It has also been shown to 
improve function in patients following meniscectomy, in the immediate post-
operative period80. However, it has not been established whether a physiotherapy 
programme can reduce symptoms and OA progression in patients outside of the 
immediate post-operative period. In order to make a full assessment of 
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physiotherapy as a comparator in the RCT, the objective of this study was to perform 
a systematic review of studies that have assessed physiotherapy interventions in 
patients with a history of meniscectomy, using outcome measures assessing OA risk, 
progression and/or symptomatic change.  
 
5.2 Methods 
 
This study has been reported in accordance with the PRISMA statement for 
reporting systematic reviews173. A protocol for this systematic review was published 
before the searches were performed and can be viewed in Appendix C. 
 
5.2.1 Eligibility criteria 
 
Study type 
• Any clinical study (RCT, non-randomised comparative study or case series) 
written in the English language. Studies that did not contain new patient data, 
for example systematic reviews were excluded, as well as case reports 
 
Participants 
• Participants must have had a previous partial or total meniscectomy and be 
out of the early post-operative period (minimum twelve weeks before being 
recruited/studied) 
• Participants that did not have a previous (partial or total) meniscectomy prior 
to entering the study were excluded 
 
Intervention 
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• Any exercise based intervention designed to address the lower limb, 
delivered or administered by a physiotherapist or equivalent health care 
practitioner 
• No minimum or maximum intervention period 
 
Comparator 
• A comparator was not a requirement for inclusion but any reasonable 
comparator was appropriate, including but not limited to, a different exercise 
intervention, a placebo or further surgery 
 
Outcome measures 
• Any outcome measures that assessed risk or progression of OA, or any 
outcome measures that assessed symptoms or function were considered 
acceptable. Studies were excluded if none of these were reported 
 
5.2.2 Search strategy 
 
The search strategy was developed using a combination of keywords and subject 
headings, which were exploded to maximise the inclusion of potentially relevant 
studies. The search strategy for Medline (Ovid) (Table 5-1) was adapted for Embase 
(Ovid), CENTRAL and the Physiotherapy Evidence Database (PEDro). The 
references of all included studies were searched for further potentially relevant 
studies.  
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Table 5-1: Ovid Medline search, performed on the 26th March 2015 
 
1 Physical Therapy Modalities/ or Physical Therapists/ 
2 (physical therapy or physiotherapy).mp.  
3 exp Exercise Therapy/ or exercise.mp. 
4 1 or 2 or 3 
5 (meniscectom* or menisectom*).mp.  
6 Menisci, Tibial/ or menisc*.mp. 
7 (loss or deficien* or removal).mp.  
8 6 and 7 
9 5 or 8 
10 4 and 9 
11 limit 10 to (english language and humans) 
 
 
5.2.3 Selection and appraisal method 
 
Figure 5-1 shows a flow diagram of the selection process. Results of the database 
searches were transferred into EndNote reference manager and duplicates were 
discarded. Our eligibility criteria were used to assess the remaining studies using the 
title and abstract. The full papers of any remaining studies were then reviewed. Two 
reviewers (NS and IA) independently assessed studies for eligibility. Any 
discrepancies were resolved by discussion and if that failed, by the judgement of 
MC.  
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Figure 5-1: Flow diagram of the study selection process 
 
5.3 Results 
 
The literature search revealed three eligible papers (Table 5-2), although it was 
determined that the paper by Ericsson et al. was a secondary analysis of the study by 
Roos and Dahlberg. Both papers were included as they offered different analyses, 
but it is important to note that the underlying study was the same. Both included 
studies were RCTs comparing a form of physiotherapy to a control group of no 
intervention. 
 
 
 
 
 
Number of records 
identified through 
database search - 378 
  Medline      143 
  Embase    180 
  CENTRAL    32 
  PEDro   23 
Number of duplicates 
removed - 44 
Records remaining 
after screening - 37 
Number of records 
removed after 
screening - 297 
Records remaining 
after full article review 
- 3 
Records remaining 
after duplicates 
removed - 334 
Number of records 
removed after full 
article review - 34 
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Table 5-2: Results of the three eligible papers  
 Paper 
Roos and Dahlberg228 Ericsson et al.98 Hall et al.120 
Study 
design 
RCT Secondary analysis of first RCT 
by Roos and Dahlberg et al. 
RCT 
Number in 
study 
166 invited. 81 positive 
responses. 56 eligible and 
randomised, 30 completed 
follow up 
166 invited. 81 positive 
responses. 56 eligible and 
randomised, 30 completed 
follow up 
415 screened, 259 eligible, 62 
randomised, 2 lost to follow 
up 
Participants Aged 35 – 45 years. History 
of a medial arthroscopic 
partial meniscectomy 
between 3 and 5 years prior 
to study. Exclusion: ACL 
rupture, marked visible 
bone on arthroscopy, 
physical limitations due to 
co-morbidities, depression, 
sick leave or disability 
pension, lack of walking 
ability, competitive athletes 
Aged 35 – 45 years. History of 
a medial arthroscopic partial 
meniscectomy between 1 and 6 
years prior to study. Exclusion: 
ACL rupture (either knee), 
marked visible bone on 
arthroscopy, physical 
limitations due to co-morbid 
condition, depression, sick 
leave or disability pension, lack 
of walking ability, competitive 
athletes 
Aged 30-50 years. History of 
medial partial meniscectomy 
between 3 months and 1 year 
prior to the study. No or mild 
pain in the knee. 
Exclusion: Kellgren and 
Lawrence grade 3-4, other 
lower limb surgery, ACL or 
PCL tears, BMI>36, other 
forms of arthritis, diabetes, 
cardiac problems limiting 
activities 
Intervention Functional exercise training 
(also called neuromuscular 
training). One initial session 
to design a personalised 
therapy programme then 3 
exercise classes a week for 
4 months +/- extra 
unsupervised exercise/sport 
Functional exercise training 
(also called neuromuscular 
training). One initial session to 
design a personalised therapy 
programme then 3 exercise 
classes a week for 4 months +/- 
extra unsupervised 
exercise/sport 
12 week  neuromuscular 
exercise programme, with a 
focus on maintaining neutral 
alignment and engaging trunk 
muscles. 8 individual sessions 
+ home sessions 
Comparator A no treatment group A no treatment group A no treatment group 
Outcomes Primary outcome: 
Change in T1 relaxation 
time, in the presence of 
contrast, between baseline 
and follow up - assessed 
using delayed gadolinium-
enhanced 
MRI of cartilage 
(dGEMRIC) 15msec versus 
-15msec (p=0.036). 
Secondary outcomes: 
1 leg jump, square hop, 1 
leg running, bicycle 
ergonometer test 
Primary outcomes: Between 
group differences in change 
from baseline to 4 month follow 
up – one leg hop distance 
(p=0.04), square hop (p=0.07), 
one leg rising (p=0.28).  
Secondary outcomes: 
Quads endurance (p=0.001), 
hamstrings strength (p=0.03), 
hamstrings endurance (p=0.15), 
quads strength (p=0.83), KOOS 
scores (p>0.7) 
Primary outcomes: Peak 
KAM during stance phase of 
normal walking pace mean 
difference 0.22 (95% CI -0.11 
– 0.55), during sit to stand 
mean difference -0.01 (95% 
CI -0.33 – 0.31). Secondary 
outcomes: Peak KAM 
through walking and peak 
knee flexion moment during 
stance phase, sit to stand, one 
leg hop, self reported pain and 
function, KOOS, pain, change 
in function, muscle strength, 
physical performance tests 
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5.3.1 Roos and Dahlberg228 
 
This was a RCT comparing a functional exercise programme to a no intervention 
group in patients with a history of partial medial meniscectomy (Table 5-2 for 
details). The authors hypothesised that exercise may prevent structural changes that 
contribute to the progression of OA following partial meniscectomy. The primary 
outcome measure was T1 relaxation times using dGEMRIC, which assesses 
glycosaminoglycan (GAG) content in articular cartilage, which is considered a 
measure of cartilage quality. The primary outcome measure was a surrogate for OA 
progression and the authors stated that it was used because more traditional 
measures, for example plain radiographs are insensitive to early OA changes. 
Despite a high dropout rate, the authors showed a statistically significant difference 
between the intervention and a control group at four months (15 msec versus -15 
msec p=0.036). They also showed a strong correlation between physical activity 
level and GAG content in the intervention group, as well as the same finding in the 
pooled group of all subjects, suggesting a dose-response effect. They concluded that 
exercise could have a role in OA prevention in high risk patients. 
 
• Assessment of quality 
 
This was a well conducted RCT and reported in line with the CONSORT 
guidelines196. One important limitation is that there were a large number of post-
randomisation withdrawals from the study (twelve in the intervention and fourteen in 
the control group). This was nearly half of the participants randomised, which 
appears very high for a short follow up study and risks introducing bias into the 
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results. This risk was shown to be minimised as the baseline characteristics between 
the participants lost to follow and those completing the study were similar; the loss 
to follow up was also similar in both groups. A second limitation was the low 
external validity; only people with a previous partial medial meniscectomy and a 
small age range were included, as well as there being a large number of exclusion 
criteria. The results of this study are therefore less generalisable to the general 
population of post-meniscectomy patients.  
 
5.3.2 Ericsson et al.98 
 
This was a secondary analysis of the study by Roos and Dahlberg, with different 
reported outcome measures228. Their hypothesis was that post-meniscectomy patients 
have functional limitations that may be a risk factor for OA; these functional 
limitations could be addressed with a functional (neuromuscular) exercise 
programme. The intervention was described in extensive detail and broadly focussed 
on the principles of neuromuscular training, but personalised to each participant. 
This was achieved by a senior physiotherapist having an initial consultation where a 
diagnosis and treatment plan was devised. The recommended number of treatment 
sessions was three per week for four months, although the number of sessions 
attended was often much lower than this (the mean number of sessions attended per 
participant was thirty-one).  
 
Despite small numbers of participants and a conservative intention-to-treat analysis, 
the authors reported statistically significant differences in a number of outcome 
measures and a trend towards significance in a number of others (Table 5-2). They 
did not show a difference in the KOOS and actual values or confidence intervals 
were not given. The authors concluded that functional exercise training may have 
 111 
positive effects on functional performance and thigh muscle strength in this 
population. 
 
• Assessment of quality 
 
The limitations of this study are as described for the limitations of the study by Roos 
and Dahlberg with respect to loss to follow up and external validity, as the 
methodology and participants were the same228. The outcome assessors were also not 
blinded. It is accepted that it was not possible to blind the participants or person 
delivering the intervention, but would have been possible to blind the outcome 
assessor and potentially others, for example the statistician. In fact, the outcome 
assessors looking at the MRI scans for the original study were blinded228. Therefore, 
there is a risk of detection bias in this study. 
 
5.3.3 Hall at al.120  
 
This was a RCT comparing a neuromuscular exercise programme to a control group 
of no intervention (Table 5-2 for details). The primary outcome measure in the trial 
was knee adduction moment (KAM). KAM is used as an indirect measure of medial 
tibiofemoral contact force and it is thought that a reduction in this could reduce the 
risk of OA. It has previously been shown that peak KAM increases following partial 
meniscectomy and remains high two years post-operatively121. The authors were 
unable to show a statistically significant difference between the intervention and 
control group in either of the primary outcome measures (peak KAM in stance phase 
of normal walking and sit to stand). Of the secondary outcome measures the 
following were improved in the intervention group compared to control: A perceived 
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improvement in physical function (relative risk 0.29, 95% CI 0.09 – 0.91) and 
overall improvement (relative risk 0.38, 95% CI 0.16 – 0.92). Other secondary 
outcomes showed no statistically significant difference (Table 5-2). The authors 
concluded that they showed no change in peak KAM and future studies should 
address the long term effects of neuromuscular exercise on structural measures of 
OA progression. 
 
• Assessment of quality 
 
This was well designed, conducted and reported in accordance with CONSORT 
guidelines for RCTs196. Of note, the study protocol was published119, a power 
calculation was performed, a randomised design with adequate allocation 
concealment was used, intervention fidelity and compliance were monitored and 
assessors were blinded. The main limitation of the study was the low external 
validity. Only twenty-four per cent of eligible patients enrolled in the trial and this 
was after an extensive exclusion list.  
 
5.3.4 Risk of bias 
 
• Missing studies 
 
Only published studies were searched for, which may exacerbate publication bias. 
Secondly, only studies written in the English language were included, which may 
result in some important studies being lost.  
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• Missing outcomes 
 
The studies of Roos and Dahlberg228 and Ericsson et al.98 used the same participant 
group, which had a loss to follow up of twenty-six out of fifty-six. This is high and 
may have introduced bias. Ericsson et al. used an intention-to-treat analysis, bringing 
forward baseline results of participants lost to follow up in order to minimise this 
effect. There was a low loss to follow up in the study by Hall et al.120. 
 
5.4 Discussion 
 
Physiotherapy is a common and widely available intervention to treat 
musculoskeletal disorders. Its effectiveness in managing patients’ symptoms with 
established OA is clear,263 and it is recommended for use on the NHS by NICE204. 
Physiotherapy is also used in the post-operative rehabilitation of patients following 
meniscectomy and a number of RCTs have shown it to be effective in improving 
patient and assessor reported outcomes80. However, its role in the prevention of the 
development of OA in patients following meniscectomy is far less clear. 
 
Patients with a history of meniscectomy have a high risk of developing symptomatic 
OA213, 229, 230. This systematic review identified only a small number of studies but 
they were RCTs and were of a medium to high quality. Both studies described 
adequate randomisation and allocation concealment, therefore reducing the risk of 
selection bias, and balancing known and unknown confounders.  
 
Roos and Dahlberg showed a statistically significant improvement in GAG content 
and a strong dose response effect of exercise228. GAG are essential components of 
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articular cartilage and it is thought that a reduced concentration signifies 
degradation, leading to OA78. Therefore, this study suggests that exercise may have a 
role preventing the development of OA. dGEMRIC involves MRI scanning after an 
articular injection of gadolinium. It is being increasingly used to evaluate articular 
cartilage breakdown and repair24, 214. However, the role of dGEMRIC in predicting 
the development of OA is yet to be definitively established78. Despite this, the study 
did show that the intervention had an effect on articular cartilage compared to 
controls. This may be suggestive of a chondroprotective effect, although the long 
term consequences are not known. 
 
Ericsson et al., using the same participants, showed an improvement in some 
measures of thigh strength and functional performance in the intervention group, 
compared to the control group98. It has previously been suggested that reduced thigh 
muscle strength and functional performance are predictors of future OA246, 260. The 
same authors, in what appears to be the same participants, showed reduced 
quadriceps strength in post-meniscectomy patients99. Therefore, an intervention that 
improves thigh strength and functional performance may reduce the risk of OA.   
 
Hall et al. found a difference in perceived improvement in function, but did not find 
a statistically significant difference in their primary outcome measure of peak KAM. 
Their conclusion that no difference was found, may have been too strong as despite 
performing a sample size calculation (power 0.8), it appears that their study may 
have been underpowered. The mean difference of 0.22 in peak KAM in the stance 
phase of normal walking exceeded the pre-stated minimum clinically important 
difference (MCID) of 0.2. Whilst inferences cannot be drawn due to a lack of 
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statistical significance, a clinically meaningful difference cannot be ruled out. This 
could only be addressed with a larger study sample. 
 
5.4.1 Limitations 
 
All included papers used surrogate primary outcome measures. A surrogate outcome 
is not of direct clinical importance but is thought to reflect later clinical outcomes. 
Surrogate outcomes are commonly used when the clinical outcome is very rare or 
has a long lag time. They are often quicker, cheaper and require fewer study 
participants to detect differences18. Detecting disease modification in OA is difficult 
due to the long lag time from exposure to clearly defined OA. Currently used 
outcome measures have limitations: Joint space width on plain radiograph (which is 
in itself a surrogate outcome) is insensitive to early OA changes; joint replacement 
only reflects end stage OA and is insensitive to early change; a combination of 
symptoms and radiographic change requires very high participant numbers to detect 
a moderate difference177. To be useful, a surrogate outcome should be an indication 
of the pathogenic process or response to a disease modifying intervention. There also 
needs to be evidence of an association between the surrogate outcome and the 
clinical outcome of importance. The different surrogate outcome measures used in 
the included studies have some justification for use and some evidence of 
associations with clinical outcomes. However, none of the surrogates is considered a 
gold standard for assessing disease modification in OA and therefore the strength of 
conclusions must reflect this.  
 
Secondly, both the included studies used a ‘no intervention’ control group in favour 
of a placebo or alternative treatment. This may mean that some of the improvements 
seen in the intervention group were as a result of a placebo effect. However, it has 
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been shown that the placebo effect is negligible for objective outcomes in patients 
with OA297.    
 
5.5 Conclusion 
 
There is some limited evidence supporting the hypothesis that physiotherapy may be 
able to reduce the risk of OA in patients with a history of partial meniscectomy. 
However, the use of surrogate measures with only partially determined utility, a low 
number of studies and low numbers of participants in the included studies, precludes 
definitive conclusions from being drawn.  
 
Although there is limited evidence that physiotherapy is chondroprotective in this 
patient population, there is good evidence that it improves symptoms, function, is 
safe and is available on the NHS. It was therefore considered to be an appropriate 
alternative treatment to meniscal allograft transplantation and was used as the 
comparator for the pilot, in chapter eight. 
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6.1 Introduction 
 
Meniscal allograft transplantation has traditionally been contraindicated in the 
presence of full thickness articular cartilage loss or severe OA, as it is thought that 
the biomechanical environment would not be favourable, resulting in a high failure 
rate68, 131, 178, 222. However, it has been reported that up to fifty per cent of patients 
present with this level of advanced chondral damage232, 276. These patients represent 
a treatment challenge and some studies have looked to extend the indications of 
meniscal allograft transplantation by performing concomitant chondral repair 
procedures, with promising clinical outcomes35, 102, 109, 233, 251. It was important to 
know whether cartilage status at the time of surgery had a significant effect on 
failure rate in order to determine whether meniscal allograft transplantation is a 
reasonable surgical intervention for this challenging patient group. If the failure rates 
for patients with advanced cartilage damage were similar to patients with relatively 
preserved articular cartilage damage, it would be reasonable to include all patients in 
a definitive evaluation as it would increase the external validity of the study. 
Conversely, if failure rates were considerably higher in patients who most surgeons 
consider to be contraindicated to meniscal transplantation, a definitive evaluation 
should not include these patients. In this case, doing may compromise the trial by 
reducing the chance of showing a real benefit of meniscal allograft transplantation, if 
one existed, by diluting the effect size.  
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Therefore the primary objective of this study was to determine whether advanced 
cartilage damage at the time of surgery was a significant predictor of failure, 
independently of other potential risk factors. The secondary objectives were to 
determine whether other baseline variables were potential predictors of failure. 
 
6.2 Materials and Methods 
 
All patients undergoing meniscal allograft transplantation at UHCW between May 
2005 and May 2014 were prospectively evaluated as part of an ongoing service 
evaluation by the knee team. The data for this study was anonymised by the knee 
team before the analysis was performed. The study was registered with the local 
Research and Development department of the hospital.  
 
Patients were eligible for meniscal allograft transplantation if they were under fifty 
years of age and were experiencing pain, with a history of (sub)total meniscectomy 
in the same compartment of the knee.  Each patient was assessed for suitability for 
meniscal allograft transplantation by combination of MRI, plain radiographs and 
arthroscopic images. Patients that had inflammatory arthritis or evidence of 
advanced joint arthrosis in compartments distinct from the recipient compartment 
were not offered meniscal allograft transplantation.   
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6.2.1 Assessment Protocol 
 
Each patient was assessed and treated according to a joint restoration philosophy, 
where the optimal environment is created for the meniscal allograft transplantation. 
Firstly, clinical assessment of limb alignment was supplemented by weight bearing 
long leg alignment radiographs and secondly, assessment of knee stability was 
performed. If malalignment was present, proximal tibial opening wedge or distal 
femoral re-alignment osteotomy was performed to alter the weight bearing 
mechanical axis and reduce the forces across the affect compartment. Ligament 
stabilisation using hamstring autograft and biological chondral surface 
reconstructions were performed in addition to meniscal allograft transplantation, 
usually as simultaneous procedures along with osteotomy if limb malalignment was 
present. Chondral lesions were treated with debridement, microfracture or 
autologous chondrocyte transplantation using the MACI technique (Genzyme, 
Europe BV, Netherlands), depending on the lesion size.  
 
The cohort was divided into three groups according to the International Cartilage 
Repair Society (ICRS) chondral grade217 of the affected compartment:   
• Group 1: This group had up to ICRS grade 3a (partial thickness) chondral 
damage on one or both condylar surfaces.  
• Group 2: This group had ICRS grade 3b (full thickness) or worse chondral 
damage on one condyle, with the opposite condylar surface having intact 
articular cartilage up to ICRS grade 3a. 
• Group 3: This group had ICRS grade 3b (full thickness) or worse chondral 
damage to both condyles.  
 121 
 
6.2.2 Surgical Technique 
 
All procedures were performed using a minimally invasive arthroscopic technique 
with soft tissue fixation through bone tunnels. The technique was discussed in detail 
in the technique paper in press at the time of submission of this thesis (appendix D). 
 
6.2.3 Rehabilitation 
 
Patients were treated with a personalised, goal orientated physiotherapy program. 
The first six weeks of rehabilitation consisted of limited weight bearing to minimise 
the traction forces on the meniscal root anchor points. Early range of motion from 0 
to 900 and active static quadriceps exercises were commenced with avoidance of 
open chain quadriceps exercises during the initial period. From six weeks, weight 
bearing, strengthening and proprioceptive rehabilitation was progressed once the 
patient achieved the required goals. From six months, a functional and sports 
specific rehabilitation program was undertaken with a return to normal activities 
from approximately nine months. 
 
6.2.4 Outcomes 
 
Failure was defined as complete removal of the allograft or conversion to joint 
replacement. The knee research team collected all outcomes data on patients. 
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6.2.5 Statistical analysis 
 
Descriptive statistics were used to analyse the baselines demographics of the whole 
series as well as a breakdown by cartilage grade. Tests for significance on 
differences between cartilage groups were performed using the Chi squared test for 
categorical variables and ANOVA for continuous variables. Kaplan Meier survival 
curves were used for whole group survival and also survival according to cartilage 
grade. Cox regression (proportional hazards model) was performed to analyse for the 
effect on outcome of each potential predictor variable, independently of others. The 
proportional hazards assumption was tested by examining the log-log plots.  
 
6.3 Results 
 
There were 124 patients in the study period with a mean follow up of 3.25 (range 1 – 
6) years. There were no patients lost to follow up for this cohort of patients. The 
mean age in this series was 30.9 (range 8 – 49) years. Table 6-1 shows the baseline 
demographics for the whole series and a breakdown by cartilage grade. Table 6-2 
shows the additional procedures to address the cartilage lesion performed on patients 
with a full thickness lesion. 
 
 
 
 
 
 
 
 
 
 
 123 
Table 6-1: Baseline demographics for the whole series and each group according to 
cartilage grade 
 
 Total Group 1 Group 2 Group 3 
Number of MAT 
 
124 70 28 26 
Mean age (years) 
 
30.9 28.4 32.2 36.1 
Male (%) 
 
67.7 62.9 71.4 77.0 
Time from meniscectomy to 
MAT in years 
8.2 5.6 9.7 13.8 
Mean age at meniscectomy 
(years) 
 
23.6 23.2 23.9 24.4 
Medial (%) 
 
20.2 20.0 14.3 26.9 
Cases with additional procedures 
performed at time of MAT (%) 
56.5 38.6 74.1 84.6 
Baseline IKDC scores 
 
40.8 40.6 44.7 37.1 
 
 
Table 6-2: Cartilage procedures performed at the time of meniscal allograft 
transplantation 
 
 Total Group 1 Group 2 Group 3 
Number of MAT 124 70 28 26 
Microfracture 25 0 10 15 
Chondrocyte implantation 12 0 6 6 
 
 
The Kaplan-Meier allograft survival curve of the whole cohort is shown in Figure 
6-1, with a six year survival of seventy per cent. The Kaplan-Meier allograft survival 
curve, grouped by cartilage grade is shown in Figure 6-2. This shows a 90%, 63% 
and 66% five year survival in groups one, two and three respectively, with the 
difference in survival rate for group one compared to groups two and three being 
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statistically significant (log-rank test significance 0.02). Table 6-3 shows the mean 
survival times for the whole group and each group by cartilage grade. 
 
Table 6-3: Mean survival times (95% CI), grouped according to cartilage grade 
 
Group Mean survival (years) 95% confidence interval (years) 
Whole group 5.4 5.1 5.7 
Cartilage grade 1 5.8 5.6 6.0 
Cartilage grade 2 4.4 4.1 4.7 
Cartilage grade 3 4.9 4.4 5.4 
 
 
 
Figure 6-1: Whole group cumulative meniscal allograft survival 
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Figure 6-2: Kaplan Meier curve, grouped according to cartilage grade 
 
The results of the Cox regression model are shown in Table 6-4. When all other 
predictor variables are corrected for, only cartilage group was a statistically 
significant predictor of survival. When comparing individual groups, the probability 
of failure in group 3 was 11.49 times more likely than group 1 at any given time 
(95% CI, 1.6 – 81.0). There was a trend towards medial allografts predicting a worse 
outcome, but this was not statistically significant (p=0.07).  
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Table 6-4: Cox regression analysis of potential predictor variables 
 
Variable Hazard ratio P value 95% CI 
Cartilage group (overall) N/A 0.047 N/A 
Cartilage group 3 (vs group 1) 11.49 0.01 1.6 – 81.0 
Cartilage group 3 (vs group 2) 4.22 0.16 0.55 – 32.3 
Baseline IKDC score 0.40 0.99 0.94 – 1.02 
Lateral (vs Medial) 0.25 0.07 0.05 – 1.10 
Male (vs female) 0.56 0.44 0.13 – 2.39 
Additional procedures (vs isolated 
MAT) 
1.65 0.51 0.37 – 7.41 
Graft source (overall) N/A 0.15 N/A 
Age at the time of MAT 0.99 0.91 0.9 – 1.1 
 
6.4 Discussion 
 
This study demonstrated that having a full thickness cartilage lesion at the time of 
meniscal allograft transplantation was a significant predictor of failure, despite 
attempts to improve the biomechanical environment of the knee. In this study, the 
overall survival of seventy per cent at six years hides the fact that within this there 
were significant differences depending on cartilage status at the time of 
transplantation. In an earlier study, using data from some of the same patients, 
advanced cartilage damage appeared to be associated with failure151. In this study 
with longer follow up, more patients and more events, cartilage group has been 
shown to be a strong predictor of failure, even when balancing for potential 
confounders. Further, the failure rate in patients with advanced cartilage damage on 
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a single surface appears to be similar to patients with advanced damage on both 
surfaces, despite the groups being different with respect to baseline characteristics. It 
has traditionally been considered that meniscal allograft transplantation is not 
suitable for patients with significant OA, leaving these patients with very few viable 
treatment options.  
 
With more recent studies showing improved results, meniscal allograft 
transplantation is being performed in patients with advanced disease at some centres. 
Farr et al. performed combined autologous chondrocyte implantation in combination 
with meniscal allograft transplantation and had a fourteen per cent failure rate at a 
greater than two year follow up102. Stone et al. reported a large series of patients 
having meniscal allograft transplantation in the presence of severe articular damage, 
reporting a failure rate of twenty per cent at a mean follow up of five years251. They 
did not find an association between articular cartilage damage severity on Cox 
regression modelling, but all patients in the study already had severe articular 
cartilage damage. Other series report lower failure rates, although numbers are low35, 
233. This series showed worse failure rates in the presence of advanced cartilage 
damage, despite additional procedures to address the cartilage lesions.  
 
It is interesting that the mean age at the time of meniscal allograft transplantation 
increases, but the time of initial meniscectomy is remarkably similar across all three 
cartilage groups. Although direct inferences cannot be drawn, it does appear that 
patients with advanced cartilage damage have similar characteristics to those with 
preserved articular cartilage, with the main difference being that they were late 
presenters. This is certainly plausible, given the known strong risk factor of 
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meniscectomy for OA213. It is possible that earlier intervention in these patients may 
have a role preventing or delaying the advanced cartilage damage. However, there is 
currently not a role for performing meniscal allograft transplantation 
prophylactically as there is little direct evidence that it is chondroprotective, despite 
the evidence for the association between meniscectomy and OA being strong183, 213, 
230, 248. 
 
6.4.1 Limitations 
 
One of the difficulties in comparing failure rates across studies is that failure is 
variably defined in the literature232, 276. Whilst complete allograft removal or 
conversion to joint replacement is a clear and hard failure definition, it does not 
directly take the patients’ symptoms into account. It has been suggested that low 
PROMs post-operatively could be included in the definition of failure. This would 
be likely to increase the failure rate of the series, but would have difficulties: Which 
measure would be used, would it take the patients pre-operative state into account, 
would an equal pre-operative and ten year post-operative score be considered a 
failure, given the likelihood of some OA progression in between?  
 
This study only looked at survival rate and did not determine the clinical outcome 
for the groups using PROMs. Whilst this is important, a previous published study 
using some of the same patients has done this analysis151. It determined that the 
clinical outcomes between patients with preserved cartilage and those with advanced 
cartilage damage were not significantly different. It is likely that the data were 
biased though, as patients that failed did not have PROMs scores collected. Since 
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these patients are likely to have worse scores and are more common in the group 
with advanced cartilage damage, this group is likely to appear better than it would if 
all data were collected. A further analysis of this data would also yield biased results, 
so it was decided that this would be unhelpful. 
 
Finally, Cox regression modelling is able to balance for known (and measured) 
confounders. It cannot balance for unknown confounders, which may have had an 
influence on the results. Only a randomised controlled trial can balance unknown 
confounders. 
 
6.5 Conclusion 
 
Whilst the overall failure rate is similar to other studies reported in the literature, 
advanced chondral damage was a significant predictor of failure in this study. These 
findings support the traditional view that meniscal allograft transplantation has a 
worse outcome in patients with advanced cartilage damage. Therefore, patients with 
advanced cartilage damage were not included in the piloting phase due to the risk of 
reducing the overall effect size of the meniscal allograft transplantation intervention. 
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7.1 Introduction 
 
Chapters two to five demonstrated that based on current knowledge, it is reasonable 
to consider that both meniscal allograft transplantation and physiotherapy might be 
effective treatments for patients with a symptomatic meniscal deficient knee. They 
have also demonstrated that there is an absence of definitive evidence to support one 
treatment over another, providing the basis for clinical equipoise between the 
treatments. 
 
RCTs are the most reliable method of determining effectiveness and they are being 
increasingly used to assess complex interventions54, 75. The second stage of the MRC 
framework for evaluating a complex intervention is the feasibility and piloting 
stage75. This stage is often neglected, but is vital to identify problems that could 
undermine a definitive evaluation92. Definitive evaluations of complex interventions 
can cost millions of pounds to perform; failure to adequately ensure a trial can be 
successfully performed is a waste of resources and ultimately unethical. Therefore, 
the primary aim was to perform a pilot study that would inform a potential definitive 
evaluation comparing meniscal allograft transplantation to physiotherapy for the 
treatment of patients with a symptomatic meniscal deficient knee. The objectives 
were: 
 
• Assess the variability and distribution of the outcome measures, to provide an 
estimate of the treatment effects and inform a sample size calculation for a 
definitive evaluation. 
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• Identify issues with the trial study design including: Recruitment, retention, 
trial delivery and intervention fidelity. 
 
7.2 Study Design 
 
The study was a comprehensive cohort design with an embedded pilot RCT. 
Therefore there was a randomised arm and a parallel non-randomised preference 
group arm. The study was performed at a single UK centre (UHCW).  Recruitment 
to randomised operative versus non-operative trials is notoriously difficult due to 
strong patient preferences.71, 270 Having a parallel preference group provided greater 
external validity as the overall recruitment rate was anticipated to be significantly 
higher.153 It may also increase the precision of the estimate of variability of the data. 
 
7.3 Trial Summary and Flow Diagram 
 
Patients between the ages of sixteen and fifty years presenting at the trial centre with 
pain in the affected compartment of the knee following a total or near total 
meniscectomy were potentially eligible to take part (see Figure 7-1 for details). 
Eligible patients were identified by the clinical team and then approached to enter 
the RCT arm by the chief investigator or research associates. If they agreed to enter, 
they were randomly allocated to an intervention. If patients were unwilling to be 
randomised but did wish to have either of the treatments being assessed in this study, 
they were asked whether they were willing to have their follow up information 
collected. Patients that did not want to be randomised but did wish to have follow up 
information collected had an MRI scan at baseline and twelve months as per 
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standard practice, as well as questionnaires at baseline, four, eight and twelve 
months.  
 
Patients were randomised by the Warwick telephone randomisation service. This 
was produced and administered by Warwick Clinical Trials Unit. 
 
The participants allocated to the operative group had a meniscal allograft 
transplantation and osteotomy if they had malalignment (defined below) of the knee 
and meniscal allograft transplantation only if they did not. The non-operative group 
had a personalised knee therapy programme and an offloading knee brace if they had 
malalignment of the knee and a personalised knee therapy programme only if they 
did not. Both the operative and non-operative treatments were used in this trust as 
standard care and the operating surgeons had extensive experience in performing the 
operations. MRI scans were performed at baseline (pre-intervention) and four, eight 
and twelve months post-intervention. The functional outcome data was collected 
using the KOOS, Lysholm and IKDC questionnaires at the same time points. These 
questionnaires were administered centrally by independent research associates. The 
participants were asked to provide details of any late complications or interventions 
related to their knee.  
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Figure 7-1: Trial participant flow diagram. Meniscal allograft transplantation 
(MAT), osteotomy (O) 
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7.4 Ethical Approval 
 
This study was reviewed by the West Midlands – Solihull Research Ethics 
committee (Ref: 13/WM/0315). It was given ethical approval on the 3rd October 
2013 (Appendix E). It was given local Research and Development approval on the 
22th November 2013 (Appendix F). The study was carried out in compliance with the 
Helsinki Declaration. 
 
7.5 Study Registration 
 
This study was registered with the International Standard Randomised Controlled 
Trial Number Register (ISRCTN14194954) and the NIHR Comprehensive Research 
Network Portfolio (UKCRN ID15557). 
 
7.6 Study Participants 
 
Patients were eligible if they were between the ages of sixteen and fifty years with a 
symptomatic, meniscal-deficient compartment of the knee and the treating surgeon 
believed that the patient may benefit from meniscal allograft transplantation. These 
broad and pragmatic criteria were chosen to maximise the external validity of the 
results of the study.  
 
Symptoms in the knee included pain, swelling or stiffness and could be present 
intermittently to be eligible. The amount of meniscal deficiency is difficult to 
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accurately quantify; it was left to the treating surgeon to decide whether there was 
enough meniscal deficiency (loss) that the patient may benefit from meniscal 
allograft transplantation. The following guidance was used in the decision making 
process: A deficient meniscal rim providing no circumferential fibre support or an 
intact rim of less than two millimetres width over the majority of the meniscus. It 
was anticipated that meniscectomy due to trauma would be the most common reason 
for meniscal deficiency. Other meniscal pathologies were also eligible, for example 
previous excision of a discoid meniscus.   
 
Patients were excluded if they had previous cartilage modifying procedures, such at 
microfracture or had significant exposed subchondral bone in the affected 
compartment due to arthritis (diagnosed on previous arthroscopy or MRI). These 
patients were excluded because chapter three demonstrated that most studies 
excluded these patients and chapter six demonstrated that advanced cartilage damage 
was a predictor of failure.  
 
Patients that had contraindications to anaesthetic as well as patients where there was 
evidence that they would be unable to adhere to trial procedures were also excluded. 
 
7.7 Recruitment 
 
Patients were recruited from elective knee clinics at UHCW. When an eligible 
patient was identified by the treating surgeon, they were referred to the chief 
investigator or research associate. 
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7.8 Consent 
 
The patients were informed about the RCT arm of the study and given a patient 
information sheet (PIS) specific to the pilot RCT (Appendix G). If patients were 
unwilling to have their treatment allocation decided by randomisation, they were 
given the opportunity to be part of the preference group (PG). A second PIS, which 
gave information about this follow up group was given to patients (Appendix G). 
This allowed participants to decide their treatment allocation but still be part of the 
study. Their data was collected at the same time points as the RCT arm, with the 
exception of not having MRI scans at four and eight months. Patients were offered as 
much time as they required to consider the study. Patients wishing to enter the study 
gave written consent (Appendix H). They were able to withdraw from the study at 
any time without prejudice.  
 
7.9 Randomisation 
 
Randomisation was by a computer generated sequence with a 1:1 allocation, 
stratified for ipsilateral limb malalignment. The Warwick Clinical Trials Unit secure 
telephone randomisation service was used to provide the participant allocation once 
the participant had consented to take part in the study. The allocated treatment was 
then reported back to the chief investigator and the treating surgeon.  
 
7.10 Blinding 
 
Participants could not be blinded to their treatment. The treating surgeons were of 
course not blind to the treatment, but did not take part in the post-operative 
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assessment of the participants; this was performed by a research associate blind to 
the treatment allocation. The MRI analysis was performed by IMorphics Ltd, 
Manchester UK; an independent medical image analysis company, who were blinded 
to the treatment allocation. 
 
7.11 Study Interventions 
 
7.11.1 Operative group 
 
Participants usually had a general anaesthetic and femoral nerve block, but the 
attending anaesthetists were able to make the final decision based on the 
participants’ clinical requirements. Participants were in a supine position with a 
thigh side support. The surgery was performed by one of the knee surgeons 
competent in meniscal transplantation and osteotomies (TS or PT). There was no 
anticipated learning curve effect in this study as both participating surgeons 
performing the operations were proficient and experienced in the procedures.  
The meniscal allograft was frozen and sourced from one of two tissue banks: NHS 
Blood and Transplant Tissue Services, Liverpool UK, or Allosource, USA, imported 
by Joint Operations. These sources had been regularly used for meniscal allograft 
transplantation as standard practice at UHCW. The lack of availability from any one 
source required that multiple sources were used. The meniscal allograft was 
dissected from the tibial bone block, marking the topographical orientation. Number 
two non-absorbable sutures were inserted in the anterior and posterior horns using a 
Bunnell type stitch and an absorbable middle traction suture was inserted at the 
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anterior aspect of the popliteal hiatus laterally or at a point forty millimetres from the 
posterior horn medially.  
Surgery was performed using an arthroscopic technique. The procedure started with 
a full assessment of the knee surfaces and the remaining amount of meniscal tissue. 
A two millimetre meniscal rim of tissue was maintained where possible. The 
meniscal bed was prepared to a fresh vascular margin before insertion of the 
allograft. Anterior and posterior meniscal root attachments were located and 
prepared using a shaver and rasp to expose bleeding bone. Guide wires were drilled 
from the anterior tibia to the insertion sites, maintaining a bone bridge on the tibia 
between the tunnels, and the guide wires were then over-drilled to create 4.5 mm 
tibial bone tunnels. Lead sutures were inserted through the tunnels and were 
retrieved through the arthroscopic portal. 
 
The meniscal allograft sutures were fed through the lead sutures and the allograft 
was parachuted into place with the assistance of the middle traction suture. Fixation 
of the meniscal roots was achieved by tying the anterior and posterior horn lead 
sutures over the bone bridge on the anterior tibia. The meniscal rim was secured by 
placing multiple, vertical stacked mattress sutures around the anterior two thirds of 
the meniscus with an inside-out technique. The posterior third of the meniscus was 
secured with all-inside fixation devices, such as the Fast-Fix 360 (Smith and 
Nephew, Andover USA). 
 
Participants were assessed for limb malalignment prior to randomisation, and then 
stratified accordingly. Participants in which the weight bearing line fell greater than 
five per cent from the centre of the tibial plateau, where 100% represents the total 
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tibial plateau width, were offered an osteotomy. A medial opening wedge high tibial 
osteotomy was performed for a varus proximal tibia and a medial closing wedge 
distal femoral osteotomy was performed for a valgus distal femur, subject to the 
surgeon’s preference and participant factors. In these procedures, the medial tibia or 
medial distal femur was exposed through a longitudinal incision and an oblique 
osteotomy was fashioned using image intensifier guidance. The final position was 
then held using a titanium locking plate and screws. 
 
All participants randomised into the operative group received a standardised, written 
physiotherapy programme for their post-operative rehabilitation. Participants were 
advised to touch weight bear with crutches for six weeks, followed by progression to 
full weight bearing by eight weeks. Cycling exercises started at four weeks when 90 
degrees bend had been achieved. Strength work started at three months and running 
was not allowed until nine months. Participants were advised of the risks of 
participating in contact sports and encouraged not to return to these activities in the 
long term.  
 
7.11.2 Non-operative group 
 
Participants had a personalised knee therapy course, specifically designed for 
patients with pain in a meniscal deficient knee. The course involved a personalised 
programme working on quadriceps control and strength, along with a core-
strengthening programme, delivered over a minimum of three months. The initial 
assessment was performed by a senior knee physiotherapist, who gave a written 
booklet of exercise prescription, an exercise diary and an instruction list of common 
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exercises. If the participant wished to continue physiotherapy nearer their home, for 
example if they were not local to the area, they were referred for continued 
physiotherapy at a local unit. They were assessed at routine follow up clinics every 
four months, where adjustments to the personalised knee therapy could be made. 
 
Participants with malalignment that were randomised to the non-operative group 
were also offered a size matched offloading knee brace. 
 
7.12 Intervention Fidelity 
 
Participants’ treatments in both the operative and non-operative groups were 
assessed for adherence to the trial protocols. In the operative group, the surgery and 
post-operative rehabilitation were reviewed by the chief investigator and a surgeon 
that was competent at performing meniscal allograft transplantation, but not directly 
involved in the treatment of trial participants (BP). A fidelity questionnaire was 
completed using the operative note and case report forms (Appendix I), with any 
disagreement resolved by discussion. All questions had to be answered in the 
affirmative for fidelity to be achieved. 
 
In the non-operative group, the treatment fidelity was determined by the chief 
investigator and a senior physiotherapist able to deliver personalised knee therapy, 
but not directly involved in the treatment of trial participants (IH). A fidelity 
questionnaire was completed using the physiotherapy case report form and 
examination of UHCW physiotherapy records, as well as communication with the 
physiotherapists at UHCW (Appendix I) with any disagreement resolved by 
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discussion. All questions had to be answered in the affirmative for fidelity to be 
achieved. 
 
7.13 Outcome Measures 
 
The primary endpoint was the mean change in cartilage volume in the central weight 
bearing portion of the affected compartment of the knee at one year post-
intervention. The change in cartilage volume was also evaluated at four and eight 
months following the intervention. All participants were scanned on a General 
Electric MRI scanner using T2 gradient Echo sequences with the same protocol 
(Appendix J), performed by MRI trained research staff at UHCW. The scans were 
then anonymised and sent to IMorphics for analysis. IMorphics are a UK based 
world leading image analysis company with over twenty years expertise in the area. 
They use advanced and proprietary modelling software to automatically identify the 
bone edges of the knee. The principle is similar to facial recognition software, where 
an active appearance model is built using a training set of images, which is made up 
of a dense set of anatomical correspondence points (over 30 000 in the knee). The 
model is then able to identify valid new shapes and appearances, so it can be applied 
to previously unseen images283. This method has been shown to be one of the best to 
automatically segment images254, with mean positional errors of the correspondence 
points of less than one millimetre284. They have also published test-retest 
variabilities for manual cartilage volume and thickness measurements, which 
compare favourably to other published studies in the knee134. 
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IMophics reputation as world leaders in biomedical image analysis has been further 
established by winning the Medical Image Computing and Computer Assisted 
Intervention (MICCAI) Grand Challenge on a number of occasions for image 
analysis on previously unseen images. This is a highly prestigious international 
biomedical image analysis competition with academic and commercial groups 
competing. One previous win included segmenting the knee bone and cartilage.  
 
IMorphics are a successful commercial company and their image analysis 
technologies and services are used by medical implant companies to perform three-
dimensional modelling. The cost of their services would normally be too high for 
this project, but due to academic links and previous successful collaborations with 
one of the supervisors of this project (Charles Hutchinson), IMorphics agreed to 
offer their services at much lower academic rates. Therefore it was possible to use 
their services. 
 
Cartilage was manually segmented by a single operator that had previously passed  
IMorphic’s training test (repeatedly segmenting parts of the knee with an intra-
observer coefficient of variation of less than three per cent), using IMorphic’s 
proprietary software134. Cartilage segmentations were also reviewed by a senior 
segmenter for consistency. The bone was automatically segmented using active 
appearance models. This semi-automated segmentation is IMorphics standard image 
analysis protocol and the previously published data comes from this protocol.  
 
The central portion of each compartment of the tibiofemoral joint is commonly used 
to determine cartilage change in studies 87, 134, 283 for two main reasons: Firstly, it has 
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been shown that global cartilage change is small and can mask rapid regional 
changes. This may particularly be expected in patients with a previous 
meniscectomy where high central stresses and low peripheral stresses in the knee 
may lead to rapid central loss and potentially peripheral cartilage volume gain. 
Secondly, the peripheral edge of cartilage is the most difficult region to segment and 
therefore most prone to measurement error. It has been shown that the coefficient of 
variation decreases if the edges of cartilage are trimmed283. The central area of the 
affected compartments of the femoral condyle and tibial plateau (medial or lateral) 
were identified using a dense set of anatomically consistent correspondence points, 
based on the meniscal window in the mean knee on the previously developed model. 
Figure 7-2 illustrates the meniscal window for the tibial plateau of the medial 
compartment. This method allows the central weight bearing area to be consistently 
determined and has been shown to have a mean positional error of around one 
millimetre285. The cartilage volume in these regions was then measured and change 
between baseline and follow up time points was calculated. 
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Figure 7-2: Illustration of the medial compartment area of interest on the tibial 
plateau, defined from the mean meniscal window in the knee model (reproduced 
with permission from IMorphics)  
 
The secondary outcome measures included the KOOS227, Lysholm score176, IKDC 
score128, mean change in cartilage thickness, bone shape change and complications. 
Cartilage thickness was identified using the same methods as described for cartilage 
volume and the same regions of interest were used. Multiple thickness measurements 
were taken within the region of interest and a mean thickness was then calculated. 
Bone shape change has shown promise as a sensitive method of identifying 
progression of OA47. The change in surface area of the affected tibiofemoral 
compartment was calculated from the automated bone segmentation. 
 
7.14 Follow-up 
 
In the RCT arm of the study, participants had MRI scans at baseline and then four, 
eight and twelve months post-intervention. In the preference group arm, the 
participants had MRI scans at baseline and at twelve months post-intervention. It 
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was the intention that all participants completed questionnaires at all time points 
(baseline, four, eight and twelve months). 
 
The follow up points were post-intervention, rather than post-randomisation. It was 
considered that more meaningful MRI data would be achieved using these time 
points if there was a long delay to surgery for participants. It would also mean that 
follow up appointments and MRI scans could be linked to standard clinical 
appointments and MRI scans, reducing the inconvenience for participants and 
potentially reducing loss to follow up. All participants completed questionnaires on 
the day of entry to the study and most had MRI scans, according to clinical need. If 
the intervention was started within four months of the day of entry into the study, the 
MRI and questionnaire were used as baseline scores. If the start of the intervention 
exceeded four months, an MRI scan and new questionnaire was completed as close 
to the start of the intervention as possible, in the RCT arm. In the preference group 
arm the MRI scan was not repeated, as this did not constitute routine follow up. 
 
In the first instance, a research associate that was blinded to the treatment allocation 
collected all functional outcome scores from the participants in person. If a 
participant missed the appointment or was not willing to attend, the outcomes pack 
was sent out by post and the participant was telephoned. If the research associate was 
unable to obtain this information within four weeks of the time point for collection, 
the information was deemed missing. Further data was collected at later time points 
as originally planned. 
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7.15 Post Recruitment Withdrawals and Exclusions 
 
Participants were able withdraw from the trial at any time. If a participant decided to 
have a different treatment to which they were randomised, they were followed up 
wherever possible and data was collected as per the protocol until the end of the trial. 
Participants could be withdrawn from the study by the chief investigator at any time 
if any safety concerns arose. 
 
During the study it became clear that the delay to surgery was a larger issue than 
anticipated. No time point for withdrawing participants from the study had been 
decided prospectively, but it was decided at a trial management group (TMG) 
meeting that if a participant had not started the intervention at one year following 
randomisation, they should be withdrawn from the study. It was decided that this 
factor was an important finding in itself and that the study had to have a defined end 
point.  
 
For the purposes of the thesis, it was decided that if participants in the RCT arm had 
a delay to starting the intervention of greater than four months following the end of 
the recruitment period, submission of the thesis would not include their completed 
follow up. If there was a delay of over two months in the preference group following 
the end of the recruitment period, submission of the thesis would not include their 
completed follow up. This was decided for logistical reasons of completing a PhD 
within the maximum allowed time out of programme from clinical training. Follow 
up outcomes in these participants will continue to be collected following the 
submission of the thesis.  
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7.16 Sample Size 
 
There were no previously performed similar studies so there was no way of gaining a 
meaningful standardised effect size. Therefore this study was a pilot and no formal 
power calculation was performed. The recruitment period was twelve months and it 
had been estimated that eighteen patients would be entered into the randomised arm 
of the trial, based on a fifty per cent recruitment rate. A sample size of eighteen had 
been chosen for a combination of being able to deliver the study within the 
timeframe of a PhD and the expectation that it would provide enough information to 
achieve the objectives of the study. It was anticipated that a sample size of eighteen 
participants would provide some guidance as to the likely size of the treatment effect 
and would allow nuisance parameters such as the variability (standard deviation) in 
the primary outcome to be estimated with some precision. Whilst it has been 
recommended that twelve participants per group would be appropriate for pilot 
studies197, it was anticipated that cartilage volume change would have a small 
variability. This would allow a similarly precise estimate with relatively fewer 
participants. If appropriate, the preference group outcomes could be combined with 
the RCT to increase the precision of the estimate of variability. 
 
It was expected that the vast majority of patients that did not want to be randomised 
would wish to be part of the preference group, as the burden on participants was not 
different from routine clinical care. Therefore it was estimated that between fourteen 
and eighteen participants would enter the preference group arm of the study. 
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7.17 Data Management 
 
The case report forms were designed by the chief investigator in conjunction with 
the trial management team. All electronic patient-identifiable information was held 
on a secure, password-protected database accessible only to essential personnel. 
Paper forms with patient-identifiable information were held in secure, locked filing 
cabinets within a restricted area of the Clinical Sciences Research Laboratories. 
Patients were identified by a code number only. Direct access to source data was 
required for trial-related monitoring. All paper and electronic data will be retained 
for at least five years after completion of the trial. 
 
7.18 Statistical Analysis 
 
The main analysis investigated the differences in the outcome measures between the 
treatment groups on an intention-to-treat basis, at twelve months post-intervention. 
As this was a pilot study, the main analysis was exploratory in nature, to assess the 
size and direction of observed differences between the two treatment groups, and the 
variability and distribution of the outcome measures at each assessment occasion. 
Changes in PROMs were assessed for approximate normal distribution and 
presented with means and standard deviations unless histograms showed a strongly 
non-normal distribution. Baseline data was summarised to check for comparability 
between treatment arms. The changes in outcome measures for the intervention and 
comparator groups were presented in their individual arms (RCT and preference 
group) as well as combined for the four, eight and twelve month time points. This 
was a relatively small study, so group means were unlikely to be estimated with 
much precision. However, the statistical significance of difference in outcomes 
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between treatment groups were formally assessed using independent samples t-tests 
at twelve months. Tests were two-sided and considered to provide evidence for a 
significant difference if p-values were less than 0.05 (5% significance level). 
Levene’s test for equality of variances was also performed to determine whether 
equality of variances could be assumed for each outcome measure. Differences 
between the RCT and preference groups were explored and if appropriate, RCT and 
preference group data was merged for an analysis of the whole cohort, as well as an 
analysis of the RCT group alone. 
 
The MRI measures (cartilage volume, cartilage thickness and bone shape change) 
were logarithm transformed (natural logarithms) to improve the distributional 
properties of approximate normality, prior to analysis. Both the baseline and twelve 
month scores were logarithm transformed and the baseline was subtracted from the 
twelve month score. The significance of differences in means between groups was 
tested on this scale using two sided independent samples t-tests. The mean log-ratio 
and 95% confidence intervals were transformed back to the original (natural) scale 
by taking antilogarithms and expressed as a per cent change by subtracting one and 
multiplying by 100.  
 
Pooled standard deviations for the change in outcome measures from baseline to 
twelve months were calculated by taking the root mean square of the standard 
deviations for each outcome measure, to allow sample size calculations for a full 
RCT to be performed67, 231. This was performed on the RCT data and the combined 
RCT and preference group data. 
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8 Meniscal Transplantation and Its Effect on 
Osteoarthritis Risk - MeTEOR: A Comprehensive 
Cohort Study Incorporating a pilot RCT – Results 
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8.1 Objectives 
 
The objectives of this study were: 
 
 
• Assess the variability and distribution of the outcome measures, to provide an 
estimate of the treatment effects and inform a sample size calculation for a 
definitive evaluation. 
 
• Identify issues with the trial study design including: Recruitment, retention, 
trial delivery and intervention fidelity. 
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8.2 Recruitment and follow up 
 
Recruitment took place between November 2013 and November 2014. There were a 
total of thirty-six participants recruited, of which twenty-one were in the RCT arm 
and fifteen in the preference group arm. Figures 8-1 to 8-3 show the recruitment rate 
for the whole group, the RCT and the preference group arms respectively. The 
expected recruitment total of thirty-six, with eighteen in the RCT arm was similar to 
the actual recruitment rate, with a slightly preferential split of fifty-eight per cent to 
forty-two per cent in favour of the RCT, compared to the preference group arm 
respectively. Considering all eligible patients, the RCT recruitment rate was fifty-
five per cent, which equates to a monthly recruitment rate of 1.75 participants. The 
chief investigator recruited all participants. 
 
Figures 8-4 and 8-5 are flow diagrams of participants through the RCT and 
preference group arms of the study respectively. A total of fifteen patients were 
excluded after screening. The most common reasons for exclusion were: A patient 
needing further concurrent surgery, and the surgeon not believing the patient would 
benefit from meniscal allograft transplantation. Only two patients declined to take 
any part in the study, both giving reasons of not living near the hospital and not 
wanting to commit to follow up. 
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Figure 8-1: Trial recruitment compared to predictions for the whole cohort 
 
 
Figure 8-2: Trial recruitment compared to predictions for the RCT arm of the study  
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Figure 8-3: Trial recruitment compared to predictions for the preference group (PG) 
arm of the study 
 
Three participants that were randomised to meniscal allograft transplantation were 
withdrawn from the study at one year, as they had not received the intervention by 
that time point. At the time of being withdrawn, two of the participants had not been 
allocated an allograft and the other had not been allocated a date for surgery.  
 
Two participants in the personalised knee therapy preference group were lost to 
follow up before the four month data points were collected. One participant left the 
country for work reasons and the other had decided to pursue the surgical 
intervention privately and did not wish to remain in the study in any form.  
 
Two participants missed their four month follow up appointments, one in the RCT 
surgical group and one in the RCT personalised knee therapy group. Both 
participants did not attend scheduled appointments and were unable to commit to 
rescheduling due to work commitments at the time.  
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Two participants that were randomised to meniscal allograft transplantation had not 
completed follow up at the time of submission of this thesis, as they had surgery 
over four months following the end of the recruitment period. The delay from 
entering the study to surgery was five months for one participant and nine months 
for the other. In the preference group, two participants in the meniscal allograft 
transplantation group had not completed follow up at the time of submission. The 
delay from entering the study to surgery was two months for one participant and five 
months for the other. There were no other missing data points or losses to follow up. 
 
One participant in the personalised knee therapy preference group decided to 
proceed with meniscal allograft transplantation within the follow up period of the 
study, due to family reasons. That participant had completed the course of 
personalised knee therapy before surgery and remained in the study.  
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Figure 8-4: Flow diagram of participants through the RCT arm of the study 
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Figure 8-5: Flow diagram of participants through the preference group (PG) arm of 
the study 
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whereas there was a higher BMI and a higher number of participants with 
malalignment in the personalised knee therapy group. 
 
Baseline MRI values appear closely matched between the RCT groups, and there 
were no major imbalances between any of the other groups. According to the 
protocol, baseline MRI scans and PROMs collected close to the day of 
randomisation from participants in the RCT arm were only valid if they were within 
four months of the start of the intervention. This was the case for all participants in 
the personalised knee therapy group but six participants in the meniscal allograft 
transplantation group had repeated baseline PROMs (five MRI scans). There was a 
trend towards a small worsening of PROMs in the repeated baseline measures, with 
all KOOS sub-domains, the KOOS4 composite and IKDC scores being lower 
(Lysholm score was the same). There were no major changes in the MRI outcomes 
between the two baseline time points. 
 
The main baseline imbalance between the RCT groups was that meniscal allograft 
transplantation group had worse scores in all KOOS sub-domains, except Symptoms. 
This does not appear to be matched in other PROMs scores, as the IKDC score was 
worse in the personalised knee therapy RCT group than the meniscal allograft 
transplantation group; Lysholm scores were similar. The baseline preference group 
KOOS scores appear to be more closely aligned with the personalised knee therapy 
RCT group. 
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Table 8-1: Baseline demographics for the four groups 
 
 RCT 
 
Preference group 
MAT PKT 
 
MAT PKT 
Mean age in years (SD) 27.5 (9.7) 27.5 (7.3) 32.1 (13.4) 26.4 (7.1) 
Male/Female 10/0 8/3 3/3 5/4 
Left/Right 2/8 6/5 2/4 3/6 
Ethnic background Caucasian: 7 
Black 
Caribbean: 1 
Mixed White 
& Asian: 1 
Greek: 1  
Caucasian: 9 
Chinese: 1 
Pakistani: 1 
Caucasian: 6 Caucasian: 9 
Medal/Lateral 
meniscectomy  
1/9 3/8 1/5 3/6 
Normal/Malalignment 7/3 7/4 4/1 4/5 
Smoker – Y/N 3/7 0/11 1/5 0/9 
Alcohol 
Low/Mod/Med/High 
5/3/1/1 8/3/0/0 4/0/1/1 7/1/1/0 
Initial injury mechanism  Sport: 9 
Other trauma: 
1  
Sport: 10 
Other trauma: 
1 
Sport: 5 
Unsure: 1 
Sport: 8 
Discoid 
meniscus: 1 
Under three previous 
knee operations 
5 of 10 4 of 11 4 of 6 7 of 9 
BMI (SD) 26.6 (2.8) 23.1 (3.1) 23.8 (5.0) 25.1 (3.9) 
Mean time from initial 
injury to assessment for 
transplant in years (SD) 
7.6 (7.3) 7.7 (3.3) 9.2 (8.2) 7.4 (3.8) 
Median time from 
randomisation to 
treatment in days 
(Interquartile range) 
198 (152 – 
548) 
35 (4 – 44) 46 (24 – 121) 28 (0 – 118) 
Surgeon performing 
MAT 
TS: 7 
PT: 0 
N/A TS: 4 
PT: 2 
N/A 
 
 
Table 8-2: Baseline MRI data, presented as mean (standard deviation) for each group 
in the RCT, preference group and combined RCT and preference group arms 
 
 RCT 
 
Preference group Combined 
MAT using ‘day 
of 
randomisation’ 
MRIs (n=10) 
MAT 
(n=10) 
PKT 
(n=11) 
MAT 
(n=6) 
PKT 
(n=9) 
MAT 
(n=16) 
PKT 
(n=20) 
Cartilage 
volume (mm3) 
2705  
(632) 
2848 
(723) 
2776 
(508) 
2429 
(1178) 
2222 
(922) 
2601 
(849) 
2527 
(757) 
Cartilage 
thickness 
(mm) 
2.02  
(0.48) 
2.00 
(0.39) 
2.16 
(0.41) 
2.10 
(0.37) 
1.75 
(0.74) 
2.04 
(0.38) 
1.98 
(0.60) 
Bone shape 
(mm2) 
3375 
(360) 
3362 
(380) 
3349 
(384) 
3165 
(756) 
3312 
(593) 
3288 
(535) 
3332 
(476) 
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Table 8-3: Baseline PROMs, presented as mean (standard deviation) for each group 
in the RCT, preference group and combined RCT and preference group arms 
 
 RCT 
 
Preference group Combined 
MAT using 
‘day of 
randomisation’ 
scores (n=10) 
MAT 
(n=10) 
PKT 
(n=11) 
MAT 
(n=6) 
PKT 
(n=9) 
MAT 
(n=16) 
PKT 
(n=20) 
KOOS 
Symptoms  
57.85  
(8.38) 
56.07 
(11.67) 
60.07 
(12.46) 
58.93 
(17.02) 
61.90 
(17.68) 
57.14 
(13.43) 
60.89 
(14.63) 
KOOS 
pain 
51.11  
(14.42) 
49.44 
(15.26) 
68.69 
(13.33) 
58.80 
(18.63) 
69.75 
(20.95) 
52.95 
(16.65) 
69.17 
(16.69) 
KOOS 
ADL 
64.4 
 (12.16) 
58.24 
(13.57) 
85.56 
(14.50) 
75.25 
(14.63) 
77.61 
(21.29) 
64.61 
(15.94) 
81.99 
(17.83) 
KOOS 
sports 
25.5 
 (12.35) 
24.00 
(11.01) 
49.46 
(25.93) 
38.33 
(23.80) 
46.11 
(30.60) 
29.38 
(17.69) 
48.00 
(27.41) 
KOOS 
QoL 
16.25  
(13.88) 
15.63 
(14.21) 
27.27 
(17.06) 
34.38 
(17.57) 
43.75 
(22.75) 
22.66 
(17.66) 
34.69 
(21.02) 
KOOS4 
composite 
37.68 
 (7.68) 
36.28 
(9.38) 
51.39 
(12.99) 
47.60 
(16.49) 
55.37 
(21.71) 
40.53 
(13.25) 
53.19 
(17.07) 
IKDC 
 
54.46  
(16.37) 
52.89 
(17.70) 
48.58 
(12.91) 
55.22 
(16.61) 
57.01 
(16.56) 
53.76 
(16.77) 
52.38 
(14.89) 
Lysholm 
 
57.90  
(17.93) 
57.90 
(18.17) 
58.73 
(11.05) 
64.60 
(16.20) 
69.11 
(17.23) 
60.38 
(17.22) 
63.40 
(14.71) 
 
8.3 Trial delivery 
 
8.3.1 Delay to surgery 
 
In the pilot RCT, there were large differences between the groups in the delay from 
randomisation to the start of the intervention (Table 8-1). The median delay to 
treatment was thirty-five days in the personalised knee therapy group and no 
participants had a delay of four months or greater. In contrast, the median time from 
randomisation to meniscal allograft transplantation was 198 days. In the RCT group, 
five participants waited over six months before having surgery; a further three 
waited for one year before being withdrawn from the study. Although the breakdown 
in time delay was not collected, the majority of the delay for participants waiting 
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over four months was the allocation of an appropriately sized allograft. There were 
five participants in the meniscal allograft transplantation preference group that had 
surgery within four months.  
 
8.3.2 Audit by the study co-sponsors  
 
The study was audited by the co-sponsors (University of Warwick and UHCW NHS 
Trust) on the 13th August 2014, during the recruitment phase. A copy of the report is 
in Appendix K. There were no major or moderate adverse findings and the study 
documentation was found to be kept to a good standard.  
 
8.3.3 Trial Management Group meetings 
 
Trial Management Group (TMG) meetings started in February 2014, once 
recruitment had started. They were initially held every three months, which was then 
extended to every four months once recruitment was on target. These meetings were 
used to resolve issues during the study that had not been anticipated beforehand, as 
well as the development of the chief investigator’s research related skills. Issues that 
were discussed included: Recruitment targets and strategies, research associate 
cover, discussion of delays to surgery and withdrawals. 
 
8.3.4 Intervention fidelity 
 
Fidelity of the interventions was determined by the chief investigator and an 
independent expert (surgeon or physiotherapist, depending on the intervention), with 
the help of the fidelity questionnaires (Appendix I). Participants were classified as 
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having had intervention fidelity if all questions were answered in the affirmative. In 
the meniscal allograft transplantation treatment groups, all thirteen participants that 
had surgery were classified as having had intervention fidelity. The median number 
of rehabilitation sessions amongst participants that had surgery was five (range of 
three to thirteen). In the personalised knee therapy treatment groups, eighteen of 
twenty participants were classified as having had intervention fidelity. Of the two 
participants that did not have fidelity, one was from the RCT arm and the other was 
from the preference group arm. One participant did not attend organised 
physiotherapy sessions and the other decided to withdraw from physiotherapy in 
favour of going on the waiting list for meniscal allograft transplantation. The median 
number of physiotherapy sessions amongst participants having personalised knee 
therapy was 4.5 (range 1 – 18) over a median of 7 months (range 0 – 12 months). 
 
8.3.5 MRI measures 
 
Tables 8-4 to 8-6 show the percentage change of the different MRI measures from 
baseline to four, eight and twelve months in the RCT arm of the trial respectively. 
These results are graphically illustrated in Figures 8-6 to 8-8. Table 8-6 also shows 
the percentage change from baseline to twelve months in the preference groups and 
combined RCT and preference group arms, which is graphically illustrated in 
Figures 8-9 to 8-11. Table 8-7 shows the significance testing for the change MRI 
outcome measures at twelve months. There were no statistically significant 
differences between the groups for any measure.  
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Table 8-4: Change in MRI outcome measures from baseline to four months in the 
RCT arm. Presented as mean (standard deviation) percentage change 
 
 RCT 
 
MAT (n=6) PKT (n=10) 
 
Cartilage volume 
(% change) 
-19.53 (20.65) -7.81 (22.27) 
 
Cartilage thickness 
(% change) 
-14.56 (27.65) -6.90 (16.36) 
 
Bone shape         
(% change) 
-3.38 (6.08) 0.07  (5.33) 
 
 
 
 
Table 8-5: Change in MRI outcome measures from baseline to eight months in the 
RCT arm. Presented as mean (standard deviation) percentage change 
 
 RCT 
 
MAT (n=6) PKT (n=11) 
 
Cartilage volume 
(% change) 
-12.40 (24.03) -8.46 (12.33) 
Cartilage thickness 
(% change) 
-11.18 (19.22) -6.90 (11.14) 
Bone shape  
(% change) 
-9.58 (10.44) -0.29 (5.11) 
 
 
 
 
Table 8-6: Change in MRI outcome measures from baseline to twelve months for 
each group in the RCT, preference group and combined RCT and preference group 
arms. Presented as mean (standard deviation) percentage change 
 
 RCT 
 
Preference group Combined 
MAT 
(n=5) 
PKT 
(n=11) 
MAT 
(n=4) 
PKT  
(n=7) 
MAT 
(n=9) 
PKT 
(n=18) 
Cartilage 
volume (% 
change) 
-8.72 
(16.63) 
-13.47 
(19.54) 
-17.69 
(17.75) 
-2.77 
(24.96) 
-12.82 
(17.06) 
-9.46 
(22.04) 
Cartilage 
thickness 
(% change) 
-7.64 
(14.09) 
-6.88 
(11.94) 
-16.62 
(14.40) 
2.59 
(14.13) 
-11.75 
(14.52) 
-3.30 
(13.49) 
Bone shape 
(% change)  
-10.51 
(23.91) 
-2.64 
(7.13) 
-11.39 
(16.58) 
-3.65 
(5.86) 
-10.92 
(19.54) 
-3.04 
(6.50) 
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Figure 8-6: Mean percentage and standard deviation change for cartilage volume at 
four, eight and twelve months. Note a negative number represents a loss  
 
 
 
 
Figure 8-7: Mean percentage and standard deviation change for cartilage thickness at 
four, eight and twelve months. Note a negative number represents a loss  
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Figure 8-8: Mean percentage and standard deviation change for bone shape at four, 
eight and twelve months. Note a negative number represents a loss  
 
 
 
 
 
Figure 8-9: Mean percentage and standard deviation change for cartilage volume in 
each group in: The RCT, preference group and combined RCT and preference group 
arms 
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Figure 8-10: Mean percentage and standard deviation change for cartilage thickness 
in each group in: The RCT, preference group and combined RCT and preference 
group arms 
 
 
 
 
Figure 8-11: Mean percentage and standard deviation change for bone shape in each 
group in: The RCT, preference group and combined RCT and preference group arms 
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Table 8-7: Significance testing results for percentage change in the MRI outcomes 
from baseline to twelve months in: The RCT, and combined RCT and preference 
group arms. A positive mean and confidence interval represents a higher number in 
the meniscal allograft transplantation group 
 
 RCT Combined  
 
Mean difference  
(95% CI) 
P value Mean difference 
(95% CI) 
P value 
Cartilage 
volume  
5.48  
(-13.53 – 28.67) 
0.556 -3.72  
(-17.72 – 12.67) 
0.624 
Cartilage 
thickness 
-0.83  
(-13.54 – 13.75) 
0.899 -8.73  
(-18.15 – 1.77) 
0.096 
Bone shape 
change 
-8.08  
(-20.78 – 6.65) 
0.233 -8.13  
(-19.99 – 5.53) 
0.223 
 
 
 
Table 8-8 shows the pooled standard deviations for change in MRI outcomes at 
twelve months post-intervention. The pooled standard deviations for the primary 
outcome measure, cartilage volume change, were 18.14 and 19.71 for the RCT and 
combined RCT and preference group arms respectively.  
 
 
 
Table 8-8: Pooled standard deviations for percentage change in MRI outcomes from 
baseline to twelve months in: The RCT and the combined RCT and preference group 
arms 
 
 RCT Combined 
Cartilage volume  18.14 19.71 
Cartilage thickness 13.06 10.55 
Bone shape change 17.64 14.56 
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8.3.6 Patient reported outcome measures 
 
Table 8-9 shows significance testing of the baseline differences between the RCT 
and preference groups. There was a trend towards higher PROMs in the meniscal 
allograft transplantation preference group, compared to the meniscal allograft 
transplantation RCT group but this was only statistically significant in the KOOS 
activities of daily living (ADLs) and Quality of Life (QoL) sub-domains and not the 
composite score, or other PROMs. Differences between the personalised knee 
therapy groups were not statistically significant. When combining the RCT groups 
and comparing them to the combined preference groups, there was also a trend 
towards higher PROMs in the preference groups but this was not statistically 
significant, except for the KOOS QoL sub-domain.  
 
 
Table 8-9: Significance testing for differences between the RCT and preference 
groups. Note all PROMs below range from 0 to 100, with 100 being the highest 
achievable score. KOOS4 is a composite score made up of the average of all KOOS 
sub-domains, except ADLs. Note a positive mean difference favours the preference 
group scores being higher. 
 
 MAT PKT Combined RCT and 
preference group 
Mean difference 
(95% CI) 
P 
value 
Mean difference 
(95% CI) 
P 
value 
Mean difference 
(95% CI) 
P 
value 
KOOS 
Symptoms 
2.86  
(-12.45 – 18.16) 
0.695 1.839 
(-12.33 – 16.01) 
0.788 2.55  
(-7.19 – 12.30) 
0.598 
KOOS Pain 
 
9.35  
(-8.97 – 27.67) 
0.292 1.07  
(-15.12 – 17.25) 
0.891 5.85  
(-6.78 – 18.48) 
0.353 
KOOS ADL 
 
17.01  
(0.63 – 33.39) 
0.043 -7.95  
(-24.79 – 8.89) 
0.335 4.11  
(-8.99 – 17.23) 
0.528 
KOOS 
Sports 
14.33  
(-10.63 – 39.30) 
0.212 -3.43  
(-29.97 – 23.10) 
0.789 5.62  
(-11.77 – 23.00) 
0.516 
KOOS QoL 
 
18.75  
(1.59 – 35.91) 
0.034 16.48  
(-2.21 – 35.17) 
0.080 18.27  
(5.67 – 30.88) 
0.006 
KOOS4 
composite 
11.32  
(-2.41 – 25.05) 
0.099 3.99  
(-12.45 – 20.43) 
0.617 8.07  
(-3.12 – 19.26) 
0.152 
IKDC 
 
2.33  
(-16.86 – 21.51) 
0.798 7.99  
(-5.65 – 21.64) 
0.234 5.43  
(-5.14 – 16.00) 
0.304 
Lysholm 
 
6.60 
(-12.77 – 25.98) 
0.477 10.47 
(-2.92 – 23.87) 
0.118 8.98  
(-1.55 – 19.51) 
0.092 
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Table 8-10 to 8-12 show the changes in PROMs from baseline to four, eight and 
twelve months respectively in the different groups. Figure 8-12 to 8-19 graphically 
demonstrate the changes in scores at the different time points. PROMs scores 
improved over time in the meniscal allograft transplantation group, whereas a 
progression in the personalised knee therapy group was not clear. Table 8-13 shows 
the mean differences and significance testing of the various groups. In the RCT, the 
differences between the groups were not statistically significant except the KOOS 
ADLs sub-domain (p=0.029), although the KOOS4 composite score was 
approaching significance (p=0.054). When combining the RCT and preference group 
participants the improvement in the meniscal allograft transplantation group was 
significant in the KOOS4 composite score and all the KOOS sub-domains except 
Sports (p=0.055). The differences were also close to, but did not reach, statistical 
significance in the IKDC (p=0.062) and Lysholm (p=0.103) scores. 
 
Table 8-10: Change in PROMs from baseline to four months. Presented as mean 
(standard deviation) for each group in the RCT, preference group and combined 
RCT and preference group arms 
 
 RCT Preference group 
 
Combined 
MAT 
(n=6) 
PKT 
(n=10) 
MAT 
(n=6) 
PKT  
(n=7) 
MAT 
(n=12) 
PKT 
(n=17) 
KOOS 
Symptoms 
7.74 
(13.25) 
8.21 
(13.58) 
-4.29 
(31.35) 
13.06 
(11.71) 
1.73 
(23.79) 
10.21 
(12.70) 
KOOS 
Pain 
5.56 
(20.86) 
14.72 
(12.15) 
6.48 
(25.13) 
3.57  
(8.13) 
6.02 
(22.03) 
10.13 
(11.82) 
KOOS 
ADL 
10.29 
(17.25) 
2.50 
(18.99) 
3.92 
(17.52) 
5.67  
(4.76) 
7.11 
(16.91) 
3.81 
(14.62) 
KOOS 
Sports 
-6.67 
(15.38) 
4.00 
(34.86) 
-5.83 
(14.63) 
10.71 
(12.05) 
-6.25 
(14.31) 
6.76 
(27.38) 
KOOS 
QoL 
11.45 
(11.47) 
5.00  
(7.68) 
0.00 
(24.69) 
9.82  
(6.10) 
5.73 
(19.30) 
6.99  
(7.29) 
KOOS4 
composite 
4.52  
(9.69) 
7.98 
(11.39) 
-0.91 
(21.98) 
9.29  
(4.95) 
1.81 
(16.44) 
8.52  
(9.09) 
IKDC 
 
1.75  
(9.52) 
4.68 
(11.47) 
-10.88 
(20.92) 
5.53  
(7.88) 
-4.57 
(16.84) 
5.03  
(9.87) 
Lysholm 
 
-3.67 
(19.18) 
14.60 
(10.89) 
-4.83 
(27.38) 
6.00 
(13.88) 
-4.25 
(22.55) 
11.06 
(12.57) 
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Table 8-11: Change in PROMs from baseline to eight months. Presented as mean 
(standard deviation) for each group in the RCT, preference group and combined 
RCT and preference group arms 
 
 RCT 
 
Preference group Combined 
MAT 
(n=6) 
PKT 
(n=11) 
MAT 
(n=4) 
PKT  
(n=7) 
MAT 
(n=10) 
PKT 
(n=18) 
KOOS 
Symptoms 
16.12 
(7.82) 
13.31 
(10.24) 
33.75 
(8.35) 
9.49 
(10.16) 
23.17 
(11.84) 
11.82 
(10.09) 
KOOS 
Pain 
28.24 
(14.32) 
11.36 
(17.01) 
31.25 
(13.10) 
3.97 
(12.41) 
29.45 
(13.17) 
8.49 
(15.44) 
KOOS 
ADL 
28.19 
(9.68) 
6.95 
(15.62) 
26.47 
(18.25) 
7.56 
(10.27) 
27.50 
(12.80) 
7.19 
(13.45) 
KOOS 
Sports 
19.17 
(19.85) 
10.45 
(34.17) 
26.25 
(19.74) 
2.86 
(18.45) 
22.00 
(19.03) 
7.50 
(28.66) 
KOOS 
QoL 
26.04 
(10.77) 
18.75 
(10.83) 
31.25 
(0.00) 
16.96 
(20.95) 
28.13 
(8.46) 
18.06 
(14.99) 
KOOS4 
composite 
22.39 
(9.44) 
13.47 
(13.87) 
30.62 
(5.68) 
8.32 
(13.58) 
25.68 
(8.85) 
11.47 
(13.60) 
IKDC 
 
11.14 
(5.87) 
9.92 
(13.39) 
24.64 
(3.44) 
11.80 
(12.27) 
16.54 
(8.47) 
10.66 
(12.63) 
Lysholm 
 
16.00 
(16.04) 
14.91 
(14.49) 
26.25 
(17.54) 
7.00 
(15.87) 
20.10 
(16.54) 
11.83 
(15.11) 
 
 
Table 8-12: Change in PROMs from baseline to twelve months. Presented as mean 
(standard deviation) for each group in the RCT, preference group and combined 
RCT and preference group arms 
 
 RCT Preference group 
 
Combined 
MAT 
(n=5) 
PKT 
(n=11) 
MAT 
(n=4) 
PKT  
(n=7) 
MAT 
(n=9) 
PKT 
(n=18) 
KOOS 
Symptoms 
21.43 
(8.75) 
13.31 
(15.49) 
35.53 
(9.32) 
11.53 
(10.49) 
27.70 
(11.23)  
12.62 
(13.45) 
KOOS 
Pain 
27.78 
(10.39) 
11.36 
(16.73) 
37.50 
(12.53) 
7.54 
(16.64) 
32.10 
(11.79) 
9.88 
(16.32) 
KOOS 
ADL 
23.82 
(10.26) 
0.80 
(19.77) 
24.63 
(16.83) 
9.18 
(14.92) 
24.18 
(12.61) 
4.06 
(18.06) 
KOOS 
Sports 
20.00 
(7.91) 
9.09 
(30.81) 
30.00 
(9.13) 
12.14 
(20.18) 
24.44 
(9.50) 
10.28 
(26.54) 
KOOS 
QoL 
28.75 
(8.39) 
19.32 
(15.17) 
32.19 
(11.79) 
13.39 
(17.47) 
30.28 
(9.52) 
17.01 
(15.87) 
KOOS4 
composite 
24.49 
(5.31) 
13.27 
(15.76) 
33.81 
(4.57) 
11.15 
(13.46) 
28.63 
(6.79) 
12.45 
(14.53) 
IKDC 
 
18.42 
(4.37) 
7.16 
(17.85) 
23.71 
(7.36) 
14.42 
(8.98) 
20.77 
(6.13) 
10.37 
(15.27) 
Lysholm 
 
22.60 
(16.56) 
16.46 
(17.57) 
25.00 
(13.95) 
7.86 
(11.10) 
23.67 
(14.55) 
13.11 
(15.61) 
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C: Combined RCT and preference group 
Figure 8-12: KOOS Symptoms mean and standard deviation change at four, eight 
and twelve months for A: RCT groups, B: Preference groups and C: Combined RCT 
and preference groups 
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B: Preference group 
 
 
 
C. Combined RCT and preference group 
 
Figure 8-13: KOOS Pain mean and standard deviation change at four, eight and 
twelve months for A: RCT groups, B: Preference groups and C: Combined RCT and 
preference groups 
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A: RCT 
 
 
 
B: Preference group 
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C: Combined RCT and preference group 
 
Figure 8-14: KOOS ADLs mean and standard deviation change at four, eight and 
twelve months for A: RCT groups, B: Preference groups and C: Combined RCT and 
preference groups 
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B: Preference group 
 
 
 
C: Combined RCT and preference group 
 
Figure 8-15: KOOS Sports mean and standard deviation change at four, eight and 
twelve months for A: RCT groups, B: Preference groups and C: Combined RCT and 
preference groups 
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A: RCT 
 
 
 
B. Preference group 
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C. Combined RCT and preference group 
 
Figure 8-16: KOOS QoL mean and standard deviation change at four, eight and 
twelve months for A: RCT groups, B: Preference groups and C: Combined RCT and 
preference groups 
 
 
 
A. RCT 
 
 
4 8 12
-30
-20
-10
0
10
20
30
40
50
Time (months)
K
O
O
S 
Q
oL
 C
ha
ng
e MAT
PKT
4 8 12
-30
-20
-10
0
10
20
30
40
50
Time (months)
K
O
O
S 
Co
m
po
sit
e 4
 C
ha
ng
e
MAT
PKT
 181 
 
B: Preference group 
 
 
 
 
 
C. Combined RCT and preference group 
 
Figure 8-17: KOOS Composite4 mean and standard deviation change at four, eight 
and twelve months for A: RCT groups, B: Preference groups and C: Combined RCT 
and preference groups 
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A: RCT 
 
 
 
B: Preference group 
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C: Combined RCT and preference group 
 
Figure 8-18: IKDC mean and standard deviation change at four, eight and twelve 
months for A: RCT groups, B: Preference groups and C: Combined RCT and 
preference groups 
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B: Preference group 
 
 
 
C: Combined RCT and preference group 
 
Figure 8-19: Lysholm mean and standard deviation change at four, eight and twelve 
months for A: RCT groups, B: Preference groups and C: Combined RCT and 
preference groups 
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Table 8-13: Significance testing for change in PROMs from baseline to twelve 
months in the RCT arm and combined RCT and preference group arms. A positive 
mean and confidence interval difference favours surgery 
 
 RCT 
 
Combined 
Mean difference  
(95% CI) 
P value Mean difference 
(95% CI) 
P value 
KOOS 
Symptoms 
8.12 (-7.97 – 24.20) 0.300 15.08 (4.33 – 25.82) 0.008 
KOOS Pain 
 
16.42 (-1.16 – 33.99) 0.065 22.22 (9.60 – 34.85) 0.001 
KOOS ADL 
 
23.02 (2.68 – 43.36) 0.029 20.12 (6.24 – 34.00) 0.006 
KOOS Sports 
 
10.91 (-19.60 – 41.42) 0.456 14.17 (-0.33 – 28.65) 0.055 
KOOS QoL 
 
9.43 (-6.28 – 25.14) 0.219 13.26 (1.37 – 25.16) 0.030 
KOOS4 
composite 
11.22 (-0.21 – 22.65) 0.054 16.18 (7.73 – 24.64) 0.001 
IKDC 
 
11.26 (-6.39 – 28.92) 0.193 10.40 (-0.58 – 21.38) 0.062 
Lysholm 
 
6.15 (-13.85 – 26.14) 0.521 10.56 (-2.29 – 23.40) 0.103 
 
Table 8-14 shows the pooled standard deviations for the change in PROMs from 
baseline to twelve months. The KOOS4 composite pooled standard deviation in the 
RCT arm was 11.76; the pooled standard deviation was 12.79 in the combined RCT 
and preference group arms.  
 
Table 8-14: Pooled standard deviations for change in PROMs from baseline to 
twelve months in the RCT arm and the combined RCT and preference group arms 
 
 RCT Combined 
KOOS4 composite 11.76 12.79 
IKDC 12.99 11.64 
Lysholm 17.07 15.09 
 
 
 186 
8.3.7 Complications 
 
In the meniscal allograft transplantation groups there were three complications in 
two participants. One participant in the RCT arm had a diagnostic arthroscopy for a 
suspected meniscal tear at six months. No tear was seen and no other procedure was 
performed. The second participant was in the preference group and had an 
arthroscopy within four months of surgery, following a fall, where a haemarthrosis 
was diagnosed. This was washed out as part of the procedure. Two months later 
another arthroscopy was performed, where a small tear of the allograft was 
diagnosed and trimmed. 
 
In the personalised knee therapy group, one participant reported soreness and 
irritation from the offloading knee brace, requiring it not be used for a period of 
time. 
 
8.4 Discussion 
 
The aim of a pilot study is to provide information that will inform the design and 
conduct of a definitive evaluation. This pilot highlighted a number of issues that 
need careful consideration in the context of a definitive evaluation. One key factor in 
determining whether a full RCT is deliverable within reasonable timescales is the 
recruitment rate. In this pilot, twenty-one of the thirty-eight eligible participants 
consented to be part of the RCT (fifty-five per cent). It is notoriously difficult to 
recruit into operative versus non-operative RCTs due strong patient preferences, 
resulting from the wide difference in treatments71. One study reviewed publicly 
funded trials and found it took nearly twice as long to recruit to operative versus 
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non-operative trials, compared to either operative or non-operative trials71. A wide 
range of recruitment rates have been reported for operative versus non-operative 
trials: Jarvik et al. reported a recruitment rate of twenty-two per cent in a multi-
centre RCT comparing surgical decompression to non-operative treatment for carpal 
tunnel syndrome144. Klazen et al. reported a recruitment rate of forty-two per cent in 
a multi-centre RCT comparing vertebroplasty to non-operative treatment for 
osteoporotic vertebral fractures157. In a pilot study comparing arthroscopic hip 
surgery to physiotherapy for the treatment of femoroacetabular impingement (UK 
FASHIoN), the recruitment rate was seventy per cent280. Although a fifty-five per 
cent recruitment rate is reasonable, it is likely to be higher than what could be 
achieved if a multi-centre RCT was performed. Lead sites of multi-centre RCTs and 
single site RCTs are known to recruit at higher rates than satellite centres189. The 
authors of the MRC framework also advise caution when interpreting recruitment 
and retention rates of pilot studies, as they may not truly reflect a full RCT75. It is 
also possible that the recruitment rate in this pilot RCT was higher because the chief 
investigator, who is medically trained, recruited all participants. However, previous 
trials have shown that trained recruiters were able to achieve similar recruitment 
rates to surgeons, in surgical RCTs84, 280. When considering a full RCT, a 
conservative strategy would be to estimate recruitment time based on a lower 
recruitment rate than fifty-five per cent. 
 
One strategy to improve recruitment rate could be to expand the eligibility criteria. 
This may also have the added benefit of increasing the external validity. However, 
Figure 8-4 shows that no single exclusion criterion accounted for more than four 
potential participants. It would also not be possible to expand the eligibility criteria 
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to account for the most common exclusions: Surgeon decision and need for other 
concurrent surgery. 
 
One of the concerns with studies that have low recruitment rates is the limited 
external validity. If a very low percentage of eligible participants entered into a RCT, 
the results of the trial can only be safely applied to future people in clinic that would 
have been willing to be randomised themselves, which would be unknown. This 
issue is particularly recognised in operative versus non-operative RCTs, where a 
comprehensive cohort study design has been suggested70, 75. A comprehensive cohort 
design was used for this study, where patients that were unwilling to be randomised 
entered preference groups and were followed up in a similar manner. This study 
design has the advantage of increasing the external validity, but has not been widely 
used as it has a high cost for a perceived relatively low additional gain70. It has been 
used successfully where the preference group data provided strong external validity 
of results of a RCT with a low recruitment rate153. However, it has also failed to be 
useful when there was a strong preference for one treatment over the other148. In this 
pilot, there was only a marginal preference for personalised knee therapy (nine 
participants) compared to meniscal allograft transplantation (six participants), in the 
preference group arm. It is likely that the recruitment rate for a full RCT will be 
lower than fifty-five per cent; a comprehensive cohort design may be important to 
demonstrate external validity in the majority of eligible patients not willing to be 
randomised. The difficulty with a comprehensive cohort design is whether it is 
appropriate to merge the outcome data from the randomised and preference groups.  
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In a pilot, merging the outcomes to get a pooled standard deviation from all 
participants has the potential advantage of increasing the precision of the estimate of 
variation in the population, in order to calculate a sample size for a definitive 
evaluation. This may be particularly useful to assess variation in PROMs in this 
study where the pilot RCT participant numbers were small, as the sample size was 
based on the primary outcome measure of MRI volume change. This pilot is also 
likely to provide an underestimate of the population standard deviation and therefore 
underestimate the sample size needed in a full RCT. In this light, the potential 
downsides of merging the RCT and preference groups appear small. In the case of 
the KOOS4 composite, the pilot RCT standard deviation was 11.76 and merged 
standard deviation was 12.79. Using the merged standard deviation in a sample size 
calculation would be more conservative, requiring a larger sample size.   
 
Merging the outcomes of the RCT and preference groups to increase the power of a 
study to detect a difference between treatments is more controversial. The main 
disadvantage of doing this is that you reduce the internal validity of the study by 
introducing the risk of selection bias. Participants not willing to be randomised are 
likely to have different characteristics than those that are, risking undermining the 
whole process of randomisation; for example they may believe one treatment to be 
far superior to the other. In this study, preference group participants were also treated 
differently, as they were followed up as per routine follow up appointments, which 
may also have an effect on the outcomes. Additionally the delay to surgery was less 
for the preference group participants, which may reflect that some participants had 
already discussed surgery with the surgeon at previous appointments and progressed 
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down the surgical route prior to enrolling in the study. This may further change the 
characteristics of participants in the preference group, compared to the RCT group.  
 
The advantage of merging the groups is that the power of the study to detect a 
difference is increased. There were no major imbalances in the baseline 
demographics between the RCT and preference groups. Differences in baseline 
PROMs were not statistically significant between the meniscal allograft 
transplantation groups, personalised knee therapy groups or the merged RCT and 
preference groups, although numbers were too small to draw conclusions with 
confidence. It was also stated a priori in a published protocol that RCT and 
preference group results would be merged if appropriate247. In this study, the mean 
difference in the KOOS4 composite score had borderline statistical significance in 
the RCT (p=0.054), but was statistically significant with merged RCT and 
preference groups (p=0.001). The IKDC and Lysholm scores were closer to 
statistical significance in the merged groups, but were not significant at the five per 
cent level. Whilst the risk of selection bias makes it impossible to draw definitive 
inferences, these results as they stand, provide evidence that surgical intervention 
may well benefit patients and that this should be tested in a full RCT. Over 
interpretation of these results as definitive evidence of effectiveness should be 
avoided for a number of reasons: The final participants that had a delay to surgery 
are yet to complete final follow up, which may change the results. The risk of 
selection bias from combining the RCT and preference groups remains, and the 
statistical analysis in this study was exploratory in nature. As such, the results may 
suggest a benefit of one treatment over another, but cannot support inferential 
conclusions. A fully powered pragmatic multi-centre RCT would be able to do so, 
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and also has higher external validity to allow a safer extrapolation of the outcome to 
other centres. Historically, the premature adoption of the results of single centre 
trials have resulted in ineffective treatments being recommended, or worse, and 
should be avoided27. 
 
This pilot showed that there was a long delay to surgery for the majority of 
participants. The median time to surgery was over six months, even excluding the 
three participants that did not have surgery within one year of entering the study. 
This causes two main concerns: Firstly, withdrawing participants from one side of a 
RCT in this way risks biasing the outcomes. However, the reason for withdrawal was 
due to the lack of availability of particular sizes of allograft. There is no obvious link 
between certain sizes of allograft and different outcomes in the general population. 
Therefore, it was not considered that withdrawing these participants would alter the 
outcomes, beyond withdrawing any participants at random. Secondly, it poses 
deliverability of a full RCT issues if thirty per cent of participants assigned to 
surgery do not receive the intervention within a year and the majority do not receive 
surgery within six months. It is likely that it would need to be shown that the delay 
to surgery could be reduced before a definitive evaluation could be undertaken. The 
delay to finding an allograft is mainly due to waiting for an adequate size match, 
although administration processes may be streamlined as well. This process could be 
reduced if more tissue banks were used, giving a larger pool of available allografts. 
This needs to be weighed against cost and each tissue provider’s credentials, for 
example whether their sterilisation, storage and administration procedures were 
considered appropriate.   
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In this pilot, a recruitment rate of fifty-five per cent equated to 1.75 participants per 
month. Whilst it is reasonable to assume that this is likely to be relatively constant at 
UHCW, it is not known how many other centres are performing the operation and 
how many eligible patients they see monthly. The majority of patients seen for 
consideration of meniscal allograft transplantation are referred from outside of the 
local area. It is likely that some other centres are performing considerably fewer 
meniscal allograft transplantations if they do not get referrals from outside their area. 
This information would need to be ascertained either before or within an internal 
pilot for a multi-centre RCT. 
 
Relatively few patients were screened and deemed ineligible for this study (thirteen 
of fifty-one). This is likely to be due to the set up at UHCW for seeing patients that 
may be suitable for meniscal allograft transplantation. The operating surgeons screen 
all referrals and if they are appropriate, requests for further information are sent, 
including: A completed proforma, radiological and arthroscopic images. Once these 
steps are completed, patients are seen in once monthly ‘meniscal reconstruction’ 
clinics. This had two main benefits relating to the study: It reduced the chance of 
potential participants being missed, and there were fewer inappropriate referrals. 
This system also explains the almost stepwise recruitment graphs: Clinics were 
cancelled over Christmas and summer due to a surgeon’s holidays; the extra patients 
were then seen in proceeding month’s clinic. In considering a full RCT, this set up 
reduces the number of clinics that researchers need to attend in order to recruit 
participants at UHCW.  
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Another key consideration in a full RCT is the choice of primary endpoint. In this 
pilot, the change in cartilage volume at one year following the intervention was 
defined as the primary endpoint. No statistically significant differences were seen for 
cartilage volume change (or any other MRI outcome measure) at twelve months. 
Whilst it is difficult to draw any conclusions with confidence due to the small 
sample size, it is interesting to note that the trend in cartilage volume change over 
time between the two RCT groups was opposite. In the meniscal allograft 
transplantation group the mean loss is initially higher, which then improved at the 
eight and twelve month time points. The reverse happened in the personalised knee 
therapy group, which might be the expected trend in a sample of participants with or 
at risk of OA. This trend is approximately matched in the cartilage thickness scores. 
It cannot be known in this study whether this is a true phenomenon or the result of 
sampling error.  
 
Cartilage volume change represents structural change in the knee and is a surrogate 
endpoint for the progression of OA. Well validated surrogate endpoints are 
commonly used in clinical trials, for example blood pressure (as a surrogate for 
cardiovascular or cerebrovascular disease) and glycosylated haemoglobin (as a 
surrogate for diabetes)145. The main advantages of using a surrogate endpoint in this 
pilot are that OA has a long lag time and patients’ symptoms are highly variable. 
Cartilage volume change can shorten the length of a clinical trial and may also 
reduce the number of participants needed to determine whether a difference between 
groups exists18. If, for example, knee replacement was used as an endpoint, an 
extremely long trial with large numbers of participants would be needed, making it 
impractical to run. The NICE clinical (national) guideline research recommendations 
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for OA state that structural changes are more closely linked to OA symptoms than 
initially thought and that prevention of structural changes is likely to prevent or 
delay OA204. It is further suggested that appropriate structural endpoints include 
changes in joint space width on plain radiographs or MRI features of OA. In chapter 
four it was suggested that joint space width may not be a useful measure in meniscal 
allograft transplantation trials due to the potential confounding effect of the allograft 
on joint space width, as well as being insensitive to early OA change. Articular 
cartilage loss is a cardinal feature of OA and has been increasingly measured, as 
MRI imaging and interpretation improves36, 42, 215. A number of studies have assessed 
cartilage changes in the knee using segmented MRI images, similar in technique to 
the one in this study, finding statistically significant losses at one year135, 223, 283. It 
has also consistently been shown that the cartilage loss in the central weight bearing 
region of the tibiofemoral joint is greater than global loss90, 135, 161, 223, 283, 288.  
 
For cartilage volume loss on MRI to be a useful surrogate endpoint, higher losses 
need to be predictive of future clinically meaningful OA. Knee replacement is 
recognised as a useful measure of end stage OA, although this also has limitations. It 
has been shown that higher rates of cartilage loss in the knee are predictive of future 
knee replacement: Cicuttini et al. studied 113 patients with mild to moderate knee 
OA, finding an odds ratio of knee replacement at four years of 2.3 for patients with 
three to eight per cent and 7.1 for greater than eight per cent yearly tibial cartilage 
volume loss, compared to patients with less than three per cent yearly loss (at two 
years); they also observed a biological gradient of cartilage loss and risk of knee 
replacement66. The results of a study by Raynauld et al. showed a stronger 
association, with an odds ratio of 18.7 for knee replacement at a mean of six years 
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with greater medial compartment loss and 3.57 for global cartilage loss (at two 
years), both of which were statistically significant223. A recent systematic review on 
the predictive value of MRI outcomes concluded that cartilage volume loss 
correlates with joint space loss, is sensitive to change and predicts outcomes in a 
continuous manner215. The authors also stated that it is a useful tool for the 
evaluation of structural changes and the prediction of knee replacement. 
 
Determining the minimum clinically important difference (MCID) is important in 
order to calculate a sample size for a definitive RCT. There is no single definitive 
method for determining the MCID, but there are two general approaches. Using an 
anchor-based approach has the advantage of being linked to an difference that is 
clinically meaningful from the patient’s perspective and is often the preferred 
method77. It is however difficult to use this approach for cartilage volume change, as 
there are no studies that have shown its effect on a clinically meaningful outcome in 
the patient group under investigation. The nearest comparison may come from the 
study by Cicuttini et al., where the odds ratio of 7.1 for patients with greater than 
eight per cent loss compared to those with less than three per cent loss provides a 
minimum difference of five per cent66.  
 
Using this as the MCID and the pooled standard deviation from this pilot of 18.14, a 
two-sided independent samples t-test with a power of 0.9 and significance level of 
0.05, 278 participants are needed in each group for a full RCT. Allowing for a fifteen 
per cent loss to follow up, 320 are needed in each group (640 in total). However, 
their results are not directly comparable to the outcome measure used in this pilot as 
only the central weight bearing area in the affected compartment was assessed. The 
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effect of this is likely to be that the sample size calculation provides an overestimate 
the number of participants needed. Relatively larger cartilage losses were seen in 
both treatment groups in this pilot, compared to studies in the literature88, 134, 283. This 
may be due to sampling error from the small sample, assessing a focal area of fast 
cartilage change, identifying ‘fast-progressor participants’ or a combination of 
factors.   
 
An alternative approach is to use a distribution-based method. One advantage of this 
approach is that it can account for change beyond some level of random variation289. 
Several distribution-based methods have been proposed, with no one method being 
definitively determined as superior289. One common method is to define the MCID 
as one half of the standard deviation of the change between pre- and post-treatment23, 
262, 289. This equates to a standardised effect size of 0.5, which is considered a 
‘moderate’ effect67, 289. Using the same power and significance parameters as before, 
eighty-five participants are needed in each group for a full RCT. Allowing for a 
fifteen per cent loss to follow up, 100 are needed in each group (200 in total). 
 
Whilst there are some advantages to using cartilage volume as the primary endpoint, 
there are also some problems with its use. Surrogate endpoints are best when the 
pathogenesis of the disease is well understood18. This is not true for OA and 
although cartilage loss is a key feature, OA is a heterogeneous and relatively poorly 
understood group of diseases, with very few effective disease modifying 
treatments36. Whilst there are some encouraging studies showing that higher rates of 
cartilage loss are predictive of future OA, there is not a wealth of high level evidence 
that can be used to accurately predict a clinically meaningful effect based on a 
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difference in the rate of cartilage volume loss. These factors limit the validity of 
cartilage volume as an outcome measure at present. Another key aspect of validating 
a surrogate endpoint is to demonstrate that a treatment-related change has an impact 
on the course of the disease; something that has not yet been demonstrated for 
cartilage change. Surrogates are also situation (or treatment) specific; therefore, the 
effect of a reduction in the loss of cartilage volume in young patients following 
meniscal allograft transplantation may not be the same as an older patient with a 
slow rate of cartilage loss145.  
 
Another limitation of cartilage volume change is the associated measurement error. 
IMorphics have previously reported their repeatability of cartilage measurement to 
be around two per cent, using the coefficient of variation (relative standard 
deviation), which compares well with other studies that have assessed the same 
thing.89, 135 Whilst this is relatively small, it does mean that observed differences may 
be due, in part, to measurement error. It is not anticipated that measurement error 
would affect one group more than another, so in a full RCT it is likely that any 
measurement error would be balanced between groups. 
 
Due to the only partial validation of cartilage volume, its surrogate nature and the 
difficulties in determining a sample size, it may be more appropriate to use another 
outcome measure as the primary endpoint. PROMs are gaining increasing popularity 
as an outcome tool, both in research and in clinical practice, due to an increased 
acknowledgement that the outcome of treatments should reflect factors that matter to 
the patient199. PROMs are widely used to assess the treatment response in RCTs with 
patients that have OA86. Although a large number of PROMs have been used, the 
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Western Ontario and McMaster Universities Arthritis Index (WOMAC) measure 
was found to be the most commonly used in OA RCTs86. The KOOS was developed 
as an extension of the WOMAC measure in the 1990s so that it could be used for 
younger and more active patients with knee injury that can result in, or has already 
resulted in OA229. It is intended for short and long term use and has been validated to 
assess the outcome after a range of knee operations in generally younger patients 
than the WOMAC measure25, 227, 237, 282. Whilst it has five domains with separate 
scores, a composite score can be created for use in clinical trials; this was 
demonstrated in a seminal RCT comparing early ACL reconstruction to potential 
delayed ACL reconstruction107. The KOOS is used in a number of large databases 
including the National Institute for Health Osteoarthritis Initiative, a large 
longitudinal prospective observational study of patients with risk factors for, or 
established OA2. The KOOS was also unanimously chosen as the primary region 
specific outcome measure to be used in studies of meniscal allograft transplantation, 
during a consensus exercise at the most recent International Meniscal Reconstruction 
Experts Forum meeting (2015) in Lyon, France.   
 
The MCID for the KOOS has not been definitively determined, but a ten point 
difference has been proposed and also used in previous clinical trials, with a standard 
deviation of fifteen107, 227. This MCID was determined based on the WOMAC score, 
where an MCID has been assessed. Whilst a formal assessment of the KOOS would 
be most appropriate, the KOOS does contain the full version of the WOMAC and is 
therefore likely to have some similar characteristics. Using these parameters, a two-
sided independent samples t-test with a power of 0.9 and significance level of 0.05, 
forty-eight participants are needed in each group for a full RCT. Allowing for two 
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groups and a fifteen per cent loss to follow up, 114 participants are needed in total. 
Using the pooled standard deviation from this pilot RCT of 11.79, thirty participants 
are needed in each group for a full RCT. Allowing for two groups and a fifteen per 
cent loss to follow up, seventy participants are needed in total. Using the combined 
RCT and preference group pooled standard deviation of 12.79, thirty-five 
participants are needed in each group for a full RCT. Allowing for two groups and a 
fifteen per cent loss to follow up, eighty-two participants are needed in total. This 
represents a range of between 70 and 114 participants needed if the KOOS was the 
primary outcome measure. 
 
The alternative method of defining the MCID as half a standard deviation of the 
change scores would give a sample of eighty-five participants in each group. 
Allowing for a fifteen per cent loss to follow up, 100 participants would be needed in 
each group (200 in total). 
 
The design of a trial depends on the research question being asked. A pragmatic trial 
is designed to ask whether an intervention works in real life conditions, and is able to 
answer whether it works, but only gives a limited insight into how it works. An 
explanatory trial asks whether an intervention works in ideal conditions and is more 
concerned with how it works, but only gives a limited insight into whether it works 
in real life conditions. Pragmatic trials have gained increasing popularity in recent 
years and are more able to drive health policy105. These terms represent the ends of a 
spectrum and a study may contain elements of both designs, depending on the 
research question201, 258.  
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With a full RCT in mind, the design of this pilot was predominantly pragmatic, with 
some explanatory components: It had broad eligibility criteria, allowing the surgeon 
to make an individual judgement as to whether he/she thought a patient would 
benefit from meniscal allograft transplantation; although patients with significant 
cartilage loss were excluded, this is representative of the majority of surgeons that 
report their indications; the intervention and comparator protocols were pragmatic, 
allowing for variation depending on the individual participant and 
surgeon/physiotherapist; the interventions themselves were not strictly meniscal 
allograft transplantation compared to physiotherapy, as osteotomy and bracing were 
used when malalignment was present. This study design allows an assessment of the 
full treatment that a patient would receive in real life conditions. One of the 
limitations of this study design is that the ‘active ingredients’ of the intervention are 
often difficult to specify54, 75, 105, but this is not a priority for pragmatic trials. 
Another factor that moves this study towards the pragmatic end of the spectrum is 
that the interventions were two different treatments that are currently being used on 
the NHS. This allows the assessment of whether one treatment is superior, regardless 
of any potential placebo effects226. 
 
The main explanatory components of this study were the choice of primary outcome 
measure and the decision to define baseline as the start date of the intervention, 
rather than the day of randomisation. As previously discussed, cartilage volume 
change is a surrogate endpoint, representing structural progression of OA. A PROM 
such as the KOOS would be considered a more pragmatic outcome measure as it 
directly reflects the range of health gains from the patients’ point of view226. When 
considering a full RCT, a PROM would be a more useful measure to drive the 
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implementation, or otherwise, of the intervention, whilst cartilage volume change 
could anchor the results by giving a biological basis for the response to the 
intervention.  
 
One of the difficulties with the evaluation of meniscal allograft transplantation is that 
there can be a long delay from the decision to start treatment to the operation. 
Waiting list delays are not uncommon in elective surgical procedures, which is 
exacerbated in the case of meniscal allograft transplantation by the need for a size 
matched graft, as well as the limited number of surgeons that can perform the 
operation. Waiting list effects can influence outcomes, particularly if the follow up 
appointments are during the early healing stage after surgery261. If, for example, a 
participant assigned to meniscal allograft transplantation had an eleven month delay 
to surgery, they would have their final twelve month assessment four weeks 
following surgery (when the post operative protocol advises non-weight bearing). It 
is unlikely that the final outcome following surgery would reflect outcome scores at 
that appointment. The most pragmatic option and most common method is to ‘start 
the clock’ on the day of randomisation, regardless of waiting list issues. This most 
closely reflects real life conditions, where waiting list delays could be considered an 
inadvertent part of the overall treatment. As the primary outcome measure in this 
pilot was explanatory, it was decided that more useful data would be collected by 
choosing the start of the intervention as the time to ‘start the clock’ on follow up. It 
was considered that repeated MRI scans of participants assigned to surgery, but not 
actually having had surgery would not yield useful data for comparison and would 
be difficult for participants to understand, potentially resulting in a higher loss to 
follow up. Whilst there are benefits to this approach when assessing cartilage volume 
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change, there are some practical and methodological downsides. Participants waiting 
for meniscal allograft transplantation may well deteriorate, given the progressive 
nature of OA and perceived lack of treatment. This may result in unbalanced groups 
at baseline, with a resulting confounding effect on the results. In this study, repeated 
baseline PROMs in participants waiting over four months for surgery were worse, 
although these differences were small and not statistically significant. From a 
practical point of view, the unknown delay to surgery means that the trial endpoint 
cannot be accurately predicted. In this study, the delay to surgery has resulted in 
delay to the final results being collected, despite recruiting all participants on time. 
This may have funding and trial delivery issues for a full RCT.  
 
In a definitive evaluation, if a PROM was the primary outcome measure and the 
research question was further towards the pragmatic end of the spectrum, it may be 
more appropriate to start the clock on the day of randomisation. In order to minimise 
the risk of the primary endpoint conflicting with early post-operative healing, the 
length of follow up could be increased to two years. The downside of this is that it 
would have cost, deliverability and loss to follow up issues. A compromise solution 
may have been found in a recent multi-centre RCT comparing two different types of 
shoulder surgery and an active monitoring group, for people with shoulder pain23. 
Follow up was collected using the day of randomisation as day zero, but alongside 
this anyone that waited more than four months for surgery were termed ‘breachers’ 
and had a further follow up appointment. 
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8.4.1 Limitations 
 
Meniscal allograft transplantation has been performed for over thirty years and 
numerous studies have reported their intervention protocols (as shown in chapter 
three). This allowed for a comparison between the intervention in this study and 
those used in other centres. The systematic review of physiotherapy in chapter five 
for this specific patient population revealed very few studies and they were mostly 
on patients with no or mild pain98, 120, 228. This limits the extent to which comparisons 
can be made between personalised knee therapy and treatments used in other centres, 
making it difficult to know how appropriate the intervention might be considered, as 
well as its external validity. Whilst it may not be possible, or even appropriate, to 
change an established intervention currently being delivered on the NHS, it is 
important to know how closely it matches other centres. When comparing it to the 
physiotherapy treatments used in the studies identified in chapter five, the techniques 
were similar: There was a focus on strength training as well as core control elements, 
with a personalised plan for each participant. The one marked difference was that the 
number of specified treatment sessions was considerably higher in the reported 
studies. In the study by Roos and Dahlberg there was one initial session then three a 
week for four months228. In the study by Hall et al. there were eight individual 
sessions and additional home sessions over twelve weeks120. The personalised knee 
therapy protocol only specified sessions to be delivered over a minimum of three 
months. Neither of the studies in the systematic review were delivered on the NHS 
and it would be unlikely to be feasible to do so. A cross-sectional survey has 
previously shown that only three per cent of physiotherapists offered greater than 
seven sessions for patients with knee OA; the majority of physiotherapists offered 
two or three (forty-one per cent) or four to five (thirty-six per cent) sessions130. The 
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number of sessions actually received by participants that had personalised knee 
therapy in this study was similar to that reported in the survey, with twenty-one per 
cent receiving two to three, thirty-seven per cent receiving four to five and twenty-
one per cent receiving six to seven sessions. Although general patients with knee OA 
are not directly comparable with the young sub-group in this study, it does suggest 
that the amount of physiotherapy that participants in this study had was similar to 
what might be realistically achievable on the NHS, given the wide geographical 
locations of participants and the need to use local physiotherapists.  
 
One potential criticism of the personalised knee therapy protocol is that it might be 
considered too non-prescriptive to allow the goals to be achieved or the fidelity to be 
assessed. In 2014, the TIDieR framework was produced which gives guidance on 
best practice for reporting intervention protocols129. Whilst this was published after 
the intervention protocols in this study were written and therefore was not used, they 
happened to be mostly reported in accordance with the framework. The main area 
where the personalised knee therapy protocol differed was that there was not enough 
detail on the amount, duration and intensity of the physiotherapy required. Whilst the 
approach taken in this study was not to attempt to alter interventions already being 
used on the NHS, this has to be balanced against the potential to improve the 
intervention and the ability to assess it.  
 
The intervention fidelity in this pilot was evaluated with a limited quantitative 
assessment. Intervention (treatment) fidelity can be defined as the ongoing 
assessment, monitoring and enhancement of the accuracy and consistency of the 
intervention to the protocol45. It can ensure that the active ingredients of the 
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intervention are delivered appropriately and consistently. It has been shown that 
higher intervention fidelity is associated with better outcomes85. However, a full 
assessment of intervention fidelity is a time consuming and costly process, 
consisting of an assessment of the intervention providers, delivery of the intervention 
as well as the understanding and adherence of the participants43. The protocols for 
both interventions in this study were necessarily pragmatic and personalised to the 
each participant and local resources. Therefore a full assessment of fidelity would 
need to use a mixed methods approach, with the gold standard being videotaping or 
audiotaping of intervention providers and participants44. This would have increased 
the time and cost, and was not considered a priority for this pilot. It has also been 
argued that one of the distinguishing features of a pragmatic study, when compared 
to an explanatory one, is the lack of measurement of fidelity and the absence of 
special methods to improve it258. This is because pragmatic studies are less 
concerned with how an intervention works, in comparison to whether it works. It is 
vital that a pragmatic study replicates a real life setting as much as possible and does 
not make any attempt to alter this within a trial, if this diverges from clinical 
practice. If fidelity was low in clinical practice, it would be inappropriate to increase 
it during a trial and then generalise the results to the clinical setting where fidelity 
was still low. 
 
Despite the disadvantages of assessing fidelity in a pragmatic study, it can be useful 
in the interpretation of full trial results, as well as allowing more accurate 
generalisability to other healthcare settings. If a definitive evaluation was 
undertaken, a more robust assessment of intervention fidelity should be considered if 
enough resources could be allocated.  
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As with fidelity, this study took a purely quantitative approach to assessing 
outcomes. This limited the amount of useful information that could be gained, when 
compared to a mixed methods approach. For example, patients unwilling to be 
randomised could have been asked for their reasons, in order to identify common 
barriers to entry. However, a mixed methods approach is more time consuming and 
costly, and the benefits of more information have to be weighed against these 
downsides.  
 
The orthopaedic group at the University of Warwick have run a number of 
successful trials at UHCW, including operative versus non-operative trials73, 74, 113, 
114, 182. A lot of the processes used in this pilot were similar and all members of the 
TMG had at least some experience of these trials. Therefore significant problems 
with the trial delivery were not anticipated and the pilot was set up to ensure this 
assumption was correct, as well as collecting data on outcome measures. It was 
considered that if major problems were identified, further feasibility or piloting work 
could then be undertaken to rectify the issue. This was thought to be more efficient 
and it is considered a reasonable approach to undergo multiple feasibility or pilot 
studies before starting a definitive evaluation75. Whilst this approach was taken, it is 
accepted that a mixed methods approach may have yielded important information 
that was not achieved in this pilot. It may be useful to consider a mixed methods 
approach in a definitive evaluation, particularly with regards to recruitment, as the 
rate achieved in the pilot is likely to be lower in a multi-centre RCT. Barriers to 
entry could then be fed back to the TMG and appropriate action taken as required. 
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In this study, RCT participants had MRI scans every four months. When conceiving 
this study, it was anticipated by experts in the field that cartilage changes on MRI 
would be detectable by four months. It was also reported in an animal model study 
comparing meniscal allograft transplantation to meniscectomy that MRI changes 
could be seen at four months150. Conversely, an observational study analysing 
cartilage changes in twenty-nine ‘fast progressor’ patients, using very similar image 
analysis techniques to the ones in this pilot, did not find significant cartilage losses at 
three or six months134. They concluded that a three month time point is not long 
enough and that six months may also be too short to detect changes. There has been 
little evidence to contradict that study and when factoring in the additional time, cost 
and strain on resources, it might be appropriate to remove the four and eight month 
scans from the outcome assessment in a full RCT. 
 
8.5 Conclusion 
 
There was an improvement in all PROMs in the meniscal allograft transplantation 
group over personalised knee therapy. These results were statistically significant in 
all the KOOS sub-domains, except Sports, and composite score in the combined 
RCT and preference group but not in the RCT group alone. Whilst these results 
suggest that meniscal allograft transplantation may benefit patients, a full RCT is 
needed to draw definitive inferences. This study showed that it is possible to recruit 
and retain participants in a RCT and that on the whole, the trial was delivered as per 
protocol. There is a significant concern regarding the delay to surgery caused by a 
combination of lack of availability of grafts and waiting list times, which would need 
to be optimised before considering a full RCT. 
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9 Conclusion 
 
9.1 Review of thesis aims and objectives 
 
Despite a traditional reluctance to undertake RCTs in surgery, where their 
proponents have been described as ‘the fifth horseman of an apocalyptical surgical 
fundamentalism’52, they have gained increasing popularity in trauma and 
orthopaedics271. Whilst there is little argument that RCTs are the gold standard study 
design to test for effectiveness of an intervention, they are expensive and time 
consuming endeavours54. The development and piloting phases are vital preparatory 
work, with a failure to perform them potentially resulting in weaker interventions 
that are less likely to work, harder to evaluate and less likely to be worth 
implementing75. As well as time and cost implications, there are also ethical 
implications of performing full RCTs that are unequipped to answer the intended 
question.  
 
The overall aim of this thesis was to provide the development and pilot work to 
inform a definitive evaluation of meniscal allograft transplantation in treating 
patients with a symptomatic meniscal deficient knee, compared to physiotherapy. In 
order to achieve this, the following specific objectives were set: 
 
• Identify the theoretical basis for why meniscal allograft transplantation may 
result in a symptomatic improvement and/or reduce or delay the progression 
of OA in patients with a symptomatic meniscal deficient knee.  
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• Systematically review the current evidence base for whether it does result in 
a symptomatic improvement and/or reduce or delay the progression of OA in 
patients with a symptomatic meniscal deficient knee. 
• Identify the theoretical basis for why physiotherapy may result in a 
symptomatic improvement and/or reduce or delay the progression of OA in 
patients with a symptomatic meniscal deficient knee.  
•  Systematically review the current evidence base for whether physiotherapy 
does result in a reduction or delayed progression of OA in patients with a 
meniscal deficient knee. 
• Perform a regression analysis of the current series of meniscal allograft 
transplants at UHCW to determine significant predictors of failure.  
• Develop and undertake a comprehensive cohort study incorporating a pilot 
RCT comparing meniscal allograft transplantation to ‘personalised knee 
therapy’ in patients with a symptomatic meniscal deficient knee. 
• Discuss whether a full RCT would be deliverable, in the light of the results of 
the findings of this thesis. 
 
In relation to the MRC framework, the first five objectives relate to the development 
work and the sixth objective relates to the piloting phase. The following chapter 
discusses the important findings from this thesis and their implications in relation to 
subsequent phases of the MRC framework. 
 
 
 
 210 
9.2 Summary of study findings 
 
Following the Introduction in chapter one, chapter two evaluated the theoretical 
basis, with supporting evidence, for why meniscal allograft transplantation and 
physiotherapy may be effective interventions. 
 
It was demonstrated that although the structure of the meniscus is still not fully 
understood, it has a micro- and macrostructure capable of distributing the forces 
through the tibiofemoral joint. It was also shown that meniscectomy changes the 
loading pattern, with consequent biochemical and biomechanical changes in the 
knee. Numerous studies have consistently shown that meniscectomy was a strong 
predictor of symptomatic OA. 
 
It was shown that meniscal allograft transplantation resulted in a loading pattern that 
was similar to a knee with a native meniscus, with reduced the peak contact 
pressures and increased total contact area, compared to a meniscectomised knee. 
Animal model studies had also shown meniscal allograft transplantation to be 
chondroprotective.  
 
Physiotherapy has a strong evidence base for improving PROMs in patients with 
symptomatic OA. It has also been shown that patients had persistent thigh weakness 
following meniscectomy, which may result in a detrimental effect on both function 
and progression of OA. Physiotherapy can target this deficit, as well as encourage a 
return to exercise and sports, which is likely to improve functional outcome and 
quality of life. 
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Chapters three and four were systematic reviews, designed to explore the patient 
reported and radiological outcomes following meniscal allograft transplantation 
respectively. Chapter three was also designed to identify common practice in order 
to maximise external validity between meniscal allograft transplantation performed 
in a trial setting and in reported clinical practice.  
 
The first systematic review identified 1374 meniscal allograft transplantations in 
thirty-five case series that met the eligibility criteria; there were no RCTs. It found 
that all used PROMs (most commonly Lysholm, IKDC, Tegner and KOOS) showed 
a significant increase from baseline to final follow up, although the mean scores 
were still well below the top score. It was also shown that most studies reported that 
meniscal allograft transplantation was contraindicated in patients over fifty years of 
age, in the presence of advanced cartilage damage or severe OA, and that 
malalignment and ligament instability must be corrected. A recent trend change was 
from cryopreserved to frozen allografts. 
 
The second systematic review, exploring the radiographic outcomes after meniscal 
allograft transplantation identified 1056 transplantations across thirty-eight studies 
that met the eligibility criteria. There were no RCTs and very few comparative 
studies to assess changes. Pooling the joint space changes across studies, there was a 
mean loss of 0.032 mm at a mean follow up of 4.5 years. When considering 
measures of meniscal transplant integrity, meniscal extrusion was an almost 
universal finding but no clear correlation with clinical scores was reported. Other 
common MRI findings included: High rates of meniscal healing to the capsule, 
altered signal intensity and altered meniscal shape compared to the native meniscus. 
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Chapter five was a systematic review of physiotherapy for the treatment of the 
meniscal deficient knee. Only two studies were identified that met the eligibility 
criteria, although these were both RCTs and one study had a second paper that had 
performed a secondary analysis using MRI data. One study found an improvement in 
one leg and square hop distances as well as some measures of thigh strength at four 
months in the physiotherapy group, compared to a no intervention control. On the 
secondary analysis a significant reduction in cartilage quality on T2 mapping was 
found in the control group. The second RCT found that difference in peak knee 
adduction moment between groups was not statistically significant. 
 
Chapter three identified a number of aspects of meniscal allograft transplantation 
where there was variation in practice across studies. The protocol for meniscal 
allograft transplantation performed at UHCW was generally in agreement with the 
majority practice and was not an outlier for any part, with the exception of not 
having advanced cartilage damage as a contraindication to surgery. Many studies 
considered that meniscal allograft transplantation would have higher complication 
rates in the presence of advanced cartilage damage, although others disputed this. 
Chapter six explored whether advanced cartilage damage was a predictor of failure 
in the current case series at UHCW using a Cox regression model to balance for 
other potential predictor variables. It was found that advanced cartilage damage at 
the time of meniscal allograft transplantation was a strong and statistically 
significant predictor of failure. 
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Chapters seven and eight refer to the piloting phase of the MRC framework and 
detail the protocol and results of a comprehensive cohort study, which incorporated a 
pilot RCT. The study was able to recruit its target of thirty-six participants within the 
allotted time of one year, with slightly favourable recruitment to the pilot RCT 
(twenty-one participants) compared to the preference group (fifteen participants). 
Three participants were withdrawn from the meniscal allograft transplantation RCT 
group due to a failure to start the intervention within one year. There were no 
participants lost to follow up in the RCT arm, although there were two participants in 
the personalised knee therapy preference group that were lost to follow up. The 
meniscal allograft transplantation intervention was delivered as per protocol for all 
participants that received the operation and personalised knee therapy was delivered 
as per protocol for eighteen of twenty participants. There were no statistically 
significant differences in any of the MRI measures between the groups at the twelve 
month time point. All PROMs at twelve months showed a greater improvement in 
the meniscal allograft transplantation groups compared to personalised knee therapy, 
which was statistically significant for the KOOS4 composite score and all sub-
domains except Sports when the RCT and preference group arms were merged. 
There were three complications in the meniscal allograft transplantation group (pain 
requiring an arthroscopy, haemarthrosis and meniscal tear). There was one 
complication in the personalised knee therapy group (soreness and irritation from an 
offloading brace). 
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9.3 Implications and future research  
 
The natural history following meniscectomy is reasonably well understood, with a 
high proportion of young patients presenting with symptomatic OA of the knee. 
Whilst efforts have increasingly focussed on preserving the native meniscus, this is 
not always possible. The need for an effective treatment in this patient population 
exists but the clinical effectiveness of meniscal allograft transplantation compared to 
alternative treatments still needs to be definitively determined. The link between 
meniscal allograft transplantation and reducing the structural progression of OA is 
even less clear.  
 
This thesis identifies some of the challenges and potential solutions to gaining higher 
quality evidence to guide best practice in treating patients with a symptomatic 
meniscal deficient knee. The pilot RCT showed that contrary to initial concerns, the 
trial was acceptable to a reasonable proportion of patients; both in terms of 
recruitment and follow up. However, there are some concerns when considering a 
definitive evaluation. The first relates to the number of centres and total number of 
meniscal allograft transplantations being performed in the UK. When the thesis was 
conceived, there was an appetite from a number of centres to get the set up to start 
performing the surgery. A number of surgeons had visited UHCW for advice on how 
to achieve this, as well as to learn surgical techniques. Since then, it is not clear how 
many surgeons were successful but it is known that some were not able to set up a 
service due to local funding and logistical reasons. At the recent International 
Meniscal Reconstruction Experts Forum meeting in Lyon, there were four UK 
surgeons identified as regularly performing the operation. It is thought that four or 
five others may also be performing the operation regularly. The first step would be to 
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identify the centres in which meniscal allograft transplantation is performed, the 
number they do each year and the indications they use. The centres in which 
meniscal allograft transplantation is performed could potentially be identified from 
tissue banks that provide the allografts, amongst other means. 
 
The second concern is the delay to surgery in the pilot study. There was an over six 
month delay for eight of the ten randomised participants, of which three were 
withdrawn after a year of waiting for the intervention. This poses issues to the trial 
design and there would need to be evidence that this had improved before starting a 
full RCT. 
 
However, despite the challenges of performing a definitive evaluation of meniscal 
allograft transplantation compared to physiotherapy identified in this thesis, a full 
trial is, in principle, warranted and deliverable.   
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Appendices 
 
 
 
Appendix A: Protocol for ‘Meniscal allograft transplantation in a symptomatic 
deficient knee systematic review’; published on the PROSPERO register of 
systematic reviews1. 
 
 
 35263(52,QWHUQDWLRQDOSURVSHFWLYHUHJLVWHURIV\VWHPDWLFUHYLHZV

0HQLVFDODOORJUDIWWUDQVSODQWDWLRQLQDV\PSWRPDWLFPHQLVFDOGHILFLHQWNQHHD
V\VWHPDWLFUHYLHZ
1LFN6PLWK0DWWKHZ&RVWD1LFROD0DF.D\7LP6SDOGLQJ

&LWDWLRQ
1LFN6PLWK0DWWKHZ&RVWD1LFROD0DF.D\7LP6SDOGLQJ0HQLVFDODOORJUDIWWUDQVSODQWDWLRQLQDV\PSWRPDWLF
PHQLVFDOGHILFLHQWNQHHDV\VWHPDWLFUHYLHZ35263(52&5'$YDLODEOHIURP
KWWSZZZFUG\RUNDFXN35263(52B5(%5$1',1*GLVSOD\BUHFRUGDVS",' &5'
5HYLHZTXHVWLRQV
7KHSULPDU\REMHFWLYHLVWRDVVHVVWKHFOLQLFDORXWFRPHIROORZLQJPHQLVFDODOORJUDIWWUDQVSODQWDWLRQ0$7XVLQJDQ\
SDWLHQWUHSRUWHGRXWFRPHPHDVXUH
7KHVHFRQGDU\REMHFWLYHLVWRSURYLGHDUHYLHZRIWKHFRPSOLFDWLRQVDQGIDLOXUHVLQGLFDWLRQVJUDIWW\SHRSHUDWLYH
WHFKQLTXHDVVRFLDWHGSURFHGXUHVUHKDELOLWDWLRQUDGLRORJLFDOILQGLQJVDQGJUDIWKHDOLQJ
6HDUFKHV
0HGOLQH(PEDVHDQGWKH&RFKUDQHOLEUDU\ZLOOEHVHDUFKHGIRUSXEOLVKHGVWXGLHV
7KH:RUOG+HDOWK2UJDQLVDWLRQ,QWHUQDWLRQDO&OLQLFDO7ULDOV5HJLVWU\3ODWIRUPKWWSDSSVZKRLQWWULDOVHDUFKDQG
&OLQLFDO7ULDOV5HJLVWU\KWWSFOLQLFDOWULDOVJRYZLOOEHVHDUFKHGIRURQJRLQJRUFRPSOHWHGWULDOV7KHൾ:HERI
6FLHQFHൿKWWSWKRPVRQUHXWHUVFRPZHERIVFLHQFHZLOOEHVHDUFKHGIRUFRQIHUHQFHSURFHHGLQJV
5HVWULFWLRQVZLOOEHIRU
KXPDQV
DQG
(QJOLVKODQJXDJH

7\SHVRIVWXG\WREHLQFOXGHG
,QFOXVLRQ
$OOFOLQLFDOFRPSDUDWLYHVWXGLHVLQFOXGLQJUDQGRPLVHGFRQWUROOHGWULDOVDQGFDVHVHULHV
([FOXVLRQ
&DVHUHSRUWV
&RQGLWLRQRUGRPDLQEHLQJVWXGLHG
3DWLHQWVZLWKDPHQLVFDOGHILFLHQWFRPSDUWPHQWRIWKHNQHHDQGZLWKDVVRFLDWHGV\PSWRPV6\PSWRPVPD\LQFOXGH
SDLQVZHOOLQJDQGRUVWLIIQHVV
3DUWLFLSDQWVSRSXODWLRQ
,QFOXVLRQ
$Q\KXPDQRIDQ\DJH
,QWHUYHQWLRQVH[SRVXUHV
,QFOXVLRQ
0HQLVFDODOORJUDIWWUDQVSODQWDWLRQE\DQ\VXUJLFDOWHFKQLTXHDQGDQ\JUDIWW\SHPD\EHXVHG
$Q\UHKDELOLWDWLRQUHJLPH
([FOXVLRQ
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1RQDOORJUDIWVIRUH[DPSOHV\QWKHWLFPHQLVFDOVFDIIROGV
&RPSDUDWRUVFRQWURO
,IDFRPSDUDWLYHVWXG\WKHFRPSDUDWRUVKRXOGEHDPDWFKHGFRQWUROJURXSRUDUHDVRQDEOHDOWHUQDWLYHWRPHQLVFDO
DOORJUDIWWUDQVSODQWDWLRQVXFKDVSK\VLRWKHUDS\RUSODFHER
2XWFRPHV
3ULPDU\RXWFRPHV
,QFOXVLRQ
6WXGLHVPXVWLQFOXGHDSDWLHQWUHSRUWHGRXWFRPHPHDVXUH,WLVH[SHFWHGWKDWWKH/\VKROP,.'&DQG7HJQHU
TXHVWLRQQDLUHVZLOOEHPRVWFRPPRQO\XVHGEXWDQ\RWKHU3520XVHGZLOOTXDOLI\IRULQFOXVLRQ
$PLQLPXPRI\HDUIROORZXSIROORZLQJVXUJHU\
6HFRQGDU\RXWFRPHV
)DLOXUHVDQGFRPSOLFDWLRQVUDGLRORJLFDOILQGLQJVVXFKDVRVWHRDUWKULWLVSURJUHVVLRQJUDIWKHDOLQJ
'DWDH[WUDFWLRQVHOHFWLRQDQGFRGLQJ
7ZRUHVHDUFKHUVZLOOUHYLHZWKHUHVXOWVRIWKHVHDUFKHVLQGHSHQGHQWO\16DQG10'LIIHUHQFHVZLOOEHUHVROYHGE\
GLVFXVVLRQDQGWKHQVHQLRUUHYLHZE\0&LIGLIIHUHQFHVDUHQRWUHVROYHG
5LVNRIELDVTXDOLW\DVVHVVPHQW
6WXGLHVZLOOEHDVVHVVHGIRUULVNRIELDV
0LVVLQJVWXGLHV
7ULDOVUHJLVWULHVZLOOEHVHDUFKHG,IDWULDOKDVEHHQUHJLVWHUHGDQGFRPSOHWHGEXWQRWSXEOLVKHGDWWHPSWVZLOOEH
PDGHWRILQGWKHUHVXOWV
0LVVLQJLQIRUPDWLRQDQGRXWFRPHV
(YLGHQFHRIPLVVLQJLQIRUPDWLRQDQGRXWFRPHVZLOOEHJDWKHUHGIURPUHYLHZLQJSURWRFROVLIDYDLODEOHDQG
FRPSDULQJWKHPHWKRGVQXPEHUVHQWHUHGWKHVWXG\ZLWKWKHUHVXOWVQXPEHUVDQDO\VHG
)RUIDLOXUHVDQGFRPSOLFDWLRQVLIWKHUHLVQRHYLGHQFHRIUHSRUWLQJWKHQWKHVHVWXGLHVZLOOEHH[FOXGHGIURPWKHGDWD
V\QWKHVLV
6WUDWHJ\IRUGDWDV\QWKHVLV
7KHPDMRULW\RIWKHV\VWHPDWLFUHYLHZZLOOEHTXDOLWDWLYH:HLJKWHGPHDQVZLOOEHXVHGWRJLYHDYHUDJH/\VKROP
,.'&DQG7HJQHUVFRUHVSUHRSHUDWLYHO\DQGDWILQDOIROORZXS:HLJKWHGPHDQVZLOODOVREHXVHGWRFDOFXODWH
DYHUDJHDJHDWWKHWLPHRIVXUJHU\IDLOXUHDQGFRPSOLFDWLRQUDWH
$QDO\VLVRIVXEJURXSVRUVXEVHWV
1RQH
&RQWDFWGHWDLOVIRUIXUWKHULQIRUPDWLRQ
1LFN6PLWK
&65/
8QLYHUVLW\RI:DUZLFN
&OLIIRUG%ULGJH5RDG
&RYHQWU\
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&9';
QLFNDVPLWK#GRFWRUVQHWXN
2UJDQLVDWLRQDODIILOLDWLRQRIWKHUHYLHZ
8QLYHUVLW\RI:DUZLFN
5HYLHZWHDP
0U1LFN6PLWK8QLYHUVLW\RI:DUZLFN
3URIHVVRU0DWWKHZ&RVWD8QLYHUVLW\RI:DUZLFN
0V1LFROD0DF.D\1RQH
0U7LP6SDOGLQJ8QLYHUVLW\+RVSLWDOV&RYHQWU\DQG:DUZLFNVKLUH
$QWLFLSDWHGRUDFWXDOVWDUWGDWH
0DUFK
$QWLFLSDWHGFRPSOHWLRQGDWH
$SULO
)XQGLQJVRXUFHVVSRQVRUV
7KLVUHYLHZKDVEHHQIXQGHGE\$UWKULWLV5HVHDUFK8.DVSDUWRID&OLQLFDO5HVHDUFK)HOORZVKLS
&RQIOLFWVRILQWHUHVW
1RQHNQRZQ
/DQJXDJH
(QJOLVK
&RXQWU\
(QJODQG
6XEMHFWLQGH[WHUPVVWDWXV
6XEMHFWLQGH[LQJDVVLJQHGE\&5'
6XEMHFWLQGH[WHUPV
+XPDQV0HQLVFL7LELDO7UDQVSODQWDWLRQ+RPRORJRXV
6WDJHRIUHYLHZ
2QJRLQJ
'DWHRIUHJLVWUDWLRQLQ35263(52
0DUFK
'DWHRISXEOLFDWLRQRIWKLVUHYLVLRQ
0DUFK
6WDJHRIUHYLHZDWWLPHRIWKLVVXEPLVVLRQ 6WDUWHG &RPSOHWHG
3UHOLPLQDU\VHDUFKHV <HV 1R
3LORWLQJRIWKHVWXG\VHOHFWLRQSURFHVV 1R 1R
)RUPDOVFUHHQLQJRIVHDUFKUHVXOWVDJDLQVWHOLJLELOLW\FULWHULD 1R 1R
'DWDH[WUDFWLRQ 1R 1R
5LVNRIELDVTXDOLW\DVVHVVPHQW 1R 1R
'DWDDQDO\VLV 1R 1R
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Appendix B: Protocol for ‘Is meniscal allograft transplantation chondroprotective? 
A systematic review of radiological outcomes’; published on the PROSPERO 
register of systematic reviews1. 
 
 
 
 35263(52,QWHUQDWLRQDOSURVSHFWLYHUHJLVWHURIV\VWHPDWLFUHYLHZV

'RHVPHQLVFDODOORJUDIWWUDQVSODQWDWLRQSURWHFWWKHNQHHIURPRVWHRDUWKULWLV"$
V\VWHPDWLFUHYLHZ
1LFN6PLWK%HQ3DUNLQVRQ&KDUOHV+XWFKLQVRQ0DWWKHZ&RVWD7LP6SDOGLQJ

&LWDWLRQ
1LFN6PLWK%HQ3DUNLQVRQ&KDUOHV+XWFKLQVRQ0DWWKHZ&RVWD7LP6SDOGLQJ'RHVPHQLVFDODOORJUDIW
WUDQVSODQWDWLRQSURWHFWWKHNQHHIURPRVWHRDUWKULWLV"$V\VWHPDWLFUHYLHZ35263(52&5'
$YDLODEOHIURPKWWSZZZFUG\RUNDFXN35263(52B5(%5$1',1*GLVSOD\BUHFRUGDVS",' &5'

5HYLHZTXHVWLRQV
'RHVPHQLVFDODOORJUDIWWUDQVSODQWDWLRQUHGXFHRUGHOD\WKHSURJUHVVLRQRIRVWHRDUWKULWLVLQSDWLHQWVZLWKD
V\PSWRPDWLFPHQLVFDOGHILFLHQWFRPSDUWPHQWRIWKHNQHH"
'RHVWKHPHQLVFXVDOORJUDIWKDYHDVLPLODUDSSHDUDQFHWRDQDWLYHPHQLVFXVXVLQJPDJQHWLFUHVRQDQFHLPDJLQJDVWKH
RXWFRPHWRRO"
6HDUFKHV
0('/,1((0%$6(DQGWKH&RFKUDQH&HQWUDO5HJLVWHURI&RQWUROOHG7ULDOV&(175$/ZLOOEHVHDUFKHG7KH
VHDUFKVWUDWHJ\ZLOOEHVHQVLWLYLW\PD[LPLVLQJ
5HVWULFWLRQVRIVWXGLHVLQYROYLQJ+XPDQVDQGDOVRZULWWHQLQWKH(QJOLVKODQJXDJHZLOOEHXVHG
7\SHVRIVWXG\WREHLQFOXGHG
$Q\FOLQLFDOVWXG\UDQGRPLVHGFRQWUROOHGWULDOQRQUDQGRPLVHGFRPSDUDWLYHVWXG\RUFDVHVHULHVZULWWHQLQWKH
(QJOLVKODQJXDJH6WXGLHVWKDWGRQRWFRQWDLQQHZSDWLHQWGDWDELRPHFKDQLFDOVWXGLHVDQGFDVHUHSRUWVZLOOEH
H[FOXGHG
&RQGLWLRQRUGRPDLQEHLQJVWXGLHG
3DWLHQWVZLWKDV\PSWRPDWLFPHQLVFDOGHILFLHQWFRPSDUWPHQWRIWKHNQHH0RVWFRPPRQO\SDWLHQWVKDYHDKLVWRU\RI
SUHYLRXVPHQLVFHFWRP\IURPDVSRUWUHODWHGLQMXU\EXWDOOSDWLHQWVZLWKNQHHV\PSWRPVDQGKDYHDPHQLVFDO
GHILFLHQF\ZLOOEHLQFOXGHG
3DUWLFLSDQWVSRSXODWLRQ
$Q\KXPDQRIDQ\DJH
,QWHUYHQWLRQVH[SRVXUHV
0HQLVFDODOORJUDIWWUDQVSODQWDWLRQXVLQJDQ\DOORJUDIWSUHVHUYLQJPHWKRGDQGDQ\JUDIWLQJWHFKQLTXH
$Q\UHKDELOLWDWLRQUHJLPHSRVWRSHUDWLYHO\
&RPSDUDWRUVFRQWURO
,IDFRPSDUDWRUJURXSH[LVWVLWVKRXOGEHDUHDVRQDEOHDOWHUQDWLYHWUHDWPHQWIRUH[DPSOHDQRQRSHUDWLYH
UHKDELOLWDWLRQJURXS,WZRXOGDOVREHFRQVLGHUHGUHDVRQDEOHWRXVHWKHSDUWLFLSDQWVൿRWKHUNQHHVDVDFRPSDUDWRU
2XWFRPHV
3ULPDU\RXWFRPHV
&KDQJHLQDQ\UDGLRORJLFDO2$SURJUHVVLRQPHDVXUH
$PLQLPXPRIRQH\HDUSRVWLQWHUYHQWLRQ
                               Page: 1 / 3
 220 
 
 
 
 
6HFRQGDU\RXWFRPHV
0DJQHWLFUHVRQDQFHLPDJLQJPHDVXUHVRIWKHPHQLVFXVLQFOXGLQJPHQLVFDODSSHDUDQFHVLJQDOLQWHQVLW\KHDOLQJDQG
H[WUXVLRQ
$PLQLPXPRIPRQWKVSRVWLQWHUYHQWLRQ
'DWDH[WUDFWLRQVHOHFWLRQDQGFRGLQJ
5HVXOWVRIWKHGDWDEDVHVHDUFKHVZLOOEHWUDQVIHUUHGLQWR(QG1RWHDQGGXSOLFDWHVZLOOEHGLVFDUGHG2XUHOLJLELOLW\
FULWHULDZLOOEHXVHGWRDVVHVVWKHUHPDLQLQJVWXGLHVXVLQJWKHWLWOHDQGDEVWUDFW7KHIXOOSDSHUVRIDQ\UHPDLQLQJ
VWXGLHVZLOOWKHQEHUHYLHZHG7ZRUHYLHZHUV16DQG%3ZLOOLQGHSHQGHQWO\DVVHVVVWXGLHVIRUHOLJLELOLW\$Q\
GLVFUHSDQFLHVZLOOEHUHVROYHGE\GLVFXVVLRQDQGLIWKDWIDLOVE\WKHMXGJHPHQWRIDVHQLRUDXWKRU76
,QRUGHUWRUHGXFHGXSOLFDWHSXEOLFDWLRQELDVLIWZRRUPRUHHOLJLEOHVWXGLHVXVHGVRPHRUDOORIWKHVDPHSDUWLFLSDQWV
ERWKVWXGLHVZLOORQO\EHLQFOXGHGLIGLIIHUHQWRXWFRPHVPHDVXUHVDUHXVHG2QO\WKHVWXG\ZLWKWKHORQJHVWIROORZXS
ZLOOEHLQFOXGHGLIWKHVDPHRXWFRPHPHDVXUHLVXVHG
5LVNRIELDVTXDOLW\DVVHVVPHQW
$TXDOLWDWLYHULVNRIELDVDVVHVVPHQWZLOOEHXQGHUWDNHQXVLQJ&RFKUDQHJXLGHOLQHV7KHULVNDQGHIIHFWRIPLVVLQJ
VWXGLHVDQGPLVVLQJRXWFRPHVZLOOEHDVVHVVHG
6WUDWHJ\IRUGDWDV\QWKHVLV
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3URIHVVRU0DWWKHZ&RVWD8QLYHUVLW\RI:DUZLFN
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Appendix C: Protocol for ‘Physiotherapy for a patient with a post-meniscectomy 
knee systematic review’; published on the PROSPERO register of systematic 
reviews1. 
 
 
PROSPERO International prospective register of systematic reviews 
Review title and timescale 
1 Review title 
Give the working title of the review. This must be in English. Ideally it should state succinctly 
the interventions or exposures being reviewed and the associated health or social problem being 
addressed in the review. 
Physiotherapy for patients with a symptomatic meniscal deficient knee: a systematic review 
2 Original language title 
For reviews in languages other than English, this field should be used to enter the title in the 
language of the review. This will be displayed together with the English language title.  
3 Anticipated or actual start date 
Give the date when the systematic review commenced, or is expected to commence. 
25/03/2015 
4 Anticipated completion date 
Give the date by which the review is expected to be completed. 
28/05/2015 
5 Stage of review at time of this submission 
Indicate the stage of progress of the review by ticking the relevant boxes. Reviews that have 
progressed beyond the point of completing data extraction at the time of initial registration are 
not eligible for inclusion in PROSPERO. This field should be updated when any amendments 
are made to a published record. 
  The review has not yet 
started  
√     
      
Review stage Started Completed  
Preliminary searches No No 
Piloting of the study selection process No No 
Formal screening of search results against eligibility criteria No No 
Data extraction No No 
Risk of bias (quality) assessment No No 
Data analysis No No 
 
  Provide any other relevant information about the stage of the review here. 
Review team details 
6 Named contact 
The named contact acts as the guarantor for the accuracy of the information presented in the 
register record. 
Dr Smith 
7 Named contact email 
Enter the electronic mail address of the named contact. 
nickasmith@doctors.net.uk 
8 Named contact address 
Enter the full postal address for the named contact.  
CSRL University of Warwick Clifford Bridge Road Coventry CV2 2DX 
9 Named contact phone number 
Enter the telephone number for the named contact, including international dialing code. 
+44 (0)7825185953 
10 Organisational affiliation of the review 
Full title of the organisational affiliations for this review, and website address if available. This 
field may be completed as 'None' if the review is not affiliated to any organisation. 
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University of Warwick 
Website address: 
11 Review team members and their organisational affiliations 
Give the title, first name and last name of all members of the team working directly on the 
review. Give the organisational affiliations of each member of the review team. 
  Title First name Last name Affiliation 
Dr Nick Smith University of Warwick 
Mr David Wright UHCW 
Professor Matt Costa University of Warwick 
Mr Tim Spalding UHCW 
 
12 Funding sources/sponsors 
Give details of the individuals, organizations, groups or other legal entities who take 
responsibility for initiating, managing, sponsoring and/or financing the review. Any unique 
identification numbers assigned to the review by the individuals or bodies listed should be 
included. 
Arthritis Research UK (grant number 20149) 
13 Conflicts of interest 
List any conditions that could lead to actual or perceived undue influence on judgements 
concerning the main topic investigated in the review. 
Are there any actual or potential conflicts of interest? 
None known 
14 Collaborators 
Give the name, affiliation and role of any individuals or organisations who are working on the 
review but who are not listed as review team members. 
  Title First name Last name Organisation details 
 
Review methods 
15 Review question(s) 
State the question(s) to be addressed / review objectives. Please complete a separate box for each 
question. 
The primary objective is to assess the outcome of patients with a symptomatic meniscal deficient 
(compartment of the) knee after any physiotherapy intervention, using any patient reported 
outcome measure. 
16 Searches 
Give details of the sources to be searched, and any restrictions (e.g. language or publication 
period). The full search strategy is not required, but may be supplied as a link or attachment. 
MEDLINE, EMBASE, CHNAHL and the Cochrane library will be searched for published 
studies. The World Health Organisation International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/) and Clinical Trials Registry (http://clinicaltrials.gov) will be 
searched for ongoing or completed trials. The ‘Web of Science’ (http://thomsonreuters.com/web-
of-science/) will be searched for conference proceedings. Restrictions will be for 'humans' and 
'English language'.  
17 URL to search strategy 
If you have one, give the link to your search strategy here. Alternatively you can e-mail this to 
PROSPERO and we will store and link to it. 
 
I give permission for this file to be made publicly available 
Yes 
18 Condition or domain being studied 
Give a short description of the disease, condition or healthcare domain being studied. This could 
include health and wellbeing outcomes. 
Patients with a meniscal deficient compartment of the knee and with associated symptoms. 
Symptoms may include pain, swelling and/or stiffness. 
19 Participants/population 
Give summary criteria for the participants or populations being studied by the review. The 
preferred format includes details of both inclusion and exclusion criteria. 
Any human of any age. 
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20 Intervention(s), exposure(s) 
Give full and clear descriptions of the nature of the interventions or the exposures to be reviewed 
Inclusion: Any exercise based therapy intervention delivered over any time period. Exclusion: 
Non-exercise based therapies, for example acupuncture, patient education. 
21 Comparator(s)/control 
Where relevant, give details of the alternatives against which the main subject/topic of the 
review will be compared (e.g. another intervention or a non-exposed control group). 
If a comparator exists, any reasonable alternative to physiotherapy would be appropriate. 
22 Types of study to be included initially 
Give details of the study designs to be included in the review. If there are no restrictions on the 
types of study design eligible for inclusion, this should be stated. 
Inclusion: All clinical comparative studies (including randomised controlled trials) and case 
series. Exclusion: Case reports. 
23 Context 
Give summary details of the setting and other relevant characteristics which help define the 
inclusion or exclusion criteria. 
24 Primary outcome(s) 
Give the most important outcomes. 
Studies must include a patient reported outcome measure. Ideally a validated and disease or joint 
specific outcome measure would be used, but any patient reported outcome measure would 
qualify for inclusion. There is no minimum time at which outcomes may be reported. 
Give information on timing and effect measures, as appropriate. 
25 Secondary outcomes 
List any additional outcomes that will be addressed. If there are no secondary outcomes enter 
None. 
Health professional reported outcome measures such as muscle strength, will be reported and 
radiological outcome measures will also be reported; particularly assessing any 
chondroprotective effects. 
  Give information on timing and effect measures, as appropriate. 
26 Data extraction, (selection and coding) 
Give the procedure for selecting studies for the review and extracting data, including the number 
of researchers involved and how discrepancies will be resolved. List the data to be extracted. 
Two researchers will review the results of the searches independently (NS and DW). Differences 
will be resolved by discussion and then senior review by MC if differences are not resolved. 
27 Risk of bias (quality) assessment 
State whether and how risk of bias will be assessed, how the quality of individual studies will be 
assessed, and whether and how this will influence the planned synthesis. 
Studies will be assessed for risk of bias. Missing studies: Trials registries will be searched. If a 
trial has been registered (and completed) but not published, attempts will be made to find the 
results. Missing information and outcomes: Evidence of missing information and outcomes will 
be gathered from reviewing protocols (if available) and comparing the methods (numbers 
entered the study) with the results (numbers analysed). 
28 Strategy for data synthesis 
Give the planned general approach to be used, for example whether the data to be used will be 
aggregate or at the level of individual participants, and whether a quantitative or narrative 
(descriptive) synthesis is planned. Where appropriate a brief outline of analytic approach should 
be given. 
The majority of the systematic review will be qualitative. Weighted means will be used to give 
average outcome measure scores if multiple studies have used the same outcome measure. 
29 Analysis of subgroups or subsets 
Give any planned exploration of subgroups or subsets within the review. ‘None planned’ is a 
valid response if no subgroup analyses are planned. 
None. 
Review general information 
30 Type of review 
Select the type of review from the drop down list. 
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Intervention 
31 Language 
Select the language(s) in which the review is being written and will be made available, from the 
drop down list. Use the control key to select more than one language. 
English 
Will a summary/abstract be made available in English? 
Yes 
32 Country 
Select the country in which the review is being carried out from the drop down list. For multi-
national collaborations select all the countries involved. Use the control key to select more than 
one country. 
England 
33 Other registration details 
Give the name of any organisation where the systematic review title or protocol is registered 
together with any unique identification number assigned. If extracted data will be stored and 
made available through a repository such as the Systematic Review Data Repository (SRDR), 
details and a link should be included here.  
34 Reference and/or URL for published protocol 
Give the citation for the published protocol, if there is one. 
Give the link to the published protocol, if there is one. This may be to an external site or to a 
protocol deposited with CRD in pdf format. 
 
I give permission for this file to be made publicly available 
Yes 
35 Dissemination plans 
Give brief details of plans for communicating essential messages from the review to the 
appropriate audiences. 
We intend to publish this review in a peer reviewed journal on completion. 
Do you intend to publish the review on completion? 
Yes 
36 Keywords 
Give words or phrases that best describe the review. (One word per box, create a new box for 
each term) 
physiotherapy 
meniscal deficiency 
knee 
patient reported outcomes 
37 Details of any existing review of the same topic by the same authors 
Give details of earlier versions of the systematic review if an update of an existing review is 
being registered, including full bibliographic reference if possible. 
38 Current review status 
Review status should be updated when the review is completed and when it is published. 
Ongoing 
39 Any additional information 
Provide any further information the review team consider relevant to the registration of the 
review. 
40 Details of final report/publication(s) 
This field should be left empty until details of the completed review are available.  
Give the full citation for the final report or publication of the systematic review. 
Give the URL where available. 
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Appendix D: Technique paper for Meniscal allograft transplantation, as performed 
at UHCW NHS Trust. Currently in press at the time of submission of this thesis. 
 
 
 
 
 
 
 
Technical Note
Arthroscopic Meniscal Allograft Transplantation With
Soft-Tissue Fixation Through Bone Tunnels
Tim Spalding, F.R.C.S.(Orth), Ben Parkinson, F.R.A.C.S.Orth,
Nick A. Smith, M.Sc., M.R.C.S., and Peter Verdonk, Ph.D.
Abstract: Meniscal allograft transplantation improves clinical outcomes for patients with symptomatic meniscus-deﬁcient
knees. We describe an established arthroscopic technique for meniscal allograft transplantation without the need for bone
ﬁxation of the meniscal horns. After preparation of the meniscal bed, the meniscus is parachuted into the knee through a
silicone cannula and the meniscal horns are ﬁxed with sutures through bone tunnels. The body of the meniscus is then
ﬁxed with a combination of all-inside and inside-out sutures. This technique is reliable and reproducible and has clinical
outcomes comparable with those of bone plug ﬁxation techniques.
The menisci of the knee act as load distributors aswell as secondary stabilizers of the knee. Meniscal
allograft transplantation is indicated for patients with a
symptomatic meniscus-deﬁcient compartment of the
knee. Arthroscopic meniscal allograft transplantation
with soft-tissue ﬁxation is a less complicated and more
minimally invasive procedure than bone plug techniques
while still obtaining stable and secure graft ﬁxation.
Technique
Our technique has been broken down into 10 key
stages under the subheadings in this section and is
shown in Video 1. The key messages of this technique
are summarized in Table 1.
Patient Positioning
The procedure is performed with the patient under
general or regional anesthesia with appropriate
prophylactic antibiotics. The patient is positioned supine
on the operating table with a thigh tourniquet, a single-
thigh side support, and a footrest supporting the knee at
90!. For a lateral meniscal transplant, the knee will be
moved to the ﬁgure-of-4 position. For a medial
meniscal transplant, the leg will be abducted and rest
against the outer hip of the operating surgeon.
Graft Preparation
The meniscal allografts are sourced from either NHS
Blood and Transplant Tissue Services (Liverpool,
England) or JRF Ortho (Centennial, Colorado) (im-
ported by Fannin, Dublin, Ireland). The allograft is
thawed to room temperature per the tissue bank’s
speciﬁc instructions (usually about 15 minutes in warm
water or 1 hour at room temperature). The graft is
dissected from the tibia, trimmed to its true margin,
and freshened by the assistant at the start of surgery.
The superior surface of the meniscus is marked to aid in
orientation (Fig 1). In the case of the lateral meniscus,
the most anterior margin of the popliteal hiatus is also
marked and a No. 2 nonabsorbable suture is placed as
an oblique vertical mattress suture. For the medial
meniscus, a similar vertical mattress suture is inserted
at a point at 40% of the circumference from posterior
to anterior. This represents the middle traction suture
(Fig 2A). No. 2 Ultrabraid sutures (Smith & Nephew,
Andover, MA) are placed into the posterior and ante-
rior horns using a modiﬁed whipstitch, with passage of
the suture a minimum of 3 times along the meniscus
and back again to ensure a good hold. It is important to
ensure that the sutures emerge on the inferior aspect of
the footprint of the meniscal horn. The prepared graft
From University Hospitals Coventry and Warwickshire NHS Trust (T.S.),
Coventry, England; Reef Orthopaedic Clinic (B.P.), Cairns, Queensland,
Australia; University of Warwick (N.A.S.), Coventry, England; and Antwerp
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research fellowship from Arthritis Research UK (grant No. 20149). P.V. re-
ceives support from DepuySynthes, Smith and Nephew, Orteq Sports Medi-
cine, Active Implants, and Episurf.
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Appendix E: Research Ethic Committee favourable ethical decision letter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NRES Committee West Midlands - Solihull 
East Midlands REC Centre 
The Old Chapel 
Royal Standard Place 
Nottingham 
NG1 6FS 
 
Telephone: 0115 8839425  
03 October 2013 
 
Mr Nicholas Smith 
Clinical Research Fellow 
University of Warwick 
Clinical Sciences Research Laboratories 
Clifford Bridge Road 
Coventry 
CV2 2DX 
 
 
Dear Mr Smith 
 
Study title: A Comprehensive Cohort Study of Meniscal Allograft 
Transplantation versus Personalised Knee Therapy for 
Patients with a Symptomatic Meniscus Deficient Knee. 
REC reference: 13/WM/0315 
IRAS project ID: 125446 
 
Thank you for your letter which was received 02 October 2013, responding  to  the  Committee’s  
request for further information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the NRES website, 
together with your contact details, unless you expressly withhold permission to do so.  
Publication will be no earlier than three months from the date of this favourable opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to 
withhold permission to publish, please contact the Co-ordinator Mrs Wendy Rees, 
NRESCommittee.WestMidlands-solihull@nhs.net  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
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Appendix F: Local Research and Development ethical approval letter. 
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Appendix G: Participant Information Sheets for the MeTEOR pilot study. 
 
     
 
 
 
 
 
Clinical trial of meniscal transplantation compared to 
personalised knee therapy 
 
Chief Investigator: Mr Nicholas Smith 
 
Participant information sheet 
 
We would like to invite you to take part in a research study. Before you decide, we 
would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through the information sheet with you and 
answer any questions you have.  
 
Contacts for further information 
If, at any time, you would like further information about this research project you 
may contact the chief investigator Nicholas Smith on telephone number 
02476968622. For independent advice contact the PALS service (Patient Advice 
Liaison Service) at freephone 0800 0284203. 
 
Background information 
The meniscus is an important structure within the knee joint. One of its key roles is 
to cushion impact and protect the gliding surface of the joint from wear. Patients that 
have damaged their meniscus resulting in removal of the majority of the meniscus 
(near total meniscectomy) are more likely to develop arthritis in the knee due to this 
wear of the joint surface.  
 
At present, there are several treatment options for a damaged meniscus ranging from 
knee therapy to a replacement meniscus also known as a ‘meniscal transplant’. 
 
What is the purpose of this study? 
Meniscal transplant is thought to provide cushioning to the joint surfaces and 
improve symptoms but it has a long recovery period and the operation carries risks 
of surgery as well as not helping with symptoms. At present there is no direct 
evidence that meniscal transplant is better or worse than a specific targeted 
rehabilitation and therapy program.  
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In this study, we will compare two treatments for patients with an injury to the 
meniscus and near total meniscectomy. One group of patients will have a course of 
personalised knee therapy and the other group will have a meniscal transplant. 
 
After the treatment, we will use scans of the knee to carefully monitor the surface of 
the knee joint to check for damage. The scans are magnetic resonance imaging 
(MRI) scans. 
 
Both of these treatments are already used within the NHS. However, it is important 
to perform studies that compare one type of treatment to another so that we can offer 
the best possible treatment in the future. 
 
What is a MRI scan and are there any side effects? 
The Magnetic Resonance Imaging (MRI) scanner uses magnetic and radio waves 
and it does not involve any exposure to x-rays or any other ionizing radiation. The 
MRI scans will produce a detailed picture of your knee surface cartilage. MRI scans 
have been used for approximately 30 years and are considered very safe. There are 
no know side effects associated with a MRI scan, although a small number of people 
may suffer from claustrophobia (a fear of confined spaces). If this happens, the scan 
will be stopped immediately. The scan does not hurt and you cannot feel it.  
 
Why have I been chosen? 
You have been chosen because you have damage to your meniscus and are now 
having symptoms in your knee due to removal of the majority of the meniscus such 
that you would be a candidate for meniscal transplant surgery. All patients like you 
will be invited to take part in this study. 
 
Do I have to take part? 
It is up to you whether you take part. If you decide to take part you will be given this 
information sheet to keep and will be asked to sign a consent form. If you decide to 
take part you are free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time or a decision not to take part will not affect the 
standard of you receive.  
 
Which treatment will I get? 
If you agree to take part, you will be allocated to either the meniscal transplant group or the 
personalised knee therapy group. The allocation process will be done by a computer and will 
be done purely by chance.  To answer the question set out in the purpose of the study, 
we will compare the results we get from one treatment group with the results from 
the other.  
 
What will happen after I have been placed in one of the two groups? 
If you are allocated to the meniscal transplant group, we will book you for meniscal 
transplant surgery. Before the surgery, you may have a course of physiotherapy and 
a brace if required.  
 
The operation itself is through keyhole surgery. Your new meniscus is from a donor 
and is inserted into the knee through a small cut at the front of the knee. It is held in 
position by strong stitches that are placed using the keyhole technique. Your small 
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wounds will then be stitched and you will have a bandage placed on the knee. After 
surgery, you will be given crutches to walk and will have a course of physiotherapy. 
You will be able to put all your weight on your leg at eight weeks after surgery. 
 
If you are allocated to the personalised knee therapy group, you will receive a knee 
therapy course that has been specifically designed to treat patients like yourself. 
Each therapy course is unique, depending on the individual patient’s needs and will 
be designed by a senior physiotherapist. The course will focus on the symptoms of 
pain and swelling of the knee and will attempt to improve strength and range of 
movement. The course will focus on the knee joint but will also address the hip, 
ankle and walking pattern as these can affect your knee. The course will be delivered 
over at least a three month period, which can be extended depending on your needs. 
 
For both groups, we will arrange a scan before your treatment and at four, eight and 
twelve months after your treatment. On the days of your scans you will be seen in 
clinic as usual and be given a set of questionnaires to fill in to assess your progress. 
The questionnaires will ask about your knee function as well as your general well 
being. The flow diagram below shows what will happen if you choose to enter the 
trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
What are the possible disadvantages and risks of taking part? 
Enter Trial 
You are randomly selected to either personalised 
knee therapy or meniscal transplant surgery 
 MRI scan and  
0 months  and start 
treatment 
 Follow up clinic  
4 months appointment and 
MRI scan 
 Follow up clinic  
8 months appointment and 
MRI scan 
 Follow up clinic  
12 months appointment and 
MRI scan 
Trial finishes 
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There are risks with meniscal transplant surgery, including surgical risks of tearing 
the new meniscus, persistent knee pain, infection and blood clots, but these are the 
same risks as for patients that do not take part in the study. The risks associated with 
personalised knee therapy are also the same for patients that do not take part in the 
study. There are no other special risks over and above what your doctor would 
normally inform you about. 
 
What are the possible benefits of taking part? 
There are no specific benefits of taking part in this research. However, this study 
may help future patients decide about the best treatment for them. 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes 
available about the treatment that is being studied. If this happens, your consultant 
will tell you about it and discuss with you whether you want to continue in the study. 
If you decide to withdraw, your surgeon will make arrangements for your care to 
continue. If you decide to continue in the study you will be asked to sign an updated 
consent form. 
 
Also, on receiving new information your surgeon might consider it to be in your best 
interest to withdraw you from the study. He/she will explain the reasons and arrange 
for your care to continue. 
 
What happens when the study ends? 
You will be in the study for twelve months following your operation. If you are still 
having problems after this time, we will arrange for you to have an appointment with 
an appropriate specialist to continue your care. 
 
What if something goes wrong? 
In the unlikely event that something does go wrong and you are harmed during the 
research and this is due to someone‘s negligence then you may have grounds for a 
legal action for compensation against the UHCW NHS Trust (Mrs Ceri Jones, R&D 
services manager, 0247696196) or University of Warwick (Miss Nicola Owen, 
Deputy Registrar, 02476522713), but you may have to pay your legal costs. The 
normal National Health Service complaints mechanisms will still be available to 
you. 
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the course of the research will 
be kept strictly confidential. Any information about you that leaves the hospital will 
have your name and address removed so that you cannot be recognised from it. Your 
GP and other doctors who may treat you, but are not part of this study will be 
notified that you are taking part in this study. 
 
What will happen to the results of the research study? 
This study is expected to last two and a half years. At the end of the study we will 
publish the findings in medical journals and at medical conferences. You will not be 
identified in any reports or publications resulting from the study. If you would like to 
obtain a copy of the published results, please ask your doctor. 
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What will happen if I decide not to participate in the research study? 
If you decide not to participate in the research study you will continue to be treated 
by your doctor with the same care as any other patient with your symptoms. 
 
Who has reviewed this study? 
This study has been reviewed and approved by Solihull Research Ethics Committee. 
 
 
 
   
 
 
   
 
Clinical trial of meniscal transplantation compared to 
personalised knee therapy  
 
 
 
Chief Investigator: Mr Nicholas Smith 
 
Participant information sheet – follow-up only 
 
As part of our research we would also like to collect information from patients that 
do not wish to take part in the clinical trial. This information sheet will explain the 
information that we would like to collect. One of our team will go through it with 
you and answer any questions that you may have. 
 
Why have I been chosen? 
We are inviting all patients that meet the criteria for the main trial but do not wish to 
take part in that trial, to have their progress monitored. Information about your 
progress is very useful to us even if you decide not to take part in the trial. 
 
Being part of the ‘follow-up only’ group will not affect your choice of treatment. 
 
What information will be collected? 
We will ask that you complete some questionnaires at the beginning of your 
treatment. When you come back to clinic for follow-up, we will ask you to fill out 
the same questionnaires at four, eight and twelve months after the start of your 
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treatment. The questionnaires will ask about your knee function and your general 
well being.  
 
In addition we would like to collect data from your ‘magnetic resonance imaging’ 
MRI scan at the beginning of treatment and 1 year after treatment has started. These 
scans would be performed whether you enter the study or not and would not involve 
any additional hospital visits. 
 
Do I have to take part? 
It is up to you whether you take part. If you decide to take part you will be asked to 
sign a consent form. If you decide to take part you are free to withdraw at any time 
and without giving a reason. A decision to withdraw at any time or a decision not to 
take part will not affect the standard of care you receive.  
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the course of the research will 
be kept strictly confidential. Any information about you that leaves the hospital will 
have your name and address removed so that you cannot be recognised from it. 
 
 
Contacts for further information 
If, at any time, you would like further information about this research project you 
may contact the chief investigator Nicholas Smith on telephone number 
02476968622. For independent advice contact the PALS service (Patient Advice 
Liaison Service) at Freephone 0800 0284203. 
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Appendix H: Consent forms for the MeTEOR study 
 
 
 
 
Patient ID Number:  _____________ 
 
Clinical trial of meniscal transplantation compared to personalised 
knee therapy Chief Investigator: Nicholas Smith 
 
CONSENT FORM 
 
Initial 
box 
1- I confirm that I have read and understand the information sheet dated 01st 
September 2013 (version 2) for the above study. I have had the opportunity 
to consider the information, ask questions and have had these answered 
satisfactorily. 
 
2- I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3- I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals 
from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give my permission for these individuals 
to have access to my records. 
 
4- I understand that appropriate personal identifying information will be 
collected, stored and used by the study office to enable follow up of my 
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health status. This is on the understanding that any information will be 
treated with the strictest security and confidentiality. 
 
5- I agree to my GP being informed of my participation in the study. 
 
6- I agree to take part in the above study.  
  
Name of patient    Date  Signature 
 
……………………….  ………….. …………………………….. 
 
Name of person taking consent   Date             Signature    Role/Title 
 
……………………….               …………..       ……………………………..      
………………………… 
 
 
 
 
 
Patient ID Number:  _____________ 
 
Clinical trial of meniscal transplantation compared to personalised 
knee therapy  FOLLOW UP ONLY          
Chief Investigator:  Nicholas Smith 
 
CONSENT FORM 
 
Initial 
box 
7- I confirm that I have read and understand the information sheet dated 17th 
July 2013 (version 1) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
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8- I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
9- I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals 
from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give my permission for these individuals 
to have access to my records. 
 
10- I understand that appropriate personal identifying information will be 
collected, stored and used by the study office to enable follow up of my 
health status. This is on the understanding that any information will be 
treated with the strictest security and confidentiality. 
 
11- I agree to take part in the above study.  
 
 Name of patient   Date  Signature 
 
 
……………………….  ………….. …………………………….. 
 
Name of person taking consent   Date          Signature     Role/Title 
 
 
……………………….               …………..       ……………………………..      
………………………… 
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Appendix I: Intervention fidelity questionnaires for the MeTEOR study 
 
 
Meniscal allograft transplantation 
 
Participant number      
Did the participant have a meniscal 
transplant? 
     
Was an NHSBT, RTI or Allosource graft 
used? 
     
Was an osteotomy performed if 
malalignment present? 
     
Any other concurrent operative procedures?      
Was written rehab advise given?      
Were crutches given?      
Number of physiotherapy sessions      
Reason for any deviations      
Any other treatments?      
 
 
Personalised knee therapy 
 
Participant number      
Was a personalised knee therapy booklet 
given? 
     
Was an offloading brace given if 
malalignment present? 
     
Was there an initial treatment session with a 
senior knee physiotherapist at UHCW? 
     
Name of physiotherapist      
Was a written prescription given to the 
participant? 
     
How many physiotherapy sessions did the 
participant have in total? 
     
Over how many months?      
Reason for any deviations      
Any other procedures?      
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Appendix J: MRI protocol settings. * TEs for T2 map: 11.8,  23.6,  35.4,  47.3,  
59.1,  70.9,  82.7, and 94.5 ms. Repetition time (TR), echo time (TE), field of view 
(FOV), number of excitations (NEX), proton density (PD), sagittal (sag), gradient 
recalled echo (GRE), coronal (cor), fat suppressed (FS).    
 
 
 
TR /ms TE/ms flip FOV 
(cm) 
Matrix NEX Thickness 
 (mm) 
Slices Time 
PD 
Sag 
2300 22.5 900 16 384x256 2 3.5/1.0 22 2.32 
GRE 
Sag 
440 12 200 16 320x224 2 3.5/1.0 22 3.21 
T2 
Sag 
1000 * 900 16 256x160 1 3/0.6 27(x8) 8.07 
Cube 
Sag 
2960 18.4 900 16 256x256 0.5 1.4/-0.7 256 4.01 
PDFS 
Cor  
2000 22.8 900 16 352x256 2 3.5/1.0 23 2.32 
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Appendix K: Audit report from the sponsors for the MeTEOR study. 
 
 
 
University of Warwick 
Coventry 
CV4 7AL 
 
22 August 2014 
 
 
 
Dear Mr Nick Smith, 
 
Re: MeTEOR – Meniscal transplantation and its Effects on Osteoarthritis Risk 
 
An audit of the MeTEOR trial documentation held at the Clinical Sciences Building, 
UHCW was undertaken on 13 August 2014 on behalf of the University of Warwick 
and UHCW NHS Trust as trial co-sponsors, by myself and Isabella Petrie, Research 
Governance Manager, UHCW. I would like to thank you for your time and 
cooperation during the visit. 
 
The trial documentation was found to be maintained to a good standard, with all 
approvals in place. 
 
A summary of the findings is given below.  
 
Findings are classified as follows: 
• Major: those that pose an immediate threat to participant safety / trial 
integrity  
• Moderate: those that compromise the integrity of certain components of 
the trial 
• Minor: those that show lack of due diligence but do not directly 
compromise the trials’ conduct 
 
Full definitions can be found in WCTU SOP 25: Auditing of Clinical Trial. 
 
Major Findings 
No. Finding Action 
 No Major findings  
Moderate Findings 
No. Finding Action 
 No Moderate findings  
Minor Findings 
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No. Finding Action 
  
1.  Version 1 of the PIS (RCT) submitted 
with the initial application to the REC is 
not present on file. 
 
Print off and file - score 
through and mark as 
superseded. 
2.  The NHS REC application form on file 
is incomplete (only 13 pages present) 
with the signature pages missing. 
Print off and file the 
complete, signed application 
form and file. 
3.  Evidence of trial initiation training is 
present for all on the delegation log 
apart from C Lawrence. 
 
Document and file details of 
training provided to C 
Lawrence. 
4.  The PI signatures on the trial delegation 
log have not been dated as per GCP. 
 
PI to add relevant dates to the  
delegation log. 
Notes: 
• Details of the funding body and organisation managing a research 
project is a HRA required element for inclusion in a PIS. These details 
are missing from the MeTEOR information sheets and should be 
included if any amendments are made to these documents in the future. 
• Some of the text in the Safety Reporting section of the protocol is 
incorrect. This has been discussed with the CI and other orthopaedic 
group trial coordinators and managers and some standard text will be 
produced to be used in future protocols. 
• Data entry checks were discussed and will be undertaken and 
documented by the trial coordinator before the final participant is 
recruited. 
 
A written response to these findings to confirm that these actions have been 
completed should be returned to me by Friday 19 September 2014 and cc’d to 
Isabella Petrie, UHCW Research Governance Manager and Graham Hewitt WMS 
REGM. 
 
Yours sincerely, 
 
Claire Daffern 
Quality Assurance Manager 
Warwick Clinical Trials Unit 
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